A	O	O
series	O	O
of	O	O
2	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
-	O	O
1	B-IUPAC	O
-	I-IUPAC	O
[	I-IUPAC	O
(	I-IUPAC	O
biphenyl	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
was	O	O
prepared	O	O
from	O	O
the	O	O
key	O	O
intermediate	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
biphenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoate	I-IUPAC	I-IUPAC
(	O	O
6a	O	O
-	O	O
c	O	O
)	O	O
in	O	O
order	O	O
to	O	O
clarify	O	O
the	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
of	O	O
various	O	O
analogues	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
biphenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ben	I-IUPAC	I-IUPAC
zimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
CV	O	O
-	O	O
11194	O	O
)	O	O
,	O	O
a	O	O
potent	O	O
and	O	O
long	O	O
acting	O	O
angiotensin	O	O
II	O	O
(	O	O
AII	O	O
)	O	O
receptor	O	O
antagonist	O	O
.	O	O
In	O	O
order	O	O
to	O	O
investigate	O	O
the	O	O
structural	O	O
requirements	O	O
for	O	O
gastroprotective	O	O
activity	O	O
in	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbutyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ammoniohexanoate	I-IUPAC	I-IUPAC
[	O	I-IUPAC
AI	O	I-IUPAC
-	O	I-IUPAC
77	O	I-IUPAC
-	O	I-IUPAC
B	O	I-IUPAC
,	O	O
1	O	O
]	O	O
,	O	O
a	O	O
product	O	O
of	O	O
Bacillus	O	O
pumilus	O	O
AI	O	O
-	O	O
77	O	O
,	O	O
nine	O	O
derivatives	O	O
were	O	O
prepared	O	O
and	O	O
then	O	O
tested	O	O
for	O	O
protective	O	O
activity	O	O
against	O	O
stress	O	O
-	O	O
induced	O	O
ulcers	O	O
in	O	O
rats	O	O
.	O	O
This	O	O
study	O	O
indicates	O	O
that	O	O
the	O	O
substitutions	O	O
with	O	O
none	O	O
or	O	O
low	O	O
polar	O	O
functional	O	O
groups	O	O
at	O	O
the	O	O
1	O	O
-	O	O
position	O	O
could	O	O
improve	O	O
the	O	O
selectivity	O	O
and	O	O
duration	O	O
of	O	O
the	O	O
bronchodilator	O	O
effects	O	O
of	O	O
xanthines	O	O
.	O	O
N	O	B-IUPAC
,	O	I-IUPAC
O	O	I-IUPAC
-	O	I-IUPAC
Dicarbethoxy	O	I-IUPAC
-	O	I-IUPAC
4	O	I-IUPAC
-	O	I-IUPAC
chlorobenzenesulfohydroxamate	O	I-IUPAC
(	O	O
1c	O	O
)	O	O
and	O	O
O	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxysaccharin	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
,	O	O
both	O	O
potential	O	O
carbethoxylating	O	O
agents	O	O
,	O	O
inhibited	O	O
yeast	O	O
aldehyde	O	O
dehydrogenase	O	O
(	O	O
AlDH	O	O
)	O	O
with	O	O
IC50	O	O
's	O	O
of	O	O
24	O	O
and	O	O
56	O	O
microM	O	O
,	O	O
respectively	O	O
.	O	O
N	O	O
-	O	O
Substituted	O	O
analogues	O	O
of	O	O
trans	B-PARTIUPAC	O
-	I-PARTIUPAC	O
7	I-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4,4	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5,6,10	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
octahydrobenzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
f	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinoline	I-IUPAC	I-IUPAC
(	O	O
trans	O	O
-	O	O
7	O	O
-	O	O
and	O	O
trans	O	O
-	O	O
9	O	O
-	O	O
OH	O	O
-	O	O
OHBQ	O	O
)	O	O
were	O	O
tested	O	O
for	O	O
dopamine	O	O
(	O	O
DA	O	O
)	O	O
D2	O	O
receptor	O	O
affinity	O	O
by	O	O
using	O	O
in	O	O
vitro	O	O
[	O	O
3H	O	O
]	O	O
spiperone	O	O
and	O	O
in	O	O
vivo	O	O
5,6	O	O
-	O	O
di	O	O
-	O	O
n	O	O
-	O	O
Pr	O	O
-	O	O
ADTN	O	O
binding	O	O
assays	O	O
.	O	O
In	O	O
contrast	O	O
with	O	O
type	O	O
I	O	O
mechanism	O	O
-	O	O
based	O	O
inactivation	O	O
,	O	O
reduction	O	O
of	O	O
enzyme	O	O
-	O	O
bound	O	O
NAD+	O	O
to	O	O
NADH	O	O
was	O	O
not	O	O
observed	O	O
.	O	O
The	O	O
X	O	O
-	O	O
ray	O	O
structures	O	O
show	O	O
that	O	O
both	O	O
complexes	O	O
have	O	O
a	O	O
pseudo	O	O
-	O	O
square	O	O
-	O	O
pyramidal	O	O
structure	O	O
of	O	O
[	O	O
RevO	O	O
]	O	O
3+	O	O
N2S2	O	O
core	O	O
with	O	O
oxygen	O	O
occupying	O	O
the	O	O
apical	O	O
position	O	O
and	O	O
the	O	O
N	O	O
-	O	O
alkyl	O	O
substitution	O	O
in	O	O
syn	O	O
-	O	O
configuration	O	O
to	O	O
the	O	O
oxo	O	O
-	O	O
rhenium	O	O
bond	O	O
.	O	O
We	O	O
hypothesized	O	O
that	O	O
the	O	O
lactam	O	O
ring	O	O
promoted	O	O
conformational	O	O
stability	O	O
to	O	O
yield	O	O
analogues	O	O
with	O	O
increased	O	O
potency	O	O
both	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
as	O	O
compared	O	O
to	O	O
that	O	O
of	O	O
their	O	O
linear	O	O
counterparts	O	O
.	O	O
1-9	O	O
)	O	O
,	O	O
a	O	O
75%	O	O
increase	O	O
in	O	O
survival	O	O
was	O	O
observed	O	O
relative	O	O
to	O	O
untreated	O	O
controls	O	O
,	O	O
and	O	O
there	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
any	O	O
host	O	O
toxicity	O	O
.	O	O
Additionally	O	O
,	O	O
we	O	O
monitored	O	O
the	O	O
dose	O	O
dependent	O	O
caspase	O	O
-	O	O
3	O	O
-	O	O
like	O	O
protease	O	O
activity	O	O
in	O	O
K562	O	O
cells	O	O
and	O	O
MCF	O	O
-	O	O
7	O	O
/	O	O
Casp	O	O
-	O	O
3	O	O
cells	O	O
treated	O	O
with	O	O
9h	O	O
,	O	O
indicating	O	O
induction	O	O
of	O	O
apoptosis	O	O
.	O	O
The	O	O
dibenzo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
dioxin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamides	I-IUPAC	I-IUPAC
are	O	O
active	O	O
against	O	O
wild	O	O
-	O	O
type	O	O
P388	O	O
leukemia	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
,	O	O
with	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
resembling	O	O
those	O	O
for	O	O
both	O	O
the	O	O
acridine	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
and	O	O
phenazine	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
series	B-MODIFIER	B-MODIFIER
of	O	O
DNA	O	O
-	O	O
intercalating	O	O
antitumor	O	O
agents	O	O
.	O	O
Compounds	O	O
4	O	O
,	O	O
7	O	O
,	O	O
and	O	O
15	O	O
were	O	O
designed	O	O
as	O	O
putative	O	O
substrates	O	O
of	O	O
the	O	O
"	O	O
hydrolytic	O	O
activity	O	O
"	O	O
of	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
adenosyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
l	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
homocysteine	I-IUPAC	I-IUPAC
(	O	O
AdoHcy	O	O
)	O	O
hydrolase	O	O
.	O	O
The	O	O
products	O	O
were	O	O
tested	O	O
for	O	O
in	O	O
vivo	O	O
antitumor	O	O
activity	O	O
against	O	O
L1210	O	O
leukemia	O	O
in	O	O
mice	O	O
to	O	O
test	O	O
whether	O	O
all	O	O
MTX	O	O
and	O	O
DCM	O	O
diesters	O	O
are	O	O
therapeutically	O	O
equivalent	O	O
in	O	O
this	O	O
species	O	O
.	O	O
The	O	O
contractile	O	O
effects	O	O
on	O	O
guinea	O	O
pig	O	O
ileum	O	O
and	O	O
aorta	O	O
,	O	O
respectively	O	O
,	O	O
could	O	O
be	O	O
blocked	O	O
concentration	O	O
-	O	O
dependently	O	O
by	O	O
the	O	O
H1	O	O
receptor	O	O
antagonist	O	O
mepyramine	O	O
,	O	O
yielding	O	O
KB	O	O
values	O	O
for	O	O
mepyramine	O	O
in	O	O
the	O	O
nanomolar	O	O
range	O	O
.	O	O
All	O	O
compounds	O	O
showed	O	O
high	O	O
affinity	O	O
for	O	O
the	O	O
DAT	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
inhibition	O	O
of	O	O
HIV	O	O
-	O	O
1'	O	O
s	O	O
cytopathic	O	O
effects	O	O
in	O	O
MT	O	O
-	O	O
4	O	O
cells	O	O
,	O	O
we	O	O
found	O	O
that	O	O
5	O	O
-	O	O
mono	O	O
-	O	O
Me	O	O
-	O	O
substituted	O	O
analogues	O	O
,	O	O
the	O	O
original	O	O
substitution	O	O
in	O	O
the	O	O
early	O	O
lead	O	O
compounds	O	O
,	O	O
and	O	O
7	O	B-MODIFIER
-	O	I-MODIFIER
mono	O	I-MODIFIER
-	O	I-MODIFIER
Me	O	I-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
analogues	O	B-MODIFIER
of	O	O
1	O	O
were	O	O
comparable	O	O
as	O	O
being	O	O
consistently	O	O
the	O	O
most	O	O
active	O	O
compounds	O	O
.	O	O
The	O	O
enantiomers	O	O
of	O	O
(	O	B-IUPAC
fluoroalkyl	O	I-IUPAC
)	O	I-IUPAC
benzilic	O	I-IUPAC
acids	O	I-IUPAC
were	O	O
prepared	O	O
via	O	O
an	O	O
enantioselective	O	O
Grignard	O	O
addition	O	O
reaction	O	O
.	O	O
Although	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxoadenosine	I-IUPAC	I-IUPAC
is	O	O
3	O	O
times	O	O
more	O	O
vasoactive	O	O
than	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminoadenosine	I-IUPAC	I-IUPAC
,	O	O
the	O	O
activities	O	O
of	O	O
the	O	O
phenyl	B-IUPAC	O
derivatives	B-MODIFIER	O
are	O	O
markedly	O	O
different	O	O
;	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenoxyadenosine	I-IUPAC	I-IUPAC
is	O	O
23	O	O
times	O	O
weaker	O	O
than	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenosine	I-IUPAC	I-IUPAC
(	O	O
CV	O	O
-	O	O
1808	O	O
)	O	O
.	O	O
(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
400	O	O
WORDS	O	O
)	O	O
The	O	O
synthesis	O	O
and	O	O
alpha	O	O
2	O	O
-	O	O
adrenergic	O	O
activity	O	O
of	O	O
a	O	O
series	O	O
of	O	O
indolin	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
2	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
yl	I-PARTIUPAC	I-PARTIUPAC
and	O	O
tetrahydroquinolin	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
imidazolines	I-IUPAC	I-IUPAC
are	O	O
described	O	O
.	O	O
In	O	O
this	O	O
experimental	O	O
system	O	O
,	O	O
recovery	O	O
from	O	O
hypoglycemia	O	O
proceeded	O	O
with	O	O
a	O	O
t	O	O
(	O	O
1/2	O	O
)	O	O
value	O	O
of	O	O
14	O	O
+	O	O
/	O	O
-	O	O
1	O	O
h	O	O
,	O	O
as	O	O
compared	O	O
with	O	O
t	O	O
(	O	O
1/2	O	O
)	O	O
=	O	O
8.0	O	O
+	O	O
/	O	O
-	O	O
1	O	O
h	O	O
for	O	O
native	O	O
insulin	O	O
and	O	O
t	O	O
(	O	O
1/2	O	O
)	O	O
=	O	O
10.0	O	O
+	O	O
/	O	O
-	O	O
1	O	O
h	O	O
for	O	O
NPH	O	O
-	O	O
insulin	O	O
.	O	O
The	O	O
results	O	O
presented	O	O
in	O	O
this	O	O
article	O	O
point	O	O
to	O	O
the	O	O
utility	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypyrazole	I-IUPAC	I-IUPAC
and	O	O
1,2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxytriazole	I-IUPAC	I-IUPAC
as	O	O
bioisosteres	O	O
of	O	O
carboxylic	O	O
acids	O	O
at	O	O
Glu	O	O
receptors	O	O
and	O	O
transporters	O	O
.	O	O
The	O	O
stereochemical	O	O
diversity	O	O
-	O	O
oriented	O	O
conformational	O	O
restriction	O	O
strategy	O	O
can	O	O
be	O	O
an	O	O
efficient	O	O
method	O	O
for	O	O
developing	O	O
specific	O	O
ligands	O	O
for	O	O
drug	O	O
target	O	O
proteins	O	O
,	O	O
especially	O	O
in	O	O
cases	O	O
where	O	O
neither	O	O
the	O	O
bioactive	O	O
conformation	O	O
nor	O	O
the	O	O
pharmacophore	O	O
is	O	O
known	O	O
.	O	O
However	O	O
,	O	O
the	O	O
present	O	O
results	O	O
,	O	O
together	O	O
with	O	O
the	O	O
previous	O	O
,	O	O
demonstrate	O	O
that	O	O
8a	O	O
and	O	O
8b	O	O
are	O	O
promising	O	O
new	O	O
prodrugs	O	O
of	O	O
ara	O	O
-	O	O
C	O	O
with	O	O
improved	O	O
efficacy	O	O
.	O	O
Our	O	O
findings	O	O
revealed	O	O
that	O	O
the	O	O
optimal	O	O
stereochemical	O	O
array	O	O
was	O	O
the	O	O
same	O	O
for	O	O
both	O	O
NMDA	O	O
(	O	O
32	O	O
and	O	O
61	O	O
)	O	O
and	O	O
AMPA	O	O
(	O	O
9	O	O
)	O	O
antagonists	O	O
identified	O	O
in	O	O
this	O	O
series	O	O
and	O	O
that	O	O
the	O	O
tetrahydroisoquinoline	O	O
(	O	O
25	O	O
)	O	O
and	O	O
the	O	O
C	B-MODIFIER	O
-	I-MODIFIER	O
1	I-MODIFIER	O
carboxy	B-IUPAC	O
(	O	O
30	O	O
)	O	O
analogs	B-MODIFIER	O
of	O	O
9	O	O
are	O	O
inactive	O	O
.	O	O
Several	O	O
compounds	O	O
prolonged	O	O
the	O	O
survival	O	O
time	O	O
of	O	O
mice	O	O
in	O	O
hypoxic	O	O
conditions	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
sc	O	O
or	O	O
ip	O	O
)	O	O
and	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
po	O	O
)	O	O
.	O	O
A	O	O
series	O	O
of	O	O
dialkyl	B-MODIFIER	B-IUPAC
N	B-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
m	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
dioxamates	I-IUPAC	I-IUPAC
was	O	O
synthesized	O	O
by	O	O
treatment	O	O
of	O	O
the	O	O
requisite	O	O
m	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylenediamines	I-IUPAC	I-IUPAC
with	O	O
an	O	O
alkyloxalyl	O	O
chloride	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
triethylamine	O	O
.	O	O
(	B-IUPAC	B-IUPAC
m	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
125I	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
Iodobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
guanidine	I-IUPAC	I-IUPAC
(	O	O
m	O	O
-	O	O
IBG	O	O
,	O	O
2b	O	O
)	O	O
gave	O	O
the	O	O
best	O	O
combination	O	O
of	O	O
high	O	O
concentration	O	O
and	O	O
selectivity	O	O
.	O	O
N	O	O
-	O	O
Methylation	O	O
reduced	O	O
affinity	O	O
greatly	O	O
as	O	O
did	O	O
increasing	O	O
the	O	O
size	O	O
of	O	O
the	O	O
acyl	O	O
moiety	O	O
.	O	O
After	O	O
aromatization	O	O
,	O	O
these	O	O
compounds	O	O
were	O	O
transformed	O	O
by	O	O
phosphorus	O	O
oxychloride	O	O
,	O	O
giving	O	O
1	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
chloro	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
methyl	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
5H	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
pyrido	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
4,3	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
b	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
benzo	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
e	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
and	O	I-IUPAC
-	B-PARTIUPAC	I-IUPAC
benzo	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	O
g	I-PARTIUPAC	O
]	I-PARTIUPAC	O
indoles	I-PARTIUPAC	O
which	O	O
were	O	O
substituted	O	O
by	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
dialkylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amines	I-IUPAC	I-IUPAC
.	O	O
Extension	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylamino	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
to	O	O
2	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
benzyl	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	O
reduced	O	O
affinity	O	O
.	O	O
Conventional	O	O
functional	O	O
group	O	O
transformation	O	O
of	O	O
5a	O	O
and	O	O
5b	O	O
provided	O	O
a	O	O
number	O	O
of	O	O
novel	O	O
3	O	B-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
allopurinol	O	B-IUPAC
nucleosides	O	B-MODIFIER
,	O	O
which	O	O
included	O	O
10a	O	O
and	O	O
18a	O	O
-	O	O
d	O	O
.	O	O
In	O	O
this	O	O
fashion	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
or	O	O
more	O	O
appropriately	O	O
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	O	O
has	O	O
been	O	O
identified	O	O
as	O	O
a	O	O
novel	O	O
PTP1B	O	O
binding	O	O
motif	O	O
.	O	O
The	O	O
pA2	O	O
values	O	O
were	O	O
8.20	O	O
(	O	O
1	O	O
)	O	O
,	O	O
6.40	O	O
(	O	O
2	O	O
)	O	O
,	O	O
6.20	O	O
(	O	O
3	O	O
)	O	O
,	O	O
6.25	O	O
(	O	O
4	O	O
)	O	O
,	O	O
6.30	O	O
(	O	O
5	O	O
)	O	O
,	O	O
6.30	O	O
(	O	O
7	O	O
)	O	O
,	O	O
6.05	O	O
(	O	O
8	O	O
)	O	O
,	O	O
6.20	O	O
(	O	O
9	O	O
)	O	O
,	O	O
6.30	O	O
(	O	O
10	O	O
)	O	O
,	O	O
6.25	O	O
(	O	O
11	O	O
)	O	O
,	O	O
6.10	O	O
(	O	O
12	O	O
)	O	O
,	O	O
6.20	O	O
(	O	O
13	O	O
)	O	O
,	O	O
6.20	O	O
(	O	O
14	O	O
)	O	O
,	O	O
and	O	O
6.35	O	O
(	O	O
15	O	O
)	O	O
.	O	O
These	O	O
compounds	O	O
did	O	O
not	O	O
bind	O	O
to	O	O
the	O	O
BZP	O	O
receptor	O	O
in	O	O
spite	O	O
of	O	O
having	O	O
structures	O	O
similar	O	O
to	O	O
those	O	O
of	O	O
beta	O	O
-	O	O
carbolines	O	O
.	O	O
The	O	O
corresponding	O	O
diamino	O	O
acids	O	O
were	O	O
obtained	O	O
from	O	O
the	O	O
diamines	O	O
and	O	O
oxocarboxylic	O	O
acids	O	O
by	O	O
catalytic	O	O
hydrogenation	O	O
.	O	O
Escherichia	O	O
coli	O	O
TK	O	O
was	O	O
inactivated	O	O
by	O	O
6	O	O
of	O	O
25	O	O
ATP	O	O
derivatives	O	O
tested	O	O
at	O	O
10	O	O
mM	O	O
,	O	O
6	O	O
h	O	O
,	O	O
0	O	O
degrees	O	O
C	O	O
;	O	O
inactivation	O	O
was	O	O
slowed	O	O
by	O	O
MgATP	O	O
in	O	O
the	O	O
case	O	O
of	O	O
N6	O	O
-	O	O
CH3	O	O
-	O	O
N6	O	O
-	O	O
R	O	O
-	O	O
ATP	O	O
[	O	O
R	O	O
=	O	O
(	O	O
CH2	O	O
)	O	O
4N	O	O
(	O	O
CH3	O	O
)	O	O
CO	O	O
(	O	O
CH2	O	O
)	O	O
5NHCOCH2I	O	O
]	O	O
.	O	O
The	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	O
derivatives	B-MODIFIER	O
11	O	O
and	O	O
27	O	O
(	O	O
APPPI	O	O
)	O	O
may	O	O
be	O	O
interesting	O	O
pharmacological	O	O
tools	O	O
due	O	O
to	O	O
their	O	O
fluorescent	O	O
properties	O	O
.	O	O
The	O	O
racemate	O	O
and	O	O
the	O	O
enantiomers	B-MODIFIER	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopropane	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
and	O	O
racemic	B-MODIFIER	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoindan	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
were	O	O
tested	O	O
for	O	O
stimulus	O	O
generalization	O	O
in	O	O
the	O	O
two	O	O
-	O	O
lever	O	O
drug	O	O
-	O	O
discrimination	O	O
paradigm	O	O
.	O	O
The	O	O
potency	O	O
and	O	O
selectivity	O	O
(	O	O
delta	O	O
vs	O	O
mu	O	O
opioid	O	O
receptor	O	O
)	O	O
were	O	O
evaluated	O	O
by	O	O
radioreceptor	O	O
binding	O	O
assays	O	O
in	O	O
the	O	O
rat	O	O
brain	O	O
using	O	O
[	O	O
3H	O	O
]	O	O
CTOP	O	O
(	O	O
mu	O	O
ligand	O	O
)	O	O
and	O	O
[	O	O
3H	O	O
]	O	O
DPDPE	O	O
(	O	O
delta	O	O
ligand	O	O
)	O	O
and	O	O
by	O	O
bioassay	O	O
with	O	O
mouse	O	O
vas	O	O
deferens	O	O
(	O	O
MVD	O	O
,	O	O
delta	O	O
receptor	O	O
assay	O	O
)	O	O
and	O	O
guinea	O	O
pig	O	O
ileum	O	O
(	O	O
GPI	O	O
,	O	O
mu	O	O
receptor	O	O
assay	O	O
)	O	O
.	O	O
Treatment	O	O
of	O	O
the	O	O
imidate	O	O
(	O	O
4	O	O
)	O	O
with	O	O
sodium	O	O
hydrogen	O	O
sulfide	O	O
gave	O	O
the	O	O
thiocarboxamide	B-IUPAC	O
derivative	B-MODIFIER	O
5	O	O
.	O	O
However	O	O
,	O	O
in	O	O
biological	O	O
investigations	O	O
using	O	O
a	O	O
subcutaneous	O	O
B16	O	O
(	O	O
hypoxic	O	O
)	O	O
melanoma	O	O
tumor	O	O
in	O	O
BDF1	O	O
hybrid	O	O
mice	O	O
with	O	O
cyclophosphamide	O	O
as	O	O
positive	O	O
control	O	O
the	O	O
most	O	O
interesting	O	O
series	O	O
of	O	O
structurally	O	O
related	O	O
analogues	O	O
were	O	O
the	O	O
potentially	O	O
monoalkylating	O	O
monoquinones	O	O
of	O	O
the	O	O
2	B-PARTIUPAC	O
-	I-PARTIUPAC	O
[	I-PARTIUPAC	O
(	O	O
leaving	O	O
group	O	O
)	O	O
methyl	B-PARTIUPAC	B-PARTIUPAC
]	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
1,4	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
benzoquinone	I-PARTIUPAC	I-PARTIUPAC
type	B-MODIFIER	O
(	O	O
i.e.	O	O
,	O	O
14	O	O
and	O	O
15	O	O
)	O	O
having	O	O
water	O	O
-	O	O
insoluble	O	O
(	O	O
acetoxy	O	O
)	O	O
and	O	O
water	O	O
-	O	O
solubilizing	O	O
(	O	O
succinate	O	O
)	O	O
groups	O	O
.	O	O
Assessment	O	O
of	O	O
the	O	O
dopaminergic	O	O
activity	O	O
of	O	O
these	O	O
catechols	O	O
and	O	O
the	O	O
results	O	O
from	O	O
the	O	O
determination	O	O
of	O	O
brain	O	O
levels	O	O
of	O	O
the	O	O
enantiomers	O	O
of	O	O
3	O	O
-	O	O
PPP	O	O
and	O	O
their	O	O
metabolites	O	O
indicate	O	O
that	O	O
the	O	O
metabolites	O	O
probably	O	O
do	O	O
not	O	O
alter	O	O
the	O	O
pharmacological	O	O
profiles	O	O
established	O	O
for	O	O
(	O	O
R	O	O
)	O	O
-	O	O
(	O	O
+	O	O
)	O	O
-	O	O
and	O	O
(	O	O
S	O	O
)	O	O
-	O	O
(	O	O
-	O	O
)	O	O
-	O	O
3	O	O
-	O	O
PPP	O	O
.	O	O
Methods	O	O
have	O	O
been	O	O
developed	O	O
for	O	O
the	O	O
preparation	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodothiophenes	I-IUPAC	I-IUPAC
.	O	O
Treatment	O	O
of	O	O
1,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxopyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
with	O	O
phosgene	O	O
in	O	O
THF	O	O
solution	O	O
gives	O	O
the	O	O
active	O	O
ester	O	O
poly	B-IUPAC	O
[	I-IUPAC	O
1,2	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxopyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
]	I-IUPAC	O
,	O	O
which	O	O
upon	O	O
treatment	O	O
with	O	O
excess	O	O
anhydrous	O	O
dimethylamine	O	O
gave	O	O
a	O	O
60%	O	O
yield	O	O
of	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxopyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
.	O	O
Reaction	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trimethylsilyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetoxyethyl	I-IUPAC	I-IUPAC
acetoxymethyl	I-IUPAC	I-IUPAC
ether	I-IUPAC	I-IUPAC
and	O	O
SnCl4	O	O
,	O	O
followed	O	O
by	O	O
ammonolysis	O	O
,	O	O
yielded	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
cytosine	I-IUPAC	I-IUPAC
(	O	O
12	O	O
)	O	O
.	O	O
The	O	O
affinity	O	O
of	O	O
the	O	O
compounds	O	O
for	O	O
the	O	O
GABA	O	O
receptors	O	O
and	O	O
for	O	O
the	O	O
neuronal	O	O
(	O	O
synaptosomal	O	O
)	O	O
GABA	O	O
uptake	O	O
system	O	O
in	O	O
vitro	O	O
has	O	O
been	O	O
measured	O	O
.	O	O
gondii	O	O
infection	O	O
in	O	O
mice	O	O
when	O	O
given	O	O
qdx8	O	O
by	O	O
peritoneal	O	O
injection	O	O
at	O	O
doses	O	O
ranging	O	O
from	O	O
62.5	O	O
(	O	O
initial	O	O
dose	O	O
)	O	O
to	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
project	O	O
was	O	O
to	O	O
further	O	O
investigate	O	O
whether	O	O
it	O	O
is	O	O
possible	O	O
to	O	O
differentiate	O	O
between	O	O
these	O	O
compounds	O	O
with	O	O
respect	O	O
to	O	O
their	O	O
affinity	O	O
for	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
-	O	O
adrenoreceptor	O	O
subtypes	O	O
and	O	O
the	O	O
affinity	O	O
for	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
1A	O	O
)	O	O
receptors	O	O
,	O	O
as	O	O
1	O	O
binds	O	O
with	O	O
high	O	O
affinity	O	O
at	O	O
both	O	O
receptor	O	O
systems	O	O
.	O	O
The	O	O
compounds	O	O
were	O	O
screened	O	O
as	O	O
potential	O	O
H1	O	O
receptor	O	O
agonists	O	O
on	O	O
the	O	O
isolated	O	O
guinea	O	O
pig	O	O
ileum	O	O
.	O	O
Five	O	O
compounds	O	O
exhibited	O	O
inhibitory	O	O
activity	O	O
in	O	O
the	O	O
same	O	O
range	O	O
as	O	O
the	O	O
standards	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trifluoromethylimidazole	I-IUPAC	I-IUPAC
(	O	O
22	O	O
)	O	O
.	O	O
Carboxylic	O	O
acid	O	O
esters	O	O
(	O	O
9-11	O	O
,	O	O
14-16	O	O
,	O	O
27-29	O	O
)	O	O
and	O	O
a	O	O
cyclic	O	O
phosphate	O	O
derivative	O	O
(	O	O
22	O	O
)	O	O
of	O	O
the	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxyalkoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
guanines	I-IUPAC	I-IUPAC
(	O	O
8	O	O
,	O	O
21	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxyalkoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
purines	I-IUPAC	I-IUPAC
(	O	O
13	O	O
,	O	O
26	O	O
)	O	O
were	O	O
also	O	O
prepared	O	O
.	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclopenta	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
f	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isoquinoline	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
which	O	O
constitutes	O	O
the	O	O
basic	O	O
ring	O	O
system	O	O
of	O	O
1	O	O
was	O	O
synthesized	O	O
in	O	O
a	O	O
multistep	O	O
procedure	O	O
starting	O	O
from	O	O
m	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetylbenzylamine	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
.	O	O
8	O	B-IUPAC
-	O	I-IUPAC
Carbamoyl	O	I-IUPAC
-	O	I-IUPAC
3	O	I-IUPAC
-	O	I-IUPAC
methylimidazo	O	I-IUPAC
[	O	I-IUPAC
5,1	O	I-IUPAC
-	O	I-IUPAC
d	O	I-IUPAC
]	O	I-IUPAC
-	O	I-IUPAC
1,2,3,5	O	I-IUPAC
-	O	I-IUPAC
tetrazin	O	I-IUPAC
-	O	I-IUPAC
4	O	I-IUPAC
(	O	I-IUPAC
3H	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
one	O	I-IUPAC
(	O	I-IUPAC
temozolomide	O	I-IUPAC
,	O	O
1	O	O
)	O	O
is	O	O
an	O	O
anticancer	O	O
prodrug	O	O
.	O	O
For	O	O
analysis	O	O
of	O	O
uPAR	O	O
binding	O	O
activity	O	O
,	O	O
we	O	O
employed	O	O
competitive	O	O
flow	O	O
cytofluorometric	O	O
receptor	O	O
binding	O	O
assays	O	O
,	O	O
using	O	O
FITC	O	O
-	O	O
uPA	O	O
as	O	O
the	O	O
ligand	O	O
and	O	O
U937	O	O
promyeloid	O	O
leukemia	O	O
cells	O	O
as	O	O
the	O	O
cellular	O	O
source	O	O
of	O	O
uPAR	O	O
.	O	O
Acids	O	O
1a	O	O
and	O	O
1c	O	O
were	O	O
the	O	O
most	O	O
active	O	O
heteroarotinoids	O	O
in	O	O
the	O	O
two	O	O
biological	O	O
assays	O	O
.	O	O
In	O	O
mouse	O	O
plasma	O	O
,	O	O
1c	O	O
was	O	O
degraded	O	O
first	O	O
to	O	O
FdUMP	O	O
and	O	O
then	O	O
to	O	O
FUdR	O	O
.	O	O
This	O	O
concept	O	O
takes	O	O
advantage	O	O
of	O	O
the	O	O
cytotoxic	O	O
properties	O	O
of	O	O
AEL	O	O
drugs	O	O
as	O	O
well	O	O
as	O	O
the	O	O
membrane	O	O
permeability	O	O
enhancing	O	O
properties	O	O
of	O	O
these	O	O
molecules	O	O
,	O	O
which	O	O
can	O	O
lead	O	O
to	O	O
enhanced	O	O
drug	O	O
diffusion	O	O
into	O	O
cells	O	O
.	O	O
In	O	O
a	O	O
comparative	O	O
study	O	O
the	O	O
benzopyran	O	O
16	O	O
was	O	O
found	O	O
to	O	O
be	O	O
more	O	O
effective	O	O
antiestrogen	O	O
than	O	O
tamoxifen	O	O
while	O	O
being	O	O
as	O	O
effective	O	O
as	O	O
LY	O	O
-	O	O
117018	O	O
.	O	O
In	O	O
this	O	O
paper	O	O
we	O	O
describe	O	O
the	O	O
synthesis	O	O
of	O	O
a	O	O
series	O	O
of	O	O
novel	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkylsemicarbazono	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylenedioxyphenylacetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
esters	I-IUPAC	I-IUPAC
(	O	O
10-19	O	O
)	O	O
carrying	O	O
an	O	O
alkylsemicarbazono	O	O
moiety	O	O
at	O	O
a	O	O
benzylic	O	O
site	O	O
.	O	O
Structure	O	O
-	O	O
-	O	O
activity	O	O
relationships	O	O
suggest	O	O
that	O	O
a	O	O
proton	O	O
at	O	O
the	O	O
C	O	O
-	O	O
1	O	O
position	O	O
appears	O	O
necessary	O	O
for	O	O
agonist	O	O
activity	O	O
and	O	O
the	O	O
acidity	O	O
of	O	O
this	O	O
proton	O	O
has	O	O
a	O	O
relatively	O	O
greater	O	O
influence	O	O
on	O	O
activity	O	O
than	O	O
pendant	O	O
steric	O	O
bulk	O	O
.	O	O
The	O	O
design	O	O
of	O	O
analogues	O	O
of	O	O
7,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydroretinoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
7,8	O	O
-	O	O
dihydro	O	O
-	O	O
RA	O	O
)	O	O
was	O	O
based	O	O
on	O	O
reported	O	O
biological	O	O
activities	O	O
of	O	O
this	O	O
retinoid	O	O
and	O	O
its	O	O
dihydro	O	O
-	O	O
TMMP	O	O
(	O	O
1	O	O
)	O	O
analogue	O	O
and	O	O
on	O	O
structural	O	O
hypotheses	O	O
.	O	O
Moreover	O	O
,	O	O
its	O	O
cerebral	O	O
uptake	O	O
can	O	O
be	O	O
modulated	O	O
by	O	O
the	O	O
synaptic	O	O
concentration	O	O
of	O	O
the	O	O
endogenous	O	O
ligand	O	O
acetylcholine	O	O
.	O	O
Instead	O	O
,	O	O
they	O	O
behaved	O	O
as	O	O
classic	O	O
inhibitors	O	O
of	O	O
tritium	O	O
release	O	O
from	O	O
[	O	O
5	O	O
-	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
dUMP	O	O
.	O	O
In	O	O
addition	O	O
,	O	O
AT2	O	O
binding	O	O
for	O	O
some	O	O
of	O	O
these	O	O
compounds	O	O
was	O	O
increased	O	O
by	O	O
as	O	O
much	O	O
as	O	O
1000	O	O
-	O	O
fold	O	O
over	O	O
the	O	O
corresponding	O	O
tetrazole	O	O
(	O	O
e.g.	O	O
,	O	O
AT2	O	O
IC50	O	O
17	O	O
nM	O	O
for	O	O
the	O	O
tert	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
sulfonylcarbamate	I-IUPAC	I-IUPAC
92	O	O
)	O	O
.	O	O
The	O	O
thione	O	O
11	O	O
rearranges	O	O
to	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosyl	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiadiazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amine	I-IUPAC	I-IUPAC
(	O	O
14	O	O
)	O	O
in	O	O
the	O	O
solid	O	O
state	O	O
or	O	O
in	O	O
solution	O	O
.	O	O
5'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Pivaloyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxaphosphorinan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorouridine	I-IUPAC	I-IUPAC
(	O	O
1c	O	O
)	O	O
was	O	O
designed	O	O
as	O	O
a	O	O
potential	O	O
membrane	O	O
-	O	O
permeable	O	O
prodrug	O	O
of	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorouridine	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
monophosphate	I-IUPAC	I-IUPAC
(	O	O
FdUMP	O	O
)	O	O
,	O	O
a	O	O
putative	O	O
active	O	O
metabolite	O	O
of	O	O
the	O	O
antitumor	O	O
drug	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluorouracil	I-IUPAC	I-IUPAC
(	O	O
FU	O	O
)	O	O
.	O	O
2,3	B-IUPAC	O
-	I-IUPAC	O
Dimethylputrescine	I-IUPAC	O
however	O	O
,	O	O
was	O	O
transported	O	O
into	O	O
the	O	O
cells	O	O
and	O	O
significantly	O	O
decreased	O	O
its	O	O
ODC	O	O
activity	O	O
.	O	O
Chloro	B-IUPAC	O
derivatives	B-MODIFIER	O
2e	O	O
-	O	O
g	O	O
,	O	O
4c	O	O
-	O	O
f	O	O
,	O	O
5d	O	O
,	O	O
and	O	O
6c	O	O
-	O	O
e	O	O
as	O	O
well	O	O
as	O	O
pyrimidine	O	O
oxacyclopentenes	O	O
9c	O	O
and	O	O
9d	O	O
are	O	O
slow	O	O
-	O	O
acting	O	O
inhibitors	O	O
of	O	O
murine	O	O
leukemia	O	O
L1210	O	O
of	O	O
IC50	O	O
10-100	O	O
microM	O	O
.	O	O
With	O	O
some	O	O
preliminary	O	O
optimization	O	O
,	O	O
the	O	O
A2a	O	O
binding	O	O
affinity	O	O
of	O	O
some	O	O
of	O	O
the	O	O
best	O	O
piperazine	O	O
derivatives	O	O
is	O	O
almost	O	O
as	O	O
good	O	O
as	O	O
that	O	O
of	O	O
compound	O	O
3	O	O
.	O	O
The	O	O
total	O	O
synthesis	O	O
time	O	O
was	O	O
50-53	O	O
min	O	O
from	O	O
the	O	O
end	O	O
of	O	O
cyclotron	O	O
fluorine	O	O
-	O	O
18	O	O
production	O	O
(	O	O
EOB	O	O
)	O	O
.	O	O
The	O	O
results	O	O
suggest	O	O
a	O	O
possible	O	O
way	O	O
of	O	O
combining	O	O
a	O	O
drug	O	O
-	O	O
delivery	O	O
and	O	O
prodrug	O	O
concept	O	O
in	O	O
a	O	O
single	O	O
liposome	O	O
system	O	O
.	O	O
Finally	O	O
,	O	O
binding	O	O
assays	O	O
performed	O	O
with	O	O
selected	O	O
quinazolines	O	O
(	O	O
2	O	O
,	O	O
3	O	O
,	O	O
and	O	O
14	O	O
)	O	O
produced	O	O
affinity	O	O
results	O	O
,	O	O
which	O	O
were	O	O
not	O	O
in	O	O
agreement	O	O
with	O	O
the	O	O
selectivity	O	O
profiles	O	O
obtained	O	O
from	O	O
functional	O	O
experiments	O	O
.	O	O
The	O	O
presence	O	O
of	O	O
a	O	O
6	O	O
-	O	O
substituent	O	O
containing	O	O
an	O	O
aryl	O	O
group	O	O
appeared	O	O
to	O	O
be	O	O
necessary	O	O
for	O	O
activity	O	O
,	O	O
which	O	O
was	O	O
increased	O	O
when	O	O
a	O	O
methyl	B-IUPAC	B-IUPAC
group	I-IUPAC	B-MODIFIER
was	O	O
substituted	B-MODIFIER	O
at	O	O
the	O	O
7	O	O
-	O	O
position	O	O
.	O	O
As	O	O
part	O	O
of	O	O
our	O	O
investigation	O	O
into	O	O
the	O	O
structure	O	O
-	O	O
activity	O	O
relationship	O	O
of	O	O
a	O	O
novel	O	O
class	O	O
of	O	O
aromatase	O	O
inhibitors	O	O
,	O	O
C	O	O
(	O	O
19	O	O
)	O	O
steroids	O	O
having	O	O
no	O	O
oxygen	O	O
function	O	O
at	O	O
C	O	O
-	O	O
3	O	O
,	O	O
we	O	O
tested	O	O
aromatase	O	O
inhibition	O	O
activity	O	O
of	O	O
polar	O	O
diol	O	O
compounds	O	O
4,19	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxyandrost	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
en	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
17	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
(	O	O
25	O	O
and	O	O
27	O	O
)	O	O
and	O	O
6,19	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxyandrost	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
en	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
17	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
(	O	O
36	O	O
and	O	O
37	O	O
)	O	O
.	O	O
None	O	O
of	O	O
the	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phosphonomethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isomers	B-MODIFIER	I-IUPAC
exhibited	O	O
any	O	O
antiviral	O	O
activity	O	O
against	O	O
DNA	O	O
viruses	O	O
or	O	O
RNA	O	O
viruses	O	O
tested	O	O
in	O	O
vitro	O	O
.	O	O
(	B-IUPAC	O
-	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
Pentazocine	I-IUPAC	O
[	O	O
(	O	O
-	O	O
)	O	O
-	O	O
1b	O	O
]	O	O
and	O	O
its	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
,	O	O
(	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylallyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,9	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzomorphan	I-IUPAC	I-IUPAC
[	O	O
(	O	O
-	O	O
)	O	O
-	O	O
4a	O	O
]	O	O
showed	O	O
the	O	O
highest	O	O
potency	O	O
for	O	O
the	O	O
sigma	O	O
2	O	O
binding	O	O
site	O	O
.	O	O
Lu	O	O
29-253	O	O
)	O	O
.	O	O
Hydrogen	O	O
bonding	O	O
is	O	O
hereby	O	O
gradually	O	O
replaced	O	O
by	O	O
van	O	O
der	O	O
Waals	O	O
interactions	O	O
involving	O	O
a	O	O
relatively	O	O
large	O	O
lipophilic	O	O
pocket	O	O
.	O	O
The	O	O
key	O	O
intermediate	O	O
was	O	O
the	O	O
protected	O	O
nonapeptide	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carbobenzoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cysteinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tyrosyldihydrophenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alanyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutaminyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
asparaginyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cysteinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
prolyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
epsilon	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tosyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
lysylglycinamide	I-IUPAC	I-IUPAC
that	O	O
was	O	O
synthesized	O	O
stepwise	O	O
by	O	O
the	O	O
solid	O	O
-	O	O
phase	O	O
technique	O	O
.	O	O
In	O	O
the	O	O
series	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	O	I-IUPAC
2	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
substitutions	B-MODIFIER	B-MODIFIER
,	O	O
the	O	O
order	O	O
of	O	O
affinity	O	O
at	O	O
the	O	O
A	O	O
(	O	O
3	O	O
)	O	O
AR	O	O
was	O	O
oxy	O	O
&	O	O
gt	O	O
;	O	O
or	O	O
=	O	O
amino	O	O
&	O	O
gt	O	O
;	O	O
thio	O	O
.	O	O
Such	O	O
chemical	O	O
and	O	O
biological	O	O
characteristics	O	O
of	O	O
MIH	O	O
would	O	O
enable	O	O
high	O	O
target	O	O
/	O	O
nontarget	O	O
ratios	O	O
in	O	O
diagnostic	O	O
and	O	O
therapeutic	O	O
nuclear	O	O
medicine	O	O
using	O	O
mAbs	O	O
and	O	O
other	O	O
polypeptides	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
surface	O	O
area	O	O
of	O	O
the	O	O
bromine	O	O
atom	O	O
,	O	O
this	O	O
value	O	O
is	O	O
2-3	O	O
times	O	O
higher	O	O
than	O	O
would	O	O
be	O	O
expected	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
hydrophobic	O	O
binding	O	O
.	O	O
They	O	O
are	O	O
thus	O	O
nonselective	O	O
oxytocin	O	O
antagonists	O	O
.	O	O
Most	O	O
compounds	O	O
displayed	O	O
low	O	O
micromolar	O	O
antitrypanosomal	O	O
activity	O	O
,	O	O
with	O	O
five	O	O
of	O	O
them	O	O
presenting	O	O
a	O	O
nanomolar	O	O
inhibitory	O	O
action	O	O
on	O	O
the	O	O
parasite	O	O
:	O	O
1,9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
nonanediguanidine	I-IUPAC	I-IUPAC
(	O	O
1c	O	O
)	O	O
,	O	O
1,12	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dodecanediguanidine	I-IUPAC	I-IUPAC
(	O	O
1d	O	O
)	O	O
,	O	O
4,4	B-IUPAC	B-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazolidinylimino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
diphenylamine	I-IUPAC	I-IUPAC
(	O	O
28a	O	O
)	O	O
,	O	O
4,4	B-IUPAC	B-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazolylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
diphenylamine	I-IUPAC	I-IUPAC
(	O	O
28b	O	O
)	O	O
,	O	O
and	O	O
4,4	B-IUPAC	B-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diguanidinodiphenylamine	I-IUPAC	I-IUPAC
(	O	O
32b	O	O
)	O	O
.	O	O
Intriguingly	O	O
,	O	O
it	O	O
was	O	O
demonstrated	O	O
in	O	O
vivo	O	O
that	O	O
5a	O	O
suppressed	O	O
the	O	O
SP	O	O
-	O	O
induced	O	O
bronchoconstriction	O	O
and	O	O
airway	O	O
edema	O	O
in	O	O
guinea	O	O
pigs	O	O
with	O	O
ED50	O	O
of	O	O
0.42	O	O
mg	O	O
/	O	O
kg	O	O
and	O	O
0.66	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
respectively	O	O
,	O	O
when	O	O
administered	O	O
intravenously	O	O
.	O	O
Although	O	O
their	O	O
affinities	O	O
for	O	O
the	O	O
estrogen	O	O
receptor	O	O
were	O	O
very	O	O
low	O	O
(	O	O
from	O	O
0.008%	O	O
to	O	O
0.02%	O	O
that	O	O
of	O	O
estradiol	O	O
)	O	O
,	O	O
they	O	O
appeared	O	O
to	O	O
be	O	O
efficient	O	O
affinity	O	O
labels	O	O
of	O	O
the	O	O
receptor	O	O
due	O	O
to	O	O
their	O	O
irreversible	O	O
inhibition	O	O
of	O	O
[	B-IUPAC	O
3H	I-IUPAC	O
]	I-IUPAC	O
estradiol	I-IUPAC	O
specific	O	O
binding	O	O
in	O	O
lamb	O	O
uterine	O	O
cytosol	O	O
.	O	O
The	O	O
syntheses	O	O
of	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolepropionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
9	O	O
,	O	O
ATPA	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
RS	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolepropionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolebutyric	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
15a	O	O
)	O	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolevaleric	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
15b	O	O
)	O	O
are	O	O
described	O	O
.	O	O
The	O	O
most	O	O
interesting	O	O
effect	O	O
of	O	O
hydroxylating	O	O
CPMENSPM	O	O
is	O	O
the	O	O
profound	O	O
reduction	O	O
in	O	O
toxicity	O	O
compared	O	O
with	O	O
that	O	O
of	O	O
the	O	O
parent	O	O
drug	O	O
.	O	O
The	O	O
structure	O	O
of	O	O
the	O	O
obtained	O	O
compounds	O	O
was	O	O
proved	O	O
by	O	O
1H	O	O
NMR	O	O
UV	O	O
,	O	O
13C	O	O
NMR	O	O
,	O	O
and	O	O
CD	O	O
spectroscopy	O	O
,	O	O
as	O	O
well	O	O
as	O	O
elemental	O	O
(	O	O
C	O	O
,	O	O
H	O	O
,	O	O
N	O	O
)	O	O
analysis	O	O
.	O	O
The	O	O
activities	O	O
of	O	O
the	O	O
24	O	O
-	O	O
one	O	O
and	O	O
delta	O	O
(	O	O
22	O	O
)	O	O
-	O	O
24	O	O
-	O	O
one	O	O
compounds	O	O
were	O	O
expected	O	O
to	O	O
be	O	O
very	O	O
low	O	O
,	O	O
because	O	O
the	O	O
carbonyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
in	O	O
these	O	O
compounds	O	O
is	O	O
located	O	O
over	O	O
the	O	O
steroid	O	O
C	O	O
-	O	O
ring	O	O
and	O	O
oriented	O	O
toward	O	O
C	O	O
-	O	O
8	O	O
.	O	O
The	O	O
non	O	O
-	O	O
nucleoside	O	O
nitrile	O	O
analogs	O	O
4a	O	O
-	O	O
m	O	O
and	O	O
carboxamide	B-IUPAC	B-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
5a	O	O
-	O	O
l	O	O
were	O	O
,	O	O
with	O	O
a	O	O
few	O	O
exceptions	O	O
,	O	O
essentially	O	O
inactive	O	O
against	O	O
HCMV	O	O
and	O	O
HSV	O	O
-	O	O
1	O	O
and	O	O
relatively	O	O
nontoxic	O	O
.	O	O
None	O	O
of	O	O
the	O	O
compounds	O	O
exhibiting	O	O
in	O	O
vitro	O	O
activity	O	O
were	O	O
active	O	O
against	O	O
S	O	O
.	O	O
Regioselective	O	O
alkylation	O	O
of	O	O
tris	B-IUPAC	O
(	I-IUPAC	B-IUPAC
trimethylsilyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminouracil	I-IUPAC	I-IUPAC
provides	O	I-IUPAC
3	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminouracils	I-IUPAC	I-IUPAC
,	O	O
which	O	O
are	O	O
converted	O	O
to	O	O
1,8	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
disubstituted	I-MODIFIER	I-MODIFIER
xanthines	B-IUPAC	B-IUPAC
by	O	O
standard	O	O
procedures	O	O
.	O	O
Enzyme	O	O
inhibition	O	O
assays	O	O
against	O	O
rat	O	O
liver	O	O
DHFR	O	O
,	O	O
Pneumocystis	O	O
carinii	O	O
DHFR	O	O
,	O	O
and	O	O
the	O	O
bifunctional	O	O
DHFR	O	O
-	O	O
TS	O	O
enzyme	O	O
from	O	O
Toxoplasma	O	O
gondii	O	O
were	O	O
carried	O	O
out	O	O
,	O	O
and	O	O
the	O	O
selectivity	O	O
ratios	O	O
IC50	O	O
(	O	O
rat	O	O
)	O	O
/	O	O
IC50	O	O
(	O	O
P	O	O
.	O	O
Oxidation	O	O
using	O	O
tert	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
hydroperoxide	I-IUPAC	I-IUPAC
gave	O	I-IUPAC
2,5,6	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tris	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dibenzylphospho	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
myo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
inositol	I-IUPAC	I-IUPAC
,	O	O
and	O	O
deprotection	O	O
using	O	O
sodium	O	O
in	O	O
liquid	O	O
ammonia	O	O
gave	O	O
racemic	B-MODIFIER	O
myo	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
inositol	I-IUPAC	I-IUPAC
1,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trisphosphate	I-IUPAC	I-IUPAC
.	O	O
Reductive	O	O
deamination	O	O
of	O	O
compounds	O	O
1a	O	O
-	O	O
k	O	O
provides	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
quinoxalinecarbonitriles	I-IUPAC	I-IUPAC
5a	O	O
-	O	O
k	O	O
,	O	O
which	O	O
are	O	O
more	O	O
potent	O	O
,	O	O
while	O	O
selectivity	O	O
is	O	O
maintained	O	O
or	O	O
increased	O	O
in	O	O
some	O	O
derivatives	O	O
.	O	O
Whereas	O	O
dihydropyridine	O	O
enantiomers	O	O
usually	O	O
show	O	O
10-15	O	O
-	O	O
fold	O	O
difference	O	O
in	O	O
activity	O	O
,	O	O
the	O	O
enantiomers	O	O
of	O	O
dihydropyrimidine	O	O
3j	O	O
show	O	O
more	O	O
than	O	O
a	O	O
1000	O	O
-	O	O
fold	O	O
difference	O	O
in	O	O
activity	O	O
.	O	O
All	O	O
of	O	O
the	O	O
compounds	O	O
studied	O	O
displayed	O	O
lower	O	O
affinity	O	O
for	O	O
PNMT	O	O
than	O	O
1	O	O
,	O	O
and	O	O
nine	O	O
of	O	O
the	O	O
eleven	O	O
compounds	O	O
studied	O	O
showed	O	O
increased	O	O
,	O	O
rather	O	O
than	O	O
the	O	O
desired	O	O
decreased	O	O
,	O	O
affinity	O	O
for	O	O
the	O	O
alpha	O	O
2	O	O
-	O	O
adrenoceptor	O	O
.	O	O
Synthesis	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoxazaphosphorin	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxide	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
,	O	O
which	O	O
is	O	O
a	O	O
benzo	O	O
annulated	O	O
analog	O	O
of	O	O
cyclophosphamide	O	B-IUPAC
[	O	I-IUPAC
2	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
aminotetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxazaphosphorin	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxide	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
]	O	O
,	O	O
was	O	O
carried	O	O
out	O	O
in	O	O
order	O	O
to	O	O
test	O	O
for	O	O
possible	O	O
increased	O	O
antitumor	O	O
activity	O	O
relative	O	O
to	O	O
1	O	O
due	O	O
to	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
oxidatively	O	O
reactive	O	O
C	O	O
-	O	O
4	O	O
benzylic	O	O
site	O	O
in	O	O
2	O	O
.	O	O
The	O	O
monocyclic	O	O
derivatives	O	O
of	O	O
[	O	O
dPen1	O	O
,	O	O
Gln4	O	O
,	O	O
Lys	O	O
(	O	O
CHO	O	O
)	O	O
8	O	O
]	O	O
oxytocin	O	O
were	O	O
antagonists	O	O
of	O	O
oxytocin	O	O
which	O	O
was	O	O
attributed	O	O
to	O	O
the	O	O
dPen1	O	O
substitution	O	O
.	O	O
The	O	O
corresponding	O	O
hydroxy	B-IUPAC	O
derivatives	B-MODIFIER	O
were	O	O
less	O	O
active	O	O
of	O	O
inactive	O	O
.	O	O
Such	O	O
type	O	O
II	O	O
(	O	O
covalent	O	O
)	O	O
mechanism	O	O
-	O	O
based	O	O
inactivation	O	O
is	O	O
supported	O	O
by	O	O
protein	O	O
labeling	O	O
with	O	O
8	O	O
-	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
4	O	O
and	O	O
concomitant	O	O
release	O	O
of	O	O
bromide	O	O
and	O	O
fluoride	O	O
ions	O	O
.	O	O
Finally	O	O
,	O	O
from	O	O
series	O	O
II	O	O
,	O	O
we	O	O
have	O	O
obtained	O	O
a	O	O
weak	O	O
antagonist	O	O
in	O	O
the	O	O
F9	O	O
cellular	O	O
differentiation	O	O
assay	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
15	O	O
,	O	O
IC50	O	O
=	O	O
700	O	O
nM	O	O
)	O	O
.	O	O
In	O	O
general	O	O
,	O	O
the	O	O
in	O	O
vitro	O	O
tracheal	O	O
relaxant	O	O
action	O	O
and	O	O
positive	O	O
chronotropic	O	O
action	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propylxanthines	I-IUPAC	I-IUPAC
were	O	O
increased	O	O
by	O	O
substitutions	O	O
with	O	O
nonpolar	O	O
functional	O	O
groups	O	O
at	O	O
the	O	O
1	O	O
-	O	O
position	O	O
,	O	O
but	O	O
decreased	O	O
by	O	O
any	O	O
substitution	O	O
at	O	O
the	O	O
7	O	O
-	O	O
position	O	O
.	O	O
gondii	O	O
,	O	O
rat	O	O
liver	O	O
,	O	O
Lactobacillus	O	O
casei	O	O
,	O	O
and	O	O
Escherichia	O	O
coli	O	O
,	O	O
and	O	O
selected	O	O
analogues	O	O
were	O	O
evaluated	O	O
as	O	O
inhibitors	O	O
of	O	O
the	O	O
growth	O	O
of	O	O
tumor	O	O
cells	O	O
in	O	O
culture	O	O
.	O	O
[	B-IUPAC	O
1,5	I-IUPAC	O
]	I-IUPAC	O
Benzodiazepines	I-IUPAC	O
,	O	O
e.g.	O	O
,	O	O
14	O	O
(	O	O
2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrid	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzodiazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
)	O	O
(	O	O
IC50	O	O
=	O	O
4.9	O	O
nM	O	O
,	O	O
Ed50	O	O
=	O	O
0.03	O	O
mg	O	O
/	O	O
kg	O	O
po	O	O
)	O	O
,	O	O
were	O	O
found	O	O
to	O	O
possess	O	O
equivalent	O	O
or	O	O
superior	O	O
potency	O	O
to	O	O
the	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyridine	I-IUPAC	I-IUPAC
PAF	O	O
antagonist	O	O
UK	O	O
-	O	O
74,505	O	O
(	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrid	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbamoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
)	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O
A	O	O
structure	O	O
-	O	O
driven	O	O
approach	O	O
was	O	O
pursued	O	O
,	O	O
which	O	O
spanned	O	O
exploration	O	O
of	O	O
three	O	O
areas	O	O
:	O	O
(	O	O
1	O	O
)	O	O
5/6	O	O
fused	O	O
heterocycles	O	O
such	O	O
as	O	O
benzoxazole	O	O
,	O	O
benzothiophene	O	O
,	O	O
benzofuran	O	O
,	O	O
and	O	O
imidazopyridine	O	O
;	O	O
(	O	O
2	O	O
)	O	O
5	O	O
-	O	O
membered	O	O
heterocycles	O	O
,	O	O
including	O	O
oxadiazole	O	O
,	O	O
oxazole	O	O
,	O	O
thiazole	O	O
,	O	O
and	O	O
thiadiazole	O	O
,	O	O
with	O	O
pendant	O	O
aryl	O	O
groups	O	O
,	O	O
and	O	O
(	O	O
3	O	O
)	O	O
thioanilide	O	O
as	O	O
a	O	O
formal	O	O
equivalent	O	O
of	O	O
benzothiazole	O	O
.	O	O
The	O	O
prepared	O	O
compounds	O	O
are	O	O
heterocyclic	O	O
analogues	O	O
of	O	O
glutamic	O	O
acid	O	O
with	O	O
differing	O	O
chain	O	O
lengths	O	O
.	O	O
Each	O	O
of	O	O
these	O	O
molecules	O	O
satisfy	O	O
the	O	O
cannabinoid	O	O
pharmacophoric	O	O
requirements	O	O
,	O	O
i.e.	O	O
,	O	O
a	O	O
phenolic	O	O
oxygen	O	O
at	O	O
C1	O	O
and	O	O
a	O	O
side	O	O
chain	O	O
of	O	O
acceptable	O	O
length	O	O
at	O	O
C3	O	O
.	O	O
Their	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
(	O	O
SAR	O	O
)	O	O
for	O	O
inhibition	O	O
of	O	O
the	O	O
isolated	O	O
enzyme	O	O
more	O	O
closely	O	O
resemble	O	O
those	O	O
of	O	O
the	O	O
[	O	O
3,2	O	O
-	O	O
d	O	O
]	O	O
than	O	O
the	O	O
[	B-IUPAC	O
3,4	I-IUPAC	O
-	I-IUPAC	O
d	I-IUPAC	O
]	I-IUPAC	O
pyridopyrimidine	I-IUPAC	O
isomers	O	O
.	O	O
All	O	O
these	O	O
peptides	O	O
were	O	O
also	O	O
tested	O	O
as	O	O
product	O	O
inhibitors	O	O
for	O	O
the	O	O
plasma	O	O
and	O	O
lung	O	O
converting	O	O
enzymes	O	O
.	O	O
Hydrazinolysis	O	O
of	O	O
compound	O	O
4	O	O
gave	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
carbomethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thiophenoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butanone	I-IUPAC	I-IUPAC
oxime	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
,	O	O
which	O	O
was	O	O
used	O	O
for	O	O
the	O	O
construction	O	O
of	O	O
the	O	O
title	O	O
compound	O	O
2	O	O
by	O	O
modification	O	O
of	O	O
the	O	O
Boon	O	O
and	O	O
Leigh	O	O
procedure	O	O
.	O	O
Within	O	O
this	O	O
series	O	O
of	O	O
derivatives	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylsemicarbazono	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylenedioxyphenylacetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
proved	O	O
to	O	O
be	O	O
the	O	O
most	O	O
active	O	O
compound	O	O
.	O	O
The	O	O
derivatives	O	O
18a	O	O
-	O	O
e	O	O
were	O	O
obtained	O	O
by	O	O
introducing	O	O
on	O	O
the	O	O
nitrogen	O	O
of	O	O
amine	O	O
4	O	O
the	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylethyl	I-IUPAC	I-IUPAC
or	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylpropyl	I-IUPAC	I-IUPAC
groups	B-MODIFIER	B-MODIFIER
which	O	O
can	O	O
be	O	O
accommodated	O	O
by	O	O
the	O	O
D	O	O
-	O	O
2	O	O
receptor	O	O
lipophilic	O	O
sites	O	O
3C	O	O
and	O	O
pi	O	O
3	O	O
,	O	O
respectively	O	O
.	O	O
B	O	O
reported	O	O
here	O	O
,	O	O
the	O	O
Ile3	O	O
analogue	O	O
of	O	O
A	O	O
,	O	O
is	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
]	O	O
AVT	O	O
(	O	O
5	O	O
below	O	O
)	O	O
and	O	O
C	O	O
is	O	O
our	O	O
previously	O	O
reported	O	O
potent	O	O
nonselective	O	O
oxytocin	O	O
antagonist	O	O
/	O	O
AVP	O	O
V1	O	O
antagonist	O	O
,	O	O
[	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mercapto	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentamethylenepropionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyltyrosine	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ornithine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
vasotocin	I-IUPAC	I-IUPAC
(	O	O
d	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
[	O	O
Tyr	O	O
(	O	O
Me	O	O
)	O	O
2	O	O
]	O	O
OVT	O	O
)	O	O
.	O	O
Analogues	O	O
1-14	O	O
were	O	O
tested	O	O
for	O	O
agonistic	O	O
and	O	O
antagonistic	O	O
activities	O	O
by	O	O
antidiuretic	O	O
,	O	O
vasopressor	O	O
,	O	O
and	O	O
oxytocic	O	O
assays	O	O
in	O	O
rats	O	O
.	O	O
However	O	O
,	O	O
two	O	O
hydantoin	O	O
derivatives	O	O
,	O	O
5	O	O
and	O	O
8	O	O
,	O	O
were	O	O
totally	O	O
inactive	O	O
in	O	O
inhibiting	O	O
AlDH	O	O
in	O	O
vivo	O	O
.	O	O
Among	O	O
ArNH	O	O
(	O	O
CH2	O	O
)	O	O
n	O	O
compounds	O	O
with	O	O
n	O	O
=	O	O
1-3	O	O
and	O	O
either	O	O
2'	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxyphenyl	I-IUPAC	I-IUPAC
or	O	O
3'	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trimethoxyphenyl	I-IUPAC	I-IUPAC
as	O	O
the	O	O
Ar	O	O
moiety	O	O
,	O	O
activity	O	O
decreased	O	O
in	O	O
the	O	O
order	O	O
n	O	O
=	O	O
1	O	O
&	O	O
gt	O	O
;	O	O
n	O	O
=	O	O
2	O	O
&	O	O
gt	O	O
;	O	O
n	O	O
=	O	O
3	O	O
.	O	O
The	O	O
compounds	O	O
initially	O	O
synthesized	O	O
for	O	O
this	O	O
study	O	O
were	O	O
(	B-PARTIUPAC	O
+	I-PARTIUPAC	O
/	I-PARTIUPAC	O
-	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
anti	I-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
syn	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2a	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3,4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphtho	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bc	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
furan	I-IUPAC	I-IUPAC
(	O	O
4a	O	O
,	O	O
b	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
their	O	O
8	O	B-IUPAC
-	O	I-IUPAC
bromo	O	I-IUPAC
derivatives	O	B-MODIFIER
4c	O	O
,	O	O
d	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
phosphate	O	O
anion	O	O
,	O	O
derived	O	O
from	O	O
P	O	O
-	O	O
O	O	O
bond	O	O
cleavage	O	O
of	O	O
these	O	O
latter	O	O
compounds	O	O
,	O	O
is	O	O
only	O	O
observed	O	O
at	O	O
low	O	O
levels	O	O
after	O	O
a	O	O
long	O	O
period	O	O
of	O	O
hydrolysis	O	O
.	O	O
Improved	O	O
rationally	O	O
designed	O	O
lead	O	O
drug	O	O
structures	O	O
against	O	O
African	O	O
trypanosomiasis	O	O
,	O	O
Chagas	O	O
disease	O	O
,	O	O
and	O	O
leishmaniasis	O	O
were	O	O
obtained	O	O
against	O	O
trypanothione	O	O
reductase	O	O
from	O	O
Trypanosoma	O	O
cruzi	O	O
.	O	O
The	O	O
fact	O	O
that	O	O
the	O	O
naphthofurans	O	O
lack	O	O
LSD	O	O
-	O	O
like	O	O
activity	O	O
suggests	O	O
that	O	O
they	O	O
do	O	O
not	O	O
bind	O	O
to	O	O
the	O	O
serotonin	O	O
receptor	O	O
in	O	O
a	O	O
way	O	O
such	O	O
that	O	O
the	O	O
tricyclic	O	O
naphthofuran	O	O
nucleus	O	O
is	O	O
bioisosteric	O	O
with	O	O
,	O	O
and	O	O
directly	O	O
superimposable	O	O
upon	O	O
,	O	O
the	O	O
A	O	O
,	O	O
B	O	O
,	O	O
and	O	O
C	O	O
rings	O	O
of	O	O
LSD	O	O
.	O	O
The	O	O
reaction	O	O
of	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azapurine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
with	O	O
2,3,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosyl	I-IUPAC	I-IUPAC
chloride	I-IUPAC	I-IUPAC
in	O	O
the	O	O
presence	O	O
of	O	O
Linde	O	O
AW	O	O
-	O	O
500	O	O
molecular	O	O
sieve	O	O
gave	O	O
a	O	O
2	O	O
:	O	O
1	O	O
mixture	O	O
of	O	O
2	O	O
and	O	O
3	O	O
,	O	O
respectively	O	O
.	O	O
Compounds	O	O
R	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoromethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	O
THIQ	I-IUPAC	O
(	O	O
R	O	O
-	O	O
12	O	O
)	O	O
and	O	O
R	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoromethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
aminosulfonyl	I-IUPAC	I-IUPAC
-	I-IUPAC	O
THIQ	I-IUPAC	O
(	O	O
R	O	O
-	O	O
13	O	O
)	O	O
and	O	O
both	O	O
enantiomers	O	O
of	O	O
3	B-IUPAC	B-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
chloromethyl	I-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
7	I-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
nitro	I-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
THIQ	I-IUPAC	I-PARTIUPAC
(	O	I-PARTIUPAC
R	O	I-PARTIUPAC
-	O	I-PARTIUPAC
and	O	O
S	O	O
-	O	O
30	O	O
)	O	O
are	O	O
the	O	O
most	O	O
selective	O	O
inhibitors	O	O
in	O	O
this	O	O
study	O	O
and	O	O
display	O	O
selectivities	O	O
(	O	O
alpha	O	O
(	O	O
2	O	O
)	O	O
-	O	O
adrenoceptor	O	O
K	O	O
(	O	O
i	O	O
)	O	O
/	O	O
PNMT	O	O
K	O	O
(	O	O
i	O	O
)	O	O
)	O	O
greater	O	O
than	O	O
200	O	O
.	O	O
Compound	O	O
32	O	O
was	O	O
100	O	O
-	O	O
fold	O	O
selective	O	O
for	O	O
CCK	O	O
(	O	O
2	O	O
)	O	O
over	O	O
CCK	O	O
(	O	O
1	O	O
)	O	O
receptors	O	O
based	O	O
on	O	O
the	O	O
affinity	O	O
estimate	O	O
obtained	O	O
in	O	O
a	O	O
guinea	O	O
pig	O	O
pancreas	O	O
radioligand	O	O
binding	O	O
assay	O	O
(	O	O
pK	O	O
(	O	O
i	O	O
)	O	O
=	O	O
5.0	O	O
)	O	O
.	O	O
Systematic	O	O
point	O	O
mutations	O	O
led	O	O
to	O	O
cyclo	O	O
[	O	O
21,29	O	O
]	O	O
[	O	O
D	O	O
-	O	O
Cys	O	O
(	O	O
21	O	O
)	O	O
Nle	O	O
(	O	O
23	O	O
)	O	O
Cys	O	O
(	O	O
29	O	O
)	O	O
]	O	O
-	O	O
uPA	O	O
(	O	O
21	O	O
)	O	O
(	O	O
-	O	O
)	O	O
(	O	O
30	O	O
)	O	O
,	O	O
which	O	O
still	O	O
binds	O	O
to	O	O
uPAR	O	O
but	O	O
is	O	O
resistant	O	O
to	O	O
proteolytic	O	O
cleavage	O	O
,	O	O
e.g.	O	O
,	O	O
by	O	O
the	O	O
tumor	O	O
-	O	O
associated	O	O
serine	O	O
proteases	O	O
uPA	O	O
and	O	O
plasmin	O	O
,	O	O
and	O	O
is	O	O
stable	O	O
in	O	O
blood	O	O
serum	O	O
or	O	O
plasma	O	O
.	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Benzylpropylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorotetralin	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
behaved	O	O
as	O	O
an	O	O
inverse	O	O
agonist	O	O
at	O	O
both	O	O
DA	O	O
D2	O	O
and	O	O
D3	O	O
receptors	O	O
.	O	O
The	O	O
antidepressant	O	O
potential	O	O
of	O	O
the	O	O
lead	O	O
compounds	O	O
40	O	O
,	O	O
45	O	O
,	O	O
and	O	O
54	O	O
was	O	O
examined	O	O
by	O	O
means	O	O
of	O	O
the	O	O
forced	O	O
swimming	O	O
test	O	O
(	O	O
FST	O	O
)	O	O
in	O	O
rats	O	O
.	O	O
In	O	O
this	O	O
series	O	O
,	O	O
DA	O	O
agonist	O	O
activity	O	O
was	O	O
found	O	O
to	O	O
be	O	O
highly	O	O
dependent	O	O
on	O	O
the	O	O
size	O	O
of	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
,	O	O
the	O	O
saturation	O	O
level	O	O
of	O	O
the	O	O
six	O	O
-	O	O
membered	O	O
ring	O	O
,	O	O
and	O	O
the	O	O
mode	O	O
of	O	O
attachment	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminothiazole	I-IUPAC	I-IUPAC
ring	B-MODIFIER	O
.	O	O
The	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
,	O	O
10	O	O
,	O	O
displayed	O	O
Ki	O	O
values	O	O
of	O	O
680	O	O
and	O	O
273	O	O
nM	O	O
at	O	O
rat	O	O
A1	O	O
and	O	O
A2A	O	O
receptors	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
3.0	O	O
nM	O	O
at	O	O
human	O	O
A3	O	O
receptors	O	O
.	O	O
The	O	O
imidazole	O	O
ring	O	O
of	O	O
10	O	O
,	O	O
13	O	O
,	O	O
and	O	O
14	O	O
was	O	O
placed	O	O
'	O	O
upside	O	O
down	O	O
'	O	O
compared	O	O
with	O	O
1	O	O
,	O	O
making	O	O
the	O	O
interaction	O	O
of	O	O
the	O	O
N	O	O
(	O	O
pi	O	O
)	O	O
-	O	O
atom	O	O
with	O	O
Tyr431	O	O
possible	O	O
.	O	O
Further	O	O
,	O	O
the	O	O
predictive	O	O
ability	O	O
of	O	O
3D	O	O
QSAR	O	O
models	O	O
was	O	O
affirmed	O	O
by	O	O
predicting	O	O
the	O	O
activity	O	O
of	O	O
novel	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
naphthamidines	I-IUPAC	I-IUPAC
.	O	O
These	O	O
5,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
,	O	O
which	O	O
are	O	O
also	O	O
potential	O	O
prodrugs	O	O
to	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
azido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxythymidine	I-IUPAC	I-IUPAC
(	O	O
AZT	O	O
)	O	O
,	O	O
were	O	O
designed	O	O
in	O	O
an	O	O
effort	O	O
to	O	O
enhance	O	O
the	O	O
duration	O	O
of	O	O
action	O	O
,	O	O
lipophilicity	O	O
,	O	O
and	O	O
cephalic	O	O
delivery	O	O
to	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O
Cell	O	O
growth	O	O
inhibition	O	O
was	O	O
studied	O	O
with	O	O
two	O	O
L5178Y	O	O
murine	O	O
leukemia	O	O
cell	O	O
lines	O	O
,	O	O
parental	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
FdUrd	O	O
)	O	O
-	O	O
resistant	O	O
,	O	O
the	O	O
latter	O	O
70	O	O
-	O	O
fold	O	O
less	O	O
sensitive	O	O
toward	O	O
FdUrd	O	O
than	O	O
the	O	O
former	O	O
.	O	O
Authentic	O	O
(	O	O
2R	O	O
,	O	O
2	O	O
"	O	O
S	O	O
)	O	O
-	O	O
2	O	O
,	O	O
obtained	O	O
from	O	O
the	O	O
amide	O	O
formed	O	O
from	O	O
(	B-IUPAC	B-IUPAC
2S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypropionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
[	O	O
(	O	O
2S	O	O
)	O	O
-	O	O
5	O	O
]	O	O
and	O	O
(	B-IUPAC	O
2S	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
alaninol	I-IUPAC	O
by	O	O
diborane	O	O
reduction	O	O
,	O	O
facilitated	O	O
examination	O	O
of	O	O
stereochemical	O	O
aspects	O	O
of	O	O
this	O	O
process	O	O
.	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Fluorosulfonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
fluorosulfonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chlorobenzoyl	I-IUPAC	I-IUPAC
,	O	O
and	O	O
bromacetyl	B-IUPAC	O
derivatives	B-MODIFIER	O
of	O	O
two	O	O
parent	O	O
amines	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hypoxanthine	I-IUPAC	I-IUPAC
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
hypoxanthine	I-IUPAC	I-IUPAC
,	O	O
were	O	O
synthesized	O	O
for	O	O
evaluation	O	O
in	O	O
this	O	O
connection	O	O
.	O	O
The	O	O
new	O	O
compounds	O	O
were	O	O
evaluated	O	O
for	O	O
their	O	O
affinity	O	O
at	O	O
the	O	O
dopamine	O	O
D1	O	O
and	O	O
D2	O	O
receptors	O	O
.	O	O
All	O	O
analogs	O	O
were	O	O
agonists	O	O
in	O	O
the	O	O
mouse	O	O
vas	O	O
deferens	O	O
(	O	O
MVD	O	O
)	O	O
and	O	O
guinea	O	O
pig	O	O
ileum	O	O
(	O	O
GPI	O	O
)	O	O
smooth	O	O
muscle	O	O
bioassays	O	O
,	O	O
displaying	O	O
MVD	O	O
and	O	O
GPI	O	O
potencies	O	O
consistent	O	O
with	O	O
their	O	O
delta	O	O
and	O	O
mu	O	O
opioid	O	O
receptor	O	O
affinities	O	O
,	O	O
respectively	O	O
.	O	O
A	O	O
similar	O	O
oxidation	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
benzylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosylpurine	I-IUPAC	I-IUPAC
(	O	O
12a	O	O
and	O	O
12b	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
erythro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
purine	I-IUPAC	I-IUPAC
(	O	O
12c	O	O
)	O	O
with	O	O
MCPBA	O	O
gave	O	O
the	O	O
corresponding	O	O
sulfoxides	O	O
(	O	O
13a	O	O
-	O	O
c	O	O
)	O	O
,	O	O
which	O	O
on	O	O
further	O	O
oxidation	O	O
furnished	O	O
the	O	O
respective	O	O
sulfones	O	O
(	O	O
14a	O	O
-	O	O
c	O	O
)	O	O
.	O	O
Moreover	O	O
,	O	O
the	O	O
marked	O	O
effectiveness	O	O
of	O	O
the	O	O
angularly	O	O
-	O	O
cyclized	O	O
[	B-IUPAC	B-IUPAC
1,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiazino	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
i	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
purinones	I-IUPAC	I-IUPAC
,	O	O
which	O	O
constitute	O	O
an	O	O
interesting	O	O
new	O	O
class	O	O
of	O	O
inhibitors	O	O
,	O	O
together	O	O
with	O	O
the	O	O
weak	O	O
activity	O	O
of	O	O
linearly	O	O
-	O	O
cyclized	O	O
derivatives	O	O
,	O	O
allowed	O	O
us	O	O
to	O	O
characterize	O	O
more	O	O
precisely	O	O
the	O	O
lipophilic	O	O
region	O	O
of	O	O
the	O	O
enzyme	O	O
facing	O	O
the	O	O
N	O	O
(	O	O
1	O	O
)	O	O
-	O	O
C	O	O
(	O	O
2	O	O
)	O	O
positions	O	O
of	O	O
the	O	O
substrate	O	O
hypoxanthine	O	O
.	O	O
Low	O	O
-	O	O
energy	O	O
conformers	O	O
of	O	O
this	O	O
analog	O	O
could	O	O
only	O	O
be	O	O
effectively	O	O
superimposed	O	O
with	O	O
low	O	O
-	O	O
energy	O	O
conformers	O	O
of	O	O
the	O	O
parent	O	O
peptide	O	O
in	O	O
which	O	O
the	O	O
Phe3	O	O
side	O	O
chain	O	O
conformation	O	O
was	O	O
limited	O	O
to	O	O
chi	O	O
1	O	O
approximately	O	O
-	O	O
60	O	O
degrees	O	O
.	O	O
Many	O	O
of	O	O
these	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
thio	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinecarboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
were	O	O
orally	O	O
active	O	O
antihypertensive	O	O
agents	O	O
in	O	O
the	O	O
spontaneously	O	O
hypertensive	O	O
rat	O	O
.	O	O
Addition	O	O
of	O	O
aryllithium	O	O
or	O	O
aryl	O	O
Grignard	O	O
reagents	O	O
to	O	O
1a	O	O
,	O	O
b	O	O
and	O	O
formic	O	O
acid	O	O
reduction	O	O
afforded	O	O
cis	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arylspiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
cyclohexane	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
'	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isobenzofurans	I-IUPAC	I-IUPAC
]	I-IUPAC	O
3a	O	O
-	O	O
f	O	O
,	O	O
which	O	O
were	O	O
converted	O	O
to	O	O
secondary	O	O
amine	O	O
analogues	O	O
5a	O	O
-	O	O
e	O	O
.	O	O
The	O	O
in	O	O
vivo	O	O
results	O	O
show	O	O
that	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
carbamate	I-IUPAC	I-IUPAC
8	O	O
and	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxyphenyl	I-IUPAC	I-IUPAC
carbamate	I-IUPAC	I-IUPAC
9	O	O
in	O	O
this	O	O
series	O	O
had	O	O
the	O	O
best	O	O
anti	O	O
-	O	O
PCP	O	O
activity	O	O
by	O	O
both	O	O
intravenous	O	O
and	O	O
oral	O	O
administration	O	O
at	O	O
a	O	O
dosage	O	O
level	O	O
of	O	O
22	O	O
mol	O	O
and	O	O
33	O	O
micromol	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
,	O	O
respectively	O	O
.	O	O
Furthermore	O	O
,	O	O
the	O	O
involvement	O	O
of	O	O
the	O	O
4	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
aminobenzyl	I-PARTIUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
in	O	O
the	O	O
anticonvulsant	O	O
activity	O	O
was	O	O
evaluated	O	O
by	O	O
testing	O	O
derivative	O	O
23	O	O
.	O	O
For	O	O
the	O	O
2	B-IUPAC	B-MODIFIER
-	I-IUPAC	I-MODIFIER
amino	I-IUPAC	I-MODIFIER
-	O	I-MODIFIER
substituted	B-MODIFIER	I-MODIFIER
benzo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
h	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
chromen	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
,	O	O
a	O	O
morpholine	O	O
substituent	O	O
at	O	O
this	O	O
position	O	O
was	O	O
essential	O	O
for	O	O
activity	O	O
.	O	O
Upon	O	O
evaluation	O	O
of	O	O
these	O	O
final	O	O
nucleosides	O	O
,	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluorocytosine	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
51	O	O
was	O	O
found	O	O
to	O	O
be	O	O
the	O	O
most	O	O
potent	O	O
compound	O	O
among	O	O
those	O	O
tested	O	O
.	O	O
The	O	O
adenosine	O	O
antagonist	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinazolin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amine	I-IUPAC	I-IUPAC
(	O	O
CGS15943	O	O
)	O	O
binds	O	O
to	O	O
human	O	O
A3	O	O
receptors	O	O
with	O	O
high	O	O
affinity	O	O
(	O	O
Ki	O	O
=	O	O
14	O	O
nM	O	O
)	O	O
,	O	O
while	O	O
it	O	O
lacks	O	O
affinity	O	O
at	O	O
rat	O	O
A3	O	O
receptors	O	O
.	O	O
These	O	O
investigations	O	O
prompted	O	O
the	O	O
synthesis	O	O
and	O	O
evaluation	O	O
of	O	O
additional	O	O
diazepine	O	O
derivatives	O	O
,	O	O
which	O	O
are	O	O
described	O	O
in	O	O
the	O	O
following	O	O
paper	O	O
.	O	O
A	O	O
series	O	O
of	O	O
substituted	B-MODIFIER	B-MODIFIER
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydronaphthoquinones	I-IUPAC	I-IUPAC
,	O	O
hydroindoloquinones	O	O
,	O	O
benzofuran	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroquinones	I-IUPAC	I-IUPAC
,	O	O
and	O	O
benzothiophene	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroquinones	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
inhibitory	O	O
activity	O	O
against	O	O
5	O	B-IUPAC
-	O	I-IUPAC
lipoxygenase	O	I-IUPAC
.	O	O
Stereospecific	O	O
glycosylation	O	O
was	O	O
achieved	O	O
by	O	O
the	O	O
use	O	O
of	O	O
2	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
O	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
acetyl	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
3,4,6	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
tri	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
O	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
benzylglucopyranosyl	I-PARTIUPAC	I-IUPAC
and	O	O
-	B-PARTIUPAC	O
mannopyranosyl	I-PARTIUPAC	O
trichloroacetimidates	I-PARTIUPAC	O
as	O	O
donors	O	O
,	O	O
with	O	O
trimethylsilyl	B-IUPAC	O
trifluoromethanesulfonate	I-IUPAC	O
as	O	O
catalyst	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
molecular	O	O
sieves	O	O
at	O	O
-	O	O
78	O	O
degrees	O	O
C	O	O
.	O	O
Spiro	O	O
-	O	O
joining	O	O
of	O	O
the	O	O
phenyl	B-IUPAC	O
and	O	O
the	O	O
piperidine	B-IUPAC	O
rings	B-MODIFIER	O
into	O	O
a	O	O
spiro	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
isobenzofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperdine	I-IUPAC	I-IUPAC
]	I-IUPAC	O
ring	B-MODIFIER	O
system	I-MODIFIER	O
resulted	O	O
in	O	O
even	O	O
more	O	O
selective	O	O
compounds	O	O
.	O	O
Z	O	O
-	O	O
Olefin	O	O
4b	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminoadenallene	I-IUPAC	I-IUPAC
(	O	O
5c	O	O
)	O	O
are	O	O
substrates	O	O
for	O	O
adenosine	O	O
deaminase	O	O
.	O	O
Each	O	O
compound	O	O
's	O	O
potential	O	O
for	O	O
preventive	O	O
and	O	O
therapeutic	O	O
activity	O	O
stems	O	O
from	O	O
the	O	O
compound	O	O
's	O	O
potential	O	O
to	O	O
block	O	O
viral	O	O
attachment	O	O
,	O	O
virus	O	O
-	O	O
cell	O	O
fusion	O	O
,	O	O
or	O	O
virus	O	O
entry	O	O
into	O	O
host	O	O
cells	O	O
or	O	O
to	O	O
counter	O	O
potential	O	O
mechanisms	O	O
of	O	O
HCV	O	O
immune	O	O
evasion	O	O
.	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Ribofuranosyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
was	O	O
obtained	O	O
by	O	O
deacetylation	O	O
of	O	O
the	O	O
corresponding	O	O
tri	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
nucleoside	I-IUPAC	I-IUPAC
11	O	O
or	O	O
by	O	O
deacetylation	O	O
and	O	O
ammonolysis	O	O
of	O	O
the	O	O
blocked	O	O
ethyl	B-IUPAC	B-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
nucleoside	I-IUPAC	I-IUPAC
10	O	O
,	O	O
which	O	O
was	O	O
prepared	O	O
from	O	O
the	O	O
stannic	O	O
chloride	O	O
catalyzed	O	O
condensation	O	O
of	O	O
the	O	O
trimethylsilyl	B-IUPAC	O
derivative	B-MODIFIER	O
of	O	O
ethyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
.	O	O
Hydrolysis	O	O
of	O	O
6	O	O
and	O	O
11	O	O
yielded	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthracene	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
anthracene	I-IUPAC	I-IUPAC
(	O	O
12	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
This	O	O
orientation	O	O
can	O	O
explain	O	O
both	O	O
the	O	O
increased	O	O
relative	O	O
potency	O	O
and	O	O
the	O	O
maximum	O	O
effect	O	O
of	O	O
10	O	O
,	O	O
13	O	O
,	O	O
and	O	O
14	O	O
compared	O	O
with	O	O
1	O	O
.	O	O
1c	O	O
was	O	O
prepared	O	O
by	O	O
condensing	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
pivaloyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxaphosphorinane	I-IUPAC	I-IUPAC
with	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorouridine	I-IUPAC	I-IUPAC
(	O	O
FUdR	O	O
)	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
triphenylphosphine	O	O
and	O	O
diethyl	O	B-IUPAC
azodicarboxylate	O	I-IUPAC
.	O	O
Tests	O	O
for	O	O
time	O	O
-	O	O
dependent	O	O
loss	O	O
of	O	O
enzyme	O	O
activity	O	O
(	O	O
inactivation	O	O
)	O	O
were	O	O
performed	O	O
under	O	O
conditions	O	O
in	O	O
which	O	O
a	O	O
large	O	O
proportion	O	O
of	O	O
each	O	O
phosphokinase	O	O
was	O	O
present	O	O
as	O	O
an	O	O
enzyme	O	O
-	O	O
inhibitor	O	O
complex	O	O
.	O	O
We	O	O
have	O	O
synthesized	O	O
five	O	O
fluorinated	O	O
derivatives	O	O
of	O	O
WAY	O	O
100635	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
{	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperazino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
}	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
cyclohe	I-IUPAC	I-IUPAC
xaneca	I-IUPAC	I-IUPAC
rboxamide	I-IUPAC	I-IUPAC
(	O	O
4a	O	O
)	O	O
,	O	O
using	O	O
various	O	O
acids	O	O
in	O	O
place	O	O
of	O	O
the	O	O
cyclohexanecarboxylic	B-IUPAC	O
acid	I-IUPAC	O
(	O	O
CHCA	O	O
,	O	O
2a	O	O
)	O	O
in	O	O
the	O	O
reaction	O	O
scheme	O	O
.	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
arylsulfonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
furoxans	I-IUPAC	I-IUPAC
were	O	O
the	O	O
most	O	O
potent	O	O
derivatives	O	O
of	O	O
the	O	O
series	O	O
.	O	O
The	O	O
cytotoxicity	O	O
of	O	O
the	O	O
topoisomerase	O	O
II	O	O
inhibitor	O	O
etoposide	O	O
was	O	O
also	O	O
potentiated	O	O
.	O	O
Efforts	O	O
to	O	O
improve	O	O
the	O	O
antiallergic	O	O
potency	O	O
of	O	O
the	O	O
title	O	O
series	O	O
by	O	O
variation	O	O
of	O	O
the	O	O
indole	O	O
substituents	O	O
(	O	O
R1	O	O
,	O	O
R2	O	O
,	O	O
R	O	O
)	O	O
and	O	O
the	O	O
length	O	O
of	O	O
the	O	O
alkanoic	O	O
chain	O	O
(	O	O
n	O	O
=	O	O
1	O	O
,	O	O
2	O	O
,	O	O
3	O	O
)	O	O
led	O	O
to	O	O
the	O	O
selection	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
pyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
acetamide	I-IUPAC	I-IUPAC
45	O	O
,	O	O
out	O	O
of	O	O
41	O	O
compounds	O	O
.	O	O
It	O	O
is	O	O
concluded	O	O
that	O	O
H2	O	O
-	O	O
receptor	O	O
antagonist	O	O
affinity	O	O
in	O	O
the	O	O
mifentidine	O	O
series	O	O
is	O	O
mostly	O	O
dependent	O	O
on	O	O
the	O	O
availability	O	O
of	O	O
the	O	O
neutral	O	O
species	O	O
.	O	O
v	O	O
.	O	O
Out	O	O
of	O	O
a	O	O
library	O	O
of	O	O
over	O	O
500	O	O
compounds	O	O
,	O	O
including	O	O
randomly	O	O
selected	O	O
small	O	O
molecules	O	O
and	O	O
rationally	O	O
designed	O	O
small	O	O
molecules	O	O
,	O	O
only	O	O
the	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
boraadamantaneamine	I-IUPAC	I-IUPAC
compounds	B-MODIFIER	B-MODIFIER
and	O	O
structurally	O	O
similar	O	O
analogues	O	O
display	O	O
a	O	O
significant	O	O
antiproliferative	O	O
effect	O	O
on	O	O
the	O	O
CD81	O	O
-	O	O
enriched	O	O
astrocytes	O	O
relative	O	O
to	O	O
the	O	O
CD81	O	O
-	O	O
deficient	O	O
cell	O	O
lines	O	O
.	O	O
With	O	O
the	O	O
HL	O	O
-	O	O
60	O	O
assay	O	O
,	O	O
1a	O	O
and	O	O
1c	O	O
were	O	O
approximately	O	O
2	O	O
-	O	O
and	O	O
5	O	O
-	O	O
fold	O	O
less	O	O
active	O	O
,	O	O
respectively	O	O
,	O	O
than	O	O
trans	O	O
-	O	O
retinoic	O	O
acid	O	O
.	O	O
These	O	O
compounds	O	O
have	O	O
the	O	O
same	O	O
affinity	O	O
at	O	O
the	O	O
D	O	O
-	O	O
2	O	O
site	O	O
as	O	O
the	O	O
DA	O	O
agonist	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethylamine	I-IUPAC	I-IUPAC
(	O	O
2a	O	O
)	O	O
and	O	O
are	O	O
about	O	O
20	O	O
times	O	O
more	O	O
selective	O	O
than	O	O
DA	O	O
for	O	O
this	O	O
binding	O	O
site	O	O
.	O	O
Conversion	O	O
of	O	O
(	O	O
+	O	O
)	O	O
-	O	O
1f	O	O
to	O	O
its	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
desoxy	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
(	O	O
+	O	O
)	O	O
-	O	O
2d	O	O
resulted	O	O
in	O	O
a	O	O
27.5	O	O
-	O	O
fold	O	O
loss	O	O
in	O	O
affinity	O	O
.	O	O
A	O	O
number	O	O
of	O	O
the	O	O
compounds	O	O
inhibited	O	O
cholesterol	O	O
and	O	O
free	O	O
fatty	O	O
acid	O	O
biosynthesis	O	O
from	O	O
[	O	O
1-14	O	O
C	O	O
]	O	O
acetate	O	O
in	O	O
rat	O	O
liver	O	O
slices	O	O
in	O	O
vitro	O	O
.	O	O
The	O	O
derived	O	O
D2A	O	O
receptor	O	O
model	O	O
can	O	O
accommodate	O	O
both	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
of	O	O
2	O	O
and	O	O
the	O	O
C11	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
of	O	O
11	O	O
[	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethylaporphine	I-IUPAC	I-IUPAC
]	O	O
.	O	O
By	O	O
contrast	O	O
,	O	O
2,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dibromopropene	I-IUPAC	I-IUPAC
(	O	O
19	O	O
)	O	O
afforded	O	O
smoothly	O	O
(	B-IUPAC	O
E	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
and	O	O
(	B-IUPAC	B-IUPAC
Z	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibromocyclopropane	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
esters	I-IUPAC	I-IUPAC
24	O	O
+	O	O
25	O	O
.	O	O
The	O	O
compounds	O	O
were	O	O
tested	O	O
in	O	O
vitro	O	O
together	O	O
with	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolepropionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
ABPA	O	O
)	O	O
as	O	O
inhibitors	O	O
of	O	O
the	O	O
binding	O	O
of	O	O
radioactive	O	O
-	O	O
labeled	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolepropionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
AMPA	O	O
)	O	O
to	O	O
rat	O	O
brain	O	O
synaptic	O	O
membranes	O	O
.	O	O
The	O	O
lead	O	O
compound	O	O
of	O	O
a	O	O
new	O	O
series	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
ethers	I-IUPAC	I-IUPAC
,	O	O
the	O	O
azetidine	O	O
derivative	O	O
A	O	O
-	O	O
85380	O	O
(	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azetidinylmethoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
)	O	O
,	O	O
is	O	O
a	O	O
potent	O	O
and	O	O
selective	O	O
ligand	O	O
for	O	O
the	O	O
human	O	O
alpha4beta2	O	O
nicotinic	O	O
acetylcholine	O	O
receptor	O	O
(	O	O
nAChR	O	O
)	O	O
subtype	O	O
.	O	O
The	O	O
N	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
6	I-MODIFIER	I-MODIFIER
glycosylated	I-MODIFIER	I-MODIFIER
imidazo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isothiazoles	I-IUPAC	I-IUPAC
also	O	O
were	O	O
inactive	O	O
in	O	O
antiproliferative	O	O
and	O	O
cytotoxicity	O	O
assays	O	O
,	O	O
except	O	O
for	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosylimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isothiazole	I-IUPAC	I-IUPAC
(	O	O
15a	O	O
)	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
isothiaz	I-IUPAC	I-IUPAC
ole	I-IUPAC	O
(	O	O
5e	O	O
)	O	O
,	O	O
which	O	O
showed	O	O
moderate	O	O
inhibition	O	O
of	O	O
L1210	O	O
cell	O	O
growth	O	O
.	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Aza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroretinoids	I-IUPAC	I-IUPAC
(	O	O
12	O	O
,	O	O
13	O	O
)	O	O
were	O	O
synthesized	O	O
from	O	O
benzeneamines	O	O
and	O	O
the	O	O
acyl	B-IUPAC	O
cyano	I-IUPAC	O
or	O	O
bromo	B-IUPAC	O
derivative	B-MODIFIER	O
of	O	O
the	O	O
monomethyl	O	O
ester	O	O
of	O	O
3,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
octatriene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
.	O	O
It	O	O
is	O	O
also	O	O
a	O	O
potent	O	O
inhibitor	O	O
of	O	O
both	O	O
cAMP	O	O
phosphodiesterase	O	O
and	O	O
platelet	O	O
aggregation	O	O
.	O	O
Aromatic	O	O
substitution	O	O
patterns	O	O
were	O	O
varied	O	O
with	O	O
the	O	O
goal	O	O
of	O	O
identifying	O	O
a	O	O
compound	O	O
having	O	O
affinities	O	O
for	O	O
the	O	O
D	O	O
(	O	O
2	O	O
)	O	O
and	O	O
D	O	O
(	O	O
4	O	O
)	O	O
receptors	O	O
in	O	O
a	O	O
ratio	O	O
similar	O	O
to	O	O
that	O	O
observed	O	O
for	O	O
the	O	O
atypical	O	O
neuroleptic	O	O
clozapine	O	O
.	O	O
carinii	O	O
DHFR	O	O
,	O	O
0.57	O	O
nM	O	O
against	O	O
M	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
the	O	O
(	B-IUPAC	B-IUPAC
diethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
on	O	O
the	O	O
piperidine	O	O
ring	O	O
conferred	O	O
a	O	O
much	O	O
larger	O	O
set	O	O
of	O	O
minimum	O	O
-	O	O
energy	O	O
conformations	O	O
on	O	O
II	O	O
.	O	O
Compounds	O	O
5	O	O
and	O	O
6	O	O
also	O	O
demonstrated	O	O
modest	O	O
anti	O	O
-	O	O
hepatitis	O	O
B	O	O
virus	O	O
activity	O	O
against	O	O
DHBV	O	O
(	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
19.9-23.6	O	O
microM	O	O
)	O	O
.	O	O
These	O	O
compounds	O	O
were	O	O
designed	O	O
to	O	O
improve	O	O
the	O	O
cell	O	O
penetration	O	O
of	O	O
a	O	O
previously	O	O
reported	O	O
series	O	O
of	O	O
2,4	B-IUPAC	B-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
diamino	I-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
6	I-IUPAC	I-PARTIUPAC
-	O	I-PARTIUPAC
substituted	B-MODIFIER	I-PARTIUPAC
-	O	I-PARTIUPAC
pyrido	B-IUPAC	I-PARTIUPAC
[	I-IUPAC	I-PARTIUPAC
2,3	I-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
d	I-IUPAC	I-PARTIUPAC
]	I-IUPAC	I-PARTIUPAC
pyrimidines	I-IUPAC	I-PARTIUPAC
which	O	O
had	O	O
shown	O	O
significant	O	O
potency	O	O
and	O	O
remarkable	O	O
selectivity	O	O
for	O	O
Toxoplasma	O	O
gondii	O	O
dihydrofolate	O	O
reductase	O	O
(	O	O
DHFR	O	O
)	O	O
,	O	O
but	O	O
had	O	O
much	O	O
lower	O	O
inhibitory	O	O
effects	O	O
on	O	O
the	O	O
growth	O	O
of	O	O
T	O	O
.	O	O
Replacing	O	O
the	O	O
A1	O	O
side	O	O
chain	O	O
of	O	O
this	O	O
derivative	O	O
with	O	O
a	O	O
tert	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
and	O	O
replacing	O	O
the	O	O
X	O	O
position	O	O
with	O	O
glutamine	O	O
led	O	O
to	O	O
a	O	O
derivative	O	O
with	O	O
an	O	O
IC50	O	O
of	O	O
2.8	O	O
nM	O	O
and	O	O
an	O	O
EC50	O	O
of	O	O
0.19	O	O
microM	O	O
,	O	O
a	O	O
26	O	O
-	O	O
fold	O	O
improvement	O	O
over	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
*	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
*	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mercaptopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
valyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoquinolinyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methionine	I-IUPAC	I-IUPAC
.	O	O
Substitution	O	O
of	O	O
the	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
by	O	O
ethyl	B-IUPAC	O
,	O	O
butyl	B-IUPAC	B-IUPAC
,	O	O
methoxymethyl	B-IUPAC	B-IUPAC
,	O	O
(	B-IUPAC	B-IUPAC
propyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
butyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
groups	B-MODIFIER	B-MODIFIER
somewhat	O	O
improved	O	O
the	O	O
original	O	O
anti	O	O
-	O	O
HIV	O	O
-	O	O
1	O	O
activity	O	O
of	O	O
HEPT	O	O
.	O	O
A	O	O
complete	O	O
[	O	O
i	O	O
-	O	O
(	O	O
i	O	O
+	O	O
3	O	O
)	O	O
]	O	O
scan	O	O
of	O	O
cyclo	O	O
(	O	O
i	O	O
,	O	O
i	O	O
+	O	O
3	O	O
)	O	O
[	O	O
MeTyr1	O	O
,	O	O
Ala15	O	O
,	O	O
Glui	O	O
,	O	O
Lys	O	O
(	O	O
i	O	O
+	O	O
3	O	O
)	O	O
,	O	O
Nle27	O	O
]	O	O
-	O	O
hGHRH	O	O
(	O	O
1-29	O	O
)	O	O
-	O	O
NH2	O	O
was	O	O
then	O	O
produced	O	O
in	O	O
order	O	O
to	O	O
test	O	O
the	O	O
effects	O	O
of	O	O
a	O	O
Glu	O	O
-	O	O
to	O	O
-	O	O
Lys	O	O
lactam	O	O
bridge	O	O
at	O	O
all	O	O
points	O	O
in	O	O
the	O	O
peptide	O	O
.	O	O
We	O	O
have	O	O
further	O	O
modified	O	O
the	O	O
flavone	O	O
structure	O	O
to	O	O
achieve	O	O
a	O	O
degree	O	O
of	O	O
selectivity	O	O
for	O	O
cloned	O	O
human	O	O
brain	O	O
A3	O	O
receptors	O	O
,	O	O
determined	O	O
in	O	O
competitive	O	O
binding	O	O
assays	O	O
versus	O	O
[	O	O
125I	O	O
]	O	O
AB	O	O
-	O	O
MECA	O	O
[	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenosine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylur	I-IUPAC	I-IUPAC
onamide	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	O	I-IUPAC
.	O	I-IUPAC
N	B-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
omega	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
Aminoalkyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
2,2,5,5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
tetramethyl	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
3	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
pyrroline	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
or	O	I-IUPAC
-	B-PARTIUPAC	I-IUPAC
pyrrolidine	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
3	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
carboxamides	I-PARTIUPAC	I-IUPAC
were	O	O
acylated	O	O
on	O	O
the	O	O
primary	O	O
amino	O	O
group	O	O
of	O	O
the	O	O
side	O	O
chain	O	O
by	O	O
means	O	O
of	O	O
reactive	O	O
acid	O	O
derivatives	O	O
(	O	O
acid	O	O
chlorides	O	O
,	O	O
activated	O	O
esters	O	O
,	O	O
phthalic	O	O
anhydrides	O	O
,	O	O
phthalimide	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoxazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
)	O	O
or	O	O
they	O	O
were	O	O
alkylated	O	O
by	O	O
forming	O	O
the	O	O
Schiff	O	O
bases	O	O
and	O	O
subsequent	O	O
sodium	O	O
borohydride	O	O
reduction	O	O
.	O	O
Analysis	O	O
of	O	O
the	O	O
SAR	O	O
established	O	O
for	O	O
previous	O	O
papers	O	O
in	O	O
this	O	O
series	O	O
prompted	O	O
the	O	O
design	O	O
and	O	O
synthesis	O	O
of	O	O
(	B-IUPAC	B-IUPAC
Z	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyloxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pent	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
enoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
3	O	O
which	O	O
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
moderately	O	O
active	O	O
inhibitor	O	O
of	O	O
the	O	O
binding	O	O
of	O	O
[	O	O
125I	O	O
]	O	O
ET	O	O
-	O	O
1	O	O
to	O	O
ETA	O	O
receptors	O	O
with	O	O
an	O	O
IC50	O	O
of	O	O
6	O	O
microM	O	O
.	O	O
The	O	O
mechanism	O	O
of	O	O
anticonvulsant	O	O
action	O	O
of	O	O
these	O	O
agents	O	O
is	O	O
not	O	O
clear	O	O
although	O	O
it	O	O
appears	O	O
that	O	O
interaction	O	O
at	O	O
the	O	O
[	O	O
3H	O	O
]	O	O
1	O	O
sites	O	O
may	O	O
be	O	O
involved	O	O
.	O	O
Hydroxymethyl	O	O
compound	O	O
14	O	O
was	O	O
obtained	O	O
by	O	O
deamination	O	O
of	O	O
reported	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diaminopyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methanol	I-IUPAC	I-IUPAC
(	O	O
12a	O	O
)	O	O
in	O	O
refluxing	O	O
1	O	O
N	O	O
NaOH	O	O
.	O	O
Similarly	O	O
,	O	O
intraperitoneal	O	O
administration	O	O
of	O	O
(	O	O
FMS	O	O
)	O	O
(	O	O
3	O	O
)	O	O
-	O	O
insulin	O	O
to	O	O
healthy	O	O
rats	O	O
had	O	O
a	O	O
prolonged	O	O
glucose	O	O
-	O	O
lowering	O	O
effect	O	O
.	O	O
At	O	O
6	O	O
h	O	O
postinjection	O	O
of	O	O
[	O	O
131I	O	O
]	O	O
MIH	O	O
-	O	O
NGA	O	O
,	O	O
80%	O	O
of	O	O
the	O	O
injected	O	O
radioactivity	O	O
was	O	O
recovered	O	O
in	O	O
the	O	O
urine	O	O
.	O	O
Our	O	O
results	O	O
highlight	O	O
the	O	O
importance	O	O
of	O	O
the	O	O
doubly	O	O
negative	O	O
charge	O	O
borne	O	O
by	O	O
the	O	O
pY	O	O
+	O	O
1	O	O
amino	O	O
acid	O	O
in	O	O
accordance	O	O
with	O	O
the	O	O
interactions	O	O
observed	O	O
in	O	O
the	O	O
complex	O	O
crystallized	O	O
between	O	O
mAZ	O	O
-	O	O
pTyr	O	O
-	O	O
(	O	O
alphaMe	O	O
)	O	O
pTyr	O	O
-	O	O
Asn	O	O
-	O	O
NH2	O	O
and	O	O
the	O	O
Grb2	O	O
SH2	O	O
domain	O	O
.	O	O
The	O	O
N	O	B-IUPAC
-	O	I-IUPAC
methyl	O	I-IUPAC
analogue	O	B-MODIFIER
2	O	O
and	O	O
N	O	B-IUPAC
-	O	I-IUPAC
formyl	O	I-IUPAC
analogue	O	B-MODIFIER
3	O	O
were	O	O
prepared	O	O
from	O	O
11	O	O
and	O	O
1	O	O
,	O	O
respectively	O	O
.	O	O
A	O	O
number	O	O
of	O	O
such	O	O
compounds	O	O
were	O	O
synthesized	O	O
,	O	O
including	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopropylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypropyl	I-IUPAC	I-IUPAC
dihydrogen	I-IUPAC	I-IUPAC
phosphorothioate	I-IUPAC	I-IUPAC
(	O	O
11	O	O
,	O	O
n	O	O
equals	O	O
3	O	O
)	O	O
,	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypropylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
dihydrogen	I-IUPAC	I-IUPAC
phosphorothioate	I-IUPAC	I-IUPAC
(	O	O
20	O	O
)	O	O
and	O	O
its	O	O
propyl	B-IUPAC	O
homolog	B-MODIFIER	O
26	O	O
,	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxytrimethylene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoethyl	I-IUPAC	I-IUPAC
dihydrogen	I-IUPAC	I-IUPAC
phosphorothioate	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
(	O	O
40	O	O
)	O	O
,	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propylaminoi1ethyl	I-IUPAC	I-IUPAC
dihydrogen	I-IUPAC	I-IUPAC
phosphorothioate	I-IUPAC	I-IUPAC
(	O	O
44	O	O
)	O	O
,	O	O
and	O	O
sodium	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypropyl	I-IUPAC	I-IUPAC
hydrogen	I-IUPAC	I-IUPAC
phosphorothioate	I-IUPAC	I-IUPAC
(	O	O
49	O	O
)	O	O
.	O	O
Finally	O	O
,	O	O
the	O	O
iron	O	O
-	O	O
clearing	O	O
efficiency	O	O
of	O	O
the	O	O
(	O	O
S	O	O
)	O	O
-	O	O
4'	O	O
-	O	O
(	O	O
HO	O	O
)	O	O
-	O	O
DADFT	O	O
conjugates	O	O
was	O	O
determined	O	O
in	O	O
a	O	O
bile	O	O
-	O	O
duct	O	O
-	O	O
cannulated	O	O
rodent	O	O
model	O	O
.	O	O
A	O	O
trend	O	O
which	O	O
suggested	O	O
that	O	O
more	O	O
lipophilic	O	O
transposed	O	O
amides	O	O
were	O	O
needed	O	O
to	O	O
increase	O	O
oral	O	O
activity	O	O
was	O	O
exploited	O	O
with	O	O
some	O	O
success	O	O
and	O	O
has	O	O
led	O	O
to	O	O
the	O	O
discovery	O	O
of	O	O
5q	O	O
(	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethylbutyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbamoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethylindol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
sulfonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzamide	I-IUPAC	I-IUPAC
)	O	I-IUPAC
,	O	O
a	O	O
transposed	O	O
amide	O	O
with	O	O
subnanomolar	O	O
affinity	O	O
for	O	O
the	O	O
leukotriene	O	O
receptor	O	O
and	O	O
an	O	O
oral	O	O
ED50	O	O
of	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
in	O	O
a	O	O
model	O	O
of	O	O
asthma	O	O
in	O	O
guinea	O	O
pigs	O	O
.	O	O
The	O	O
selectivity	O	O
of	O	O
9	O	O
as	O	O
a	O	O
glial	O	O
GABA	O	O
uptake	O	O
inhibitor	O	O
was	O	O
largely	O	O
lost	O	O
by	O	O
replacing	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
9	O	O
by	O	O
an	O	O
ethyl	B-IUPAC	O
group	B-MODIFIER	O
,	O	O
compound	O	O
10	O	O
being	O	O
an	O	O
almost	O	O
equipotent	O	O
inhibitor	O	O
of	O	O
glial	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
280	O	O
microM	O	O
)	O	O
and	O	O
neuronal	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
400	O	O
microM	O	O
)	O	O
GABA	O	O
uptake	O	O
.	O	O
Silylation	O	O
of	O	O
1	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
xanthines	B-IUPAC	B-IUPAC
followed	O	O
by	O	O
alkylation	O	O
at	O	O
the	O	O
7	O	O
-	O	O
position	O	O
provides	O	O
a	O	O
facile	O	O
route	O	O
to	O	O
paraxanthine	O	O
analogs	O	O
.	O	O
These	O	O
chlorins	O	O
on	O	O
reacting	O	O
with	O	O
osmium	O	O
tetraoxide	O	O
produced	O	O
the	O	O
corresponding	O	O
vic	O	O
-	O	O
dihydroxybacteriochlorins	O	O
.	O	O
Optimization	O	O
of	O	O
structural	O	O
parameters	O	O
for	O	O
this	O	O
activity	O	O
yielded	O	O
compounds	O	O
54	O	O
,	O	O
55	O	O
,	O	O
34	O	O
,	O	O
65	O	O
,	O	O
and	O	O
22	O	O
,	O	O
which	O	O
were	O	O
selected	O	O
for	O	O
further	O	O
study	O	O
in	O	O
the	O	O
renal	O	O
hypertensive	O	O
dog	O	O
(	O	O
RHD	O	O
)	O	O
.	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Pentyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylhydantoin	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
,	O	O
the	O	O
most	O	O
potent	O	O
binder	O	O
to	O	O
the	O	O
sodium	O	O
channel	O	O
in	O	O
this	O	O
study	O	O
,	O	O
had	O	O
the	O	O
same	O	O
affinity	O	O
as	O	O
DPH	O	O
(	O	O
IC50	O	O
=	O	O
40	O	O
microM	O	O
)	O	O
,	O	O
revealing	O	O
that	O	O
one	O	O
phenyl	O	O
ring	O	O
is	O	O
sufficient	O	O
for	O	O
good	O	O
interactions	O	O
.	O	O
While	O	O
acetylation	O	O
of	O	O
the	O	O
N	O	O
-	O	O
terminus	O	O
of	O	O
16	O	O
(	O	O
i.e.	O	O
,	O	O
18	O	O
)	O	O
or	O	O
of	O	O
[	O	O
CalphaMe	O	O
-	O	O
Leu27	O	O
]	O	O
astressin	O	O
(	O	O
i.e.	O	O
,	O	O
19	O	O
)	O	O
did	O	O
not	O	O
have	O	O
a	O	O
significant	O	O
effect	O	O
on	O	O
in	O	O
vitro	O	O
potency	O	O
,	O	O
elongation	O	O
of	O	O
the	O	O
N	O	O
-	O	O
terminus	O	O
by	O	O
one	O	O
or	O	O
three	O	O
residues	O	O
in	O	O
addition	O	O
to	O	O
acetylation	O	O
resulted	O	O
in	O	O
cyclo	O	O
(	O	O
30-33	O	O
)	O	O
[	O	O
DPhe12	O	O
,	O	O
Nle21	O	O
,	O	O
CalphaMe	O	O
-	O	O
Leu27	O	O
,	O	O
Glu3	O	O
0	O	O
,	O	O
DHis32	O	O
,	O	O
Lys33	O	O
,	O	O
Nle38	O	O
]	O	O
Ac	O	O
-	O	O
hCRF	O	O
(	O	O
11-41	O	O
)	O	O
(	O	O
21	O	O
)	O	O
,	O	O
cyclo	O	O
(	O	O
30-33	O	O
)	O	O
[	O	O
DPhe12	O	O
,	O	O
Nle21	O	O
,	O	O
CalphaMe	O	O
-	O	O
Leu27	O	O
,	O	O
Glu30	O	O
,	O	O
Lys33	O	O
,	O	O
Nle38	O	O
]	O	O
Ac	O	O
-	O	O
hCRF	O	O
(	O	O
9-41	O	O
)	O	O
(	O	O
22	O	O
)	O	O
,	O	O
and	O	O
cyclo	O	O
(	O	O
30-33	O	O
)	O	O
[	O	O
DPhe12	O	O
,	O	O
Nle21	O	O
,	O	O
CalphaMe	O	O
-	O	O
Leu27	O	O
,	O	O
Glu30	O	O
,	O	O
DHis32	O	O
,	O	O
Lys33	O	O
,	O	O
Nle38	O	O
]	O	O
Ac	O	O
-	O	O
hCRF	O	O
(	O	O
9-41	O	O
)	O	O
(	O	O
23	O	O
)	O	O
that	O	O
were	O	O
longer	O	O
-	O	O
acting	O	O
than	O	O
6	O	O
and	O	O
8	O	O
(	O	O
ca.	O	O
2	O	O
h	O	O
inhibition	O	O
of	O	O
ACTH	O	O
secretion	O	O
at	O	O
25	O	O
micrograms	O	O
/	O	O
adrenalectomized	O	O
rat	O	O
)	O	O
.	O	O
N	O	B-IUPAC
-	O	I-IUPAC
Methylacetazolamide	O	I-IUPAC
was	O	O
shown	O	O
to	O	O
be	O	O
active	O	O
topically	O	O
in	O	O
reducing	O	O
intraocular	O	O
pressure	O	O
(	O	O
IOP	O	O
)	O	O
to	O	O
a	O	O
small	O	O
but	O	O
statistically	O	O
significant	O	O
level	O	O
in	O	O
the	O	O
normotensive	O	O
rabbit	O	O
eye	O	O
.	O	O
This	O	O
hypothesis	O	O
can	O	O
be	O	O
tested	O	O
by	O	O
using	O	O
two	O	O
photoaffinity	O	O
probes	O	O
that	O	O
differ	O	O
only	O	O
in	O	O
the	O	O
N	O	O
-	O	O
unsubstituted	O	O
imine	O	O
vs	O	O
negatively	O	O
charged	O	O
(	O	O
delta	O	O
(	O	O
-	O	O
)	O	O
)	O	O
tip	O	O
.	O	O
Those	O	O
compounds	O	O
,	O	O
structurally	O	O
related	O	O
to	O	O
previously	O	O
described	O	O
potassium	O	O
channel	O	O
openers	O	O
such	O	O
as	O	O
the	O	O
benzothiadiazine	O	O
dioxide	O	O
BPDZ	O	O
73	O	O
,	O	O
were	O	O
tested	O	O
as	O	O
putative	O	O
K	O	O
(	O	O
ATP	O	O
)	O	O
channel	O	O
activators	O	O
on	O	O
the	O	O
pancreatic	O	O
endocrine	O	O
tissue	O	O
and	O	O
on	O	O
the	O	O
vascular	O	O
smooth	O	O
muscle	O	O
tissue	O	O
.	O	O
Further	O	O
evaluation	O	O
of	O	O
the	O	O
growth	O	O
inhibitory	O	O
activity	O	O
of	O	O
3	O	O
against	O	O
the	O	O
MTX	O	O
-	O	O
resistant	O	O
subline	O	O
of	O	O
CCRF	O	O
-	O	O
CEM	O	O
cells	O	O
(	O	O
R30dm	O	O
)	O	O
with	O	O
decreased	O	O
FPGS	O	O
indicated	O	O
that	O	O
poly	O	O
-	O	O
gamma	O	O
-	O	O
glutamylation	O	O
was	O	O
important	O	O
for	O	O
its	O	O
action	O	O
.	O	O
DPEAP	O	O
(	O	O
2	O	O
)	O	O
,	O	O
a	O	O
pyrrolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amine	I-IUPAC	I-IUPAC
substituted	O	B-MODIFIER
at	O	O
the	O	O
amino	O	O
group	O	O
(	O	O
N	O	O
(	O	O
4	O	O
)	O	O
)	O	O
,	O	O
was	O	O
found	O	O
to	O	O
exhibit	O	O
high	O	O
affinity	O	O
for	O	O
human	O	O
A	O	O
(	O	O
3	O	O
)	O	O
ARs	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
28	O	O
nM	O	O
)	O	O
,	O	O
whereas	O	O
N	O	O
(	O	O
4	O	O
)	O	O
-	O	O
unsubstituted	O	O
analogues	O	O
were	O	O
inactive	O	O
.	O	O
All	O	O
compounds	O	O
tested	O	O
,	O	O
except	O	O
for	O	O
13	O	O
and	O	O
14	O	O
,	O	O
exhibited	O	O
high	O	O
affinity	O	O
(	O	O
Ki	O	O
=	O	O
0.035-0.22	O	O
mM	O	O
range	O	O
relative	O	O
to	O	O
deoxyuridine	O	O
,	O	O
Ki	O	O
=	O	O
0.125	O	O
)	O	O
for	O	O
the	O	O
murine	O	O
NBMPR	O	O
-	O	O
sensitive	O	O
erythrocyte	O	O
nucleoside	O	O
transport	O	O
system	O	O
,	O	O
suggesting	O	O
that	O	O
these	O	O
iodohydrins	O	O
are	O	O
good	O	O
permeants	O	O
of	O	O
cell	O	O
membranes	O	O
.	O	O
Modeling	O	O
of	O	O
ligand	O	O
-	O	O
receptor	O	O
binding	O	O
site	O	O
interactions	O	O
yielded	O	O
an	O	O
interaction	O	O
site	O	O
model	O	O
for	O	O
the	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
that	O	O
describes	O	O
a	O	O
gradual	O	O
change	O	O
in	O	O
binding	O	O
mode	O	O
for	O	O
C11	B-PARTIUPAC	O
-	I-PARTIUPAC	O
hydroxy	I-PARTIUPAC	O
,	O	O
-	B-PARTIUPAC	B-PARTIUPAC
methoxy	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
and	O	O
-	B-PARTIUPAC	O
phenyl	I-PARTIUPAC	O
-	O	O
substituted	B-MODIFIER	O
derivatives	I-MODIFIER	O
.	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Dimethylthiocarbamoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
(	O	O
6a	O	O
-	O	O
e	O	O
)	O	O
rearranged	O	O
to	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylcarbamoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thio	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
(	O	O
7a	O	O
-	O	O
e	O	O
)	O	O
in	O	O
good	O	O
yields	O	O
.	O	O
Thus	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
estradiol	I-IUPAC	I-IUPAC
1	O	O
exhibited	O	O
similar	O	O
estrogen	O	O
receptor	O	O
affinity	O	O
as	O	O
the	O	O
catechol	O	O
estrogen	O	O
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyestradiol	I-IUPAC	I-IUPAC
,	O	O
and	O	O
may	O	O
prove	O	O
useful	O	O
in	O	O
the	O	O
examination	O	O
of	O	O
the	O	O
biological	O	O
effects	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyestrogens	I-IUPAC	I-IUPAC
.	O	O
Their	O	O
antiantidiuretic	O	O
pA2	O	O
values	O	O
are	O	O
as	O	O
follows	O	O
:	O	O
1	O	O
,	O	O
8.24	O	O
+	O	O
/	O	O
-	O	O
0.08	O	O
;	O	O
2	O	O
,	O	O
7.96	O	O
+	O	O
/	O	O
-	O	O
0.07	O	O
;	O	O
3	O	O
,	O	O
7.62	O	O
+	O	O
/	O	O
-	O	O
0.09	O	O
;	O	O
4	O	O
,	O	O
7.52	O	O
+	O	O
/	O	O
-	O	O
0.03	O	O
;	O	O
5	O	O
,	O	O
7.21	O	O
+	O	O
/	O	O
-	O	O
0.07	O	O
;	O	O
6	O	O
,	O	O
7.22	O	O
+	O	O
/	O	O
-	O	O
0.12	O	O
;	O	O
7	O	O
,	O	O
7.19	O	O
+	O	O
/	O	O
-	O	O
0.08	O	O
;	O	O
8	O	O
,	O	O
7.12	O	O
+	O	O
/	O	O
-	O	O
0.09	O	O
;	O	O
9	O	O
,	O	O
6.99	O	O
+	O	O
/	O	O
-	O	O
0.06	O	O
;	O	O
10	O	O
,	O	O
6.07	O	O
+	O	O
/	O	O
-	O	O
0.11	O	O
;	O	O
11	O	O
,	O	O
6.07	O	O
+	O	O
/	O	O
-	O	O
0.11	O	O
;	O	O
12	O	O
,	O	O
5.85	O	O
+	O	O
/	O	O
-	O	O
0.05	O	O
;	O	O
13	O	O
,	O	O
approximately	O	O
5.57	O	O
;	O	O
14	O	O
,	O	O
a	O	O
weak	O	O
agonist	O	O
(	O	O
0.004	O	O
U	O	O
/	O	O
mg	O	O
)	O	O
.	O	O
Several	O	O
derivatives	O	O
of	O	O
4,5	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
disubstituted	I-MODIFIER	I-MODIFIER
imidazole	B-IUPAC	B-IUPAC
,	O	O
2,4,5	B-MODIFIER	O
-	I-MODIFIER	O
trisubstituted	I-MODIFIER	B-MODIFIER
pyrimidine	B-IUPAC	B-IUPAC
,	O	O
2	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
purine	B-IUPAC	B-IUPAC
,	O	O
thiazolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
purine	I-IUPAC	I-IUPAC
,	O	I-IUPAC
[	B-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiazino	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
purine	I-IUPAC	I-IUPAC
,	O	O
thiazolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
i	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
purine	I-IUPAC	I-IUPAC
,	O	I-IUPAC
[	B-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiazino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
i	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
purine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
6	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
pyrazolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
and	O	O
tested	O	O
as	O	O
inhibitors	O	O
of	O	O
the	O	O
xanthine	O	O
oxidase	O	O
enzyme	O	O
.	O	O
The	O	O
co	O	O
-	O	O
injection	O	O
of	O	O
PBR	O	O
-	O	O
selective	O	O
2	O	O
reduced	O	O
the	O	O
[	O	O
(	O	O
11	O	O
)	O	O
C	O	O
]	O	O
ligand	O	O
binding	O	O
in	O	O
the	O	O
two	O	O
regions	O	O
,	O	O
suggesting	O	O
that	O	O
binding	O	O
in	O	O
the	O	O
rat	O	O
brain	O	O
was	O	O
specific	O	O
to	O	O
PBR	O	O
.	O	O
Accordingly	O	O
,	O	O
antitumor	O	O
agents	O	O
can	O	O
be	O	O
made	O	O
selective	O	O
for	O	O
tumors	O	O
by	O	O
virtue	O	O
of	O	O
high	O	O
activity	O	O
under	O	O
hypoxic	O	O
conditions	O	O
.	O	O
Compounds	O	O
3-6	O	O
were	O	O
deblocked	O	O
with	O	O
chlorotrimethylsilane	B-IUPAC	O
and	O	O
sodium	O	O
iodide	O	O
in	O	O
acetonitrile	O	O
to	O	O
the	O	O
corresponding	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
vinyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
uracils	I-IUPAC	I-IUPAC
(	O	O
7-10	O	O
)	O	O
,	O	O
which	O	O
on	O	O
treatment	O	O
with	O	O
potassium	O	O
hydroxide	O	O
in	O	O
dioxane	O	O
yielded	O	O
the	O	O
corresponding	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acylethynyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
uracils	I-IUPAC	I-IUPAC
(	O	O
11-14	O	O
)	O	O
.	O	O
Compounds	O	O
1-3	O	O
inhibited	O	O
growth	O	O
of	O	O
Detroit	O	O
98	O	O
and	O	O
L	O	O
cells	O	O
in	O	O
cell	O	O
culture	O	O
,	O	O
with	O	O
IC50s	O	O
ranging	O	O
from	O	O
2	O	O
to	O	O
0.018	O	O
microM	O	O
.	O	O
The	O	O
same	O	O
reactions	O	O
with	O	O
the	O	O
alpha	O	O
-	O	O
keto	O	O
sugar	O	O
gave	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
erythro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thymine	I-IUPAC	I-IUPAC
and	O	O
its	O	O
beta	O	O
-	O	O
anomer	O	O
.	O	O
casei	O	O
and	O	O
were	O	O
of	O	O
low	O	O
activity	O	O
(	O	O
IC50	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
M	O	O
)	O	O
.	O	O
All	O	O
the	O	O
peptides	O	O
have	O	O
similar	O	O
sets	O	O
of	O	O
low	O	O
-	O	O
energy	O	O
conformations	O	O
of	O	O
their	O	O
common	O	O
flexible	O	O
elements	O	O
,	O	O
the	O	O
Phe3	O	O
side	O	O
chain	O	O
and	O	O
the	O	O
peptide	O	O
group	O	O
between	O	O
the	O	O
first	O	O
residue	O	O
and	O	O
the	O	O
rigid	O	O
tripeptide	O	O
cycle	O	O
.	O	O
In	O	O
contrast	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
,	O	O
which	O	O
is	O	O
not	O	O
metabolized	O	O
to	O	O
the	O	O
corresponding	O	O
(	O	B-IUPAC
carboxyalkyl	O	I-IUPAC
)	O	I-IUPAC
hydroxypyridinone	O	I-IUPAC
,	O	O
was	O	O
found	O	O
to	O	O
be	O	O
superior	O	O
to	O	O
Deferiprone	O	O
and	O	O
therefore	O	O
deserves	O	O
further	O	O
consideration	O	O
as	O	O
an	O	O
orally	O	O
active	O	O
iron	O	O
chelator	O	O
with	O	O
potential	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
iron	O	O
overload	O	O
associated	O	O
with	O	O
transfusion	O	O
-	O	O
dependent	O	O
thalassemia	O	O
.	O	O
The	O	O
synthesis	O	O
and	O	O
pharmacological	O	O
profile	O	O
of	O	O
a	O	O
series	O	O
of	O	O
neuroprotective	O	O
adenosine	O	O
agonists	O	O
are	O	O
described	O	O
.	O	O
Selective	O	O
protection	O	O
of	O	O
(	B-IUPAC	B-IUPAC
9R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxoerythromycin	I-IUPAC	I-IUPAC
A	I-IUPAC	O
allowed	O	O
for	O	O
elimination	O	O
of	O	O
the	O	O
12	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
hydroxyl	I-PARTIUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
to	O	O
afford	O	O
a	O	O
versatile	O	O
12,21	O	O
-	O	O
olefin	O	O
intermediate	O	O
.	O	O
Another	O	O
route	O	O
using	O	O
Grewe	O	O
cyclization	O	O
was	O	O
also	O	O
examined	O	O
for	O	O
the	O	O
synthesis	O	O
of	O	O
3	O	O
.	O	O
)	O	O
indicated	O	O
that	O	O
the	O	O
epoxyalkyl	O	O
group	O	O
on	O	O
the	O	O
phenolic	O	O
oxygen	O	O
had	O	O
an	O	O
optimal	O	O
length	O	O
of	O	O
four	O	O
carbons	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
turnover	O	O
ratio	O	O
(	O	O
the	O	O
ratio	O	O
of	O	O
molecules	O	O
undergoing	O	O
turnover	O	O
compared	O	O
to	O	O
those	O	O
that	O	O
inactivate	O	O
the	O	O
enzyme	O	O
)	O	O
for	O	O
chymotrypsin	O	O
.	O	O
A	O	O
residual	O	O
enzymatic	O	O
activity	O	O
at	O	O
an	O	O
infinite	O	O
inhibitor	O	O
concentration	O	O
and	O	O
thus	O	O
a	O	O
catalytically	O	O
active	O	O
ternary	O	O
enzyme	O	O
-	O	O
substrate	O	O
-	O	O
inhibitor	O	O
complex	O	O
was	O	O
concluded	O	O
.	O	O
The	O	O
TS	O	O
inhibition	O	O
of	O	O
the	O	O
analogues	O	O
1b	O	O
-	O	O
g	O	O
was	O	O
estimated	O	O
by	O	O
calculating	O	O
the	O	O
inverse	O	O
relative	O	O
potency	O	O
,	O	O
defined	O	O
as	O	O
the	O	O
ratio	O	O
IC50	O	O
(	O	O
compound	O	O
)	O	O
/	O	O
IC50	O	O
(	O	O
1a	O	O
)	O	O
.	O	O
These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
binding	O	O
of	O	O
hydantoins	O	O
to	O	O
the	O	O
sodium	O	O
channel	O	O
may	O	O
be	O	O
enhanced	O	O
by	O	O
(	O	O
a	O	O
)	O	O
a	O	O
free	O	O
imide	O	O
NH	O	O
group	O	O
and	O	O
(	O	O
b	O	O
)	O	O
an	O	O
increased	O	O
log	O	O
P	O	O
.	O	O
Among	O	O
the	O	O
pteridines	O	O
,	O	O
the	O	O
most	O	O
potent	O	O
against	O	O
P	O	O
.	O	O
The	O	O
aldehydes	O	O
were	O	O
converted	O	O
to	O	O
the	O	O
cyanohydrin	B-IUPAC	O
trimethylsilyl	I-IUPAC	O
ethers	I-IUPAC	O
,	O	O
which	O	O
,	O	O
in	O	O
turn	O	O
,	O	O
were	O	O
reduced	O	O
to	O	O
the	O	O
dimethoxyphenethanolamines	B-IUPAC	O
.	O	O
Thus	O	O
,	O	O
hydrophobicity	O	O
of	O	O
the	O	O
para	O	O
substituent	O	O
alone	O	O
cannot	O	O
account	O	O
for	O	O
the	O	O
dramatic	O	O
enhancement	O	O
of	O	O
hallucinogenic	O	O
activity	O	O
.	O	O
A	O	O
second	O	O
in	O	O
vivo	O	O
model	O	O
used	O	O
to	O	O
evaluate	O	O
PAF	O	O
antagonists	O	O
determines	O	O
the	O	O
ability	O	O
of	O	O
test	O	O
compounds	O	O
to	O	O
decrease	O	O
the	O	O
area	O	O
of	O	O
skin	O	O
wheals	O	O
induced	O	O
by	O	O
an	O	O
intradermal	O	O
injection	O	O
of	O	O
PAF	O	O
.	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Aza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxospiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4.5	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
decan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
propylamino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorote	I-IUPAC	I-IUPAC
tralin	I-IUPAC	I-IUPAC
(	O	O
18	O	O
)	O	O
bound	O	O
with	O	O
very	O	O
high	O	O
affinity	O	O
to	O	O
both	O	O
DA	O	O
D3	O	O
and	O	O
5	O	O
-	O	O
HT1A	O	O
receptors	O	O
(	O	O
Ki	O	O
=	O	O
0.2	O	O
nM	O	O
)	O	O
and	O	O
was	O	O
also	O	O
characterized	O	O
as	O	O
a	O	O
dopaminergic	O	O
antagonist	O	O
.	O	O
Net	O	O
Pu	O	O
removal	O	O
[	O	O
Pu	O	O
excretion	O	O
(	O	O
treated	O	O
)	O	O
-	O	O
PU	O	O
excretion	O	O
(	O	O
control	O	O
)	O	O
]	O	O
,	O	O
expressed	O	O
as	O	O
percent	O	O
of	O	O
injected	O	O
Pu	O	O
,	O	O
was	O	O
as	O	O
follows	O	O
:	O	O
Na	O	O
salts	O	O
and	O	O
Zn	O	O
(	O	O
II	O	O
)	O	O
complexes	O	O
,	O	O
respectively	O	O
,	O	O
of	O	O
3	O	O
-	O	O
LIHOPO	O	O
(	O	O
54	O	O
,	O	O
56	O	O
)	O	O
,	O	O
3,4	O	O
-	O	O
LIHOPO	O	O
(	O	O
58	O	O
,	O	O
60	O	O
)	O	O
,	O	O
3,4,3	O	O
-	O	O
LIHOPO	O	O
(	O	O
73	O	O
,	O	O
76	O	O
)	O	O
;	O	O
Na	O	O
salts	O	O
of	O	O
MEHOPO	O	O
(	O	O
46	O	O
)	O	O
,	O	O
DFO	O	O
-	O	O
HOPO	O	O
(	O	O
78	O	O
)	O	O
;	O	O
Fe	O	O
(	O	O
III	O	O
)	O	O
complex	O	O
of	O	O
3,4,3	O	O
-	O	O
LIHOPO	O	O
(	O	O
79	O	O
)	O	O
.	O	O
Attempts	O	O
to	O	O
obtain	O	O
crystals	O	O
of	O	O
a	O	O
single	O	O
stereoisomer	O	O
failed	O	O
in	O	O
different	O	O
solvents	O	O
,	O	O
while	O	O
methanol	O	O
crystallization	O	O
of	O	O
the	O	O
product	O	O
obtained	O	O
from	O	O
(	B-IUPAC	B-IUPAC
+	I-IUPAC	I-IUPAC
/	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydrofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methylene	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
acetoacetate	I-IUPAC	I-IUPAC
and	O	O
methyl	B-IUPAC	B-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminocrotonate	I-IUPAC	I-IUPAC
yielded	O	O
good	O	O
-	O	O
quality	O	O
crystals	O	O
of	O	O
the	O	O
most	O	O
insoluble	O	O
racemate	O	O
which	O	O
proved	O	O
to	O	O
be	O	O
a	O	O
mixture	O	O
of	O	O
the	O	O
(	O	O
SS	O	O
)	O	O
/	O	O
(	O	O
RR	O	O
)	O	O
enantiomers	O	O
by	O	O
X	O	O
-	O	O
ray	O	O
crystallography	O	O
.	O	O
It	O	O
was	O	O
anticipated	O	O
that	O	O
1c	O	O
would	O	O
be	O	O
hydrolyzed	O	O
in	O	O
vivo	O	O
by	O	O
carboxylate	O	O
esterase	O	O
(	O	O
E	O	O
.	O	O
The	O	O
antibacterial	O	O
activity	O	O
of	O	O
these	O	O
derivatives	O	O
was	O	O
studied	O	O
with	O	O
the	O	O
finding	O	O
that	O	O
the	O	O
optimal	O	O
1	O	O
-	O	O
and	O	O
7	O	O
-	O	O
position	O	O
substituents	O	O
for	O	O
Gram	O	O
positive	O	O
activity	O	O
are	O	O
cyclopropyl	O	O
and	O	O
4	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
2,6	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
dimethylpyridinyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
,	O	O
respectively	O	O
.	O	O
New	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzhydryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylurea	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
and	O	O
their	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzhydryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylthiourea	I-IUPAC	I-IUPAC
isosteres	B-MODIFIER	B-MODIFIER
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
their	O	O
human	O	O
CB1	O	O
and	O	O
CB2	O	O
cannabinoid	O	O
receptor	O	O
affinity	O	O
.	O	O
gondii	O	O
DHFR	O	O
.	O	O
44	O	O
also	O	O
inhibited	O	O
platelet	O	O
aggregation	O	O
ex	O	O
vivo	O	O
in	O	O
guinea	O	O
pigs	O	O
.	O	O
Monoiodination	O	O
of	O	O
25	O	O
to	O	O
yield	O	O
26	O	O
and	O	O
of	O	O
27	O	O
to	O	O
yield	O	O
28	O	O
resulted	O	O
in	O	O
an	O	O
additional	O	O
4	O	O
-	O	O
fold	O	O
increase	O	O
in	O	O
affinity	O	O
at	O	O
sst1	O	O
.	O	O
Of	O	O
the	O	O
series	O	O
studied	O	O
,	O	O
the	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triamine	I-IUPAC	I-IUPAC
system	B-MODIFIER	B-MODIFIER
6	O	O
had	O	O
significantly	O	O
higher	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
values	O	O
(	O	O
lower	O	O
cytotoxicity	O	O
)	O	O
in	O	O
the	O	O
L1210	O	O
,	O	O
CHO	O	O
,	O	O
and	O	O
CHO	O	O
-	O	O
MG	O	O
cell	O	O
lines	O	O
.	O	O
6beta	B-IUPAC	O
-	I-IUPAC	O
Acyloxy	I-IUPAC	O
(	I-IUPAC	O
nor	I-IUPAC	O
)	I-IUPAC	O
tropane	I-IUPAC	O
,	O	O
two	O	O
other	O	O
(	O	O
nor	O	O
)	O	O
tropanes	O	O
,	O	O
and	O	O
the	O	O
classical	O	O
muscarinic	O	O
agonists	O	O
had	O	O
higher	O	O
affinity	O	O
versus	O	O
agonist	O	O
binding	O	O
compared	O	O
to	O	O
antagonist	O	O
binding	O	O
for	O	O
transfected	O	O
m	O	O
(	O	O
4	O	O
)	O	O
-	O	O
receptors	O	O
.	O	O
A	O	O
good	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
the	O	O
electronic	O	O
properties	O	O
of	O	O
the	O	O
substituent	O	O
and	O	O
the	O	O
inhibitory	O	O
activity	O	O
and	O	O
stability	O	O
.	O	O
The	O	O
results	O	O
of	O	O
these	O	O
investigations	O	O
allow	O	O
certain	O	O
speculations	O	O
to	O	O
be	O	O
made	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
role	O	O
of	O	O
the	O	O
furan	O	O
ring	O	O
in	O	O
the	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
arylspiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
isobenzofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidines	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
and	O	O
antitetrabenazine	O	O
activity	O	O
.	O	O
The	O	O
antagonist	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
butylpropylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorotetralin	I-IUPAC	I-IUPAC
(	O	O
16	O	O
)	O	O
bound	O	O
with	O	O
high	O	O
affinity	O	O
(	O	O
Ki	O	O
=	O	O
4.4	O	O
nM	O	O
)	O	O
to	O	O
the	O	O
DA	O	O
D3	O	O
receptor	O	O
and	O	O
was	O	O
the	O	O
most	O	O
D3	O	O
-	O	O
selective	O	O
compound	O	O
(	O	O
10	O	O
-	O	O
fold	O	O
)	O	O
.	O	O
Most	O	O
of	O	O
the	O	O
BTCP	O	O
homologues	O	O
displayed	O	O
greater	O	O
ability	O	O
to	O	O
inhibit	O	O
[	O	O
3H	O	O
]	O	O
DA	O	O
uptake	O	O
in	O	O
rat	O	O
forebrain	O	O
synaptosomes	O	O
than	O	O
cocaine	O	O
.	O	O
Different	O	O
substituents	O	O
were	O	O
introduced	O	O
in	O	O
the	O	O
1	O	O
-	O	O
position	O	O
of	O	O
the	O	O
piperidine	O	O
ring	O	O
in	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	O
derivative	I-MODIFIER	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
relationships	O	O
for	O	O
compounds	O	O
with	O	O
the	O	O
4,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethyloctenoate	I-IUPAC	I-IUPAC
at	O	O
C6	O	O
(	O	O
S1	O	O
analogues	O	O
)	O	O
were	O	O
different	O	O
from	O	O
those	O	O
for	O	O
analogues	O	O
lacking	O	O
the	O	O
C6	O	O
ester	O	O
(	O	O
H1	O	O
analogues	O	O
)	O	O
,	O	O
with	O	O
a	O	O
greater	O	O
dependence	O	O
on	O	O
the	O	O
nature	O	O
of	O	O
the	O	O
C3	O	O
-	O	O
substituent	O	O
for	O	O
the	O	O
H1	O	O
series	O	O
.	O	O
carinii	O	O
DHFR	O	O
were	O	O
the	O	O
2,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxybenzyl	I-IUPAC	I-IUPAC
(	O	O
5j	O	O
)	O	O
,	O	O
3	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxybenzyl	I-IUPAC	I-IUPAC
(	O	O
5k	O	O
)	O	O
,	O	O
and	O	O
3,4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
trimethoxybenzyl	I-IUPAC	I-IUPAC
(	O	O
5l	O	O
)	O	O
analogues	B-MODIFIER	O
,	O	O
with	O	O
IC50	O	O
values	O	O
of	O	O
0.057	O	O
,	O	O
0.10	O	O
,	O	O
and	O	O
0.091	O	O
microM	O	O
,	O	O
respectively	O	O
.	O	O
In	O	O
agreement	O	O
with	O	O
these	O	O
findings	O	O
,	O	O
disruption	O	O
of	O	O
the	O	O
protein	O	O
-	O	O
protein	O	O
interaction	O	O
between	O	O
uPAR	O	O
present	O	O
on	O	O
tumor	O	O
cells	O	O
and	O	O
its	O	O
ligand	O	O
uPA	O	O
evolved	O	O
as	O	O
an	O	O
attractive	O	O
intervention	O	O
strategy	O	O
to	O	O
impair	O	O
tumor	O	O
growth	O	O
and	O	O
metastasis	O	O
.	O	O
,	O	O
its	O	O
N3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
trifluoroacetyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
(	O	O
4b	O	O
)	O	O
,	O	O
was	O	O
a	O	O
good	O	O
in	O	O
vivo	O	O
inhibitor	O	O
of	O	O
AlDH	O	O
,	O	O
mimicking	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
parent	O	O
N1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethylchlorpropamide	I-IUPAC	I-IUPAC
.	O	O
At	O	O
60	O	O
min	O	O
post	O	O
-	O	O
iv	O	O
-	O	O
injection	O	O
,	O	O
the	O	O
specific	O	O
uptakes	O	O
,	O	O
as	O	O
measured	O	O
by	O	O
[	O	O
striatum	O	O
-	O	O
cerebellum	O	O
]	O	O
/	O	O
cerebellum	O	O
(	O	O
[	O	O
ST	O	O
-	O	O
CB	O	O
]	O	O
/	O	O
CB	O	O
)	O	O
ratio	O	O
,	O	O
were	O	O
1.72	O	O
and	O	O
2.79	O	O
for	O	O
2A	O	O
,	O	O
B	O	O
,	O	O
respectively	O	O
.	O	O
In	O	O
vitro	O	O
,	O	O
5a	O	O
inhibited	O	O
SP	O	O
-	O	O
induced	O	O
contraction	O	O
of	O	O
isolated	O	O
guinea	O	O
pig	O	O
trachea	O	O
strips	O	O
with	O	O
IC50	O	O
of	O	O
2.3	O	O
x	O	O
10	O	O
(	O	O
-	O	O
6	O	O
)	O	O
M	O	O
and	O	O
caused	O	O
no	O	O
contraction	O	O
when	O	O
used	O	O
alone	O	O
in	O	O
this	O	O
preparation	O	O
up	O	O
to	O	O
3.2	O	O
x	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
M	O	O
.	O	O
The	O	O
prototypes	O	O
,	O	O
belonging	O	O
to	O	O
five	O	O
chemical	O	O
series	O	O
,	O	O
were	O	O
evaluated	O	O
for	O	O
their	O	O
estrogen	O	O
receptor	O	O
affinity	O	O
and	O	O
for	O	O
estrogen	O	O
agonist	O	O
-	O	O
antagonist	O	O
activities	O	O
.	O	O
carinii	O	O
enzyme	O	O
and	O	O
thus	O	O
were	O	O
nonselective	O	O
.	O	O
Among	O	O
the	O	O
thymine	O	O
,	O	O
uracil	O	O
,	O	O
and	O	O
5	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
uracil	B-IUPAC	B-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
,	O	O
thymine	O	O
(	O	O
alpha	O	O
-	O	O
isomer	O	O
)	O	O
and	O	O
uracil	O	O
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
derivatives	O	O
exhibited	O	O
moderate	O	O
anti	O	O
-	O	O
HIV	O	O
activity	O	O
.	O	O
Compound	O	O
4	O	O
was	O	O
also	O	O
relatively	O	O
neurotoxic	O	O
(	O	O
TD50	O	O
=	O	O
124	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O
The	O	O
stereochemical	O	O
course	O	O
of	O	O
the	O	O
enzymatic	O	O
reaction	O	O
was	O	O
not	O	O
significantly	O	O
altered	O	O
at	O	O
glutathione	O	O
concentrations	O	O
as	O	O
low	O	O
as	O	O
25	O	O
microM	O	O
.	O	O
In	O	O
vivo	O	O
experiments	O	O
with	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylacetazolamide	I-IUPAC	I-IUPAC
suggest	O	O
that	O	O
ocular	O	O
metabolism	O	O
to	O	O
acetazolamide	O	O
was	O	O
responsible	O	O
for	O	O
the	O	O
observed	O	O
topical	O	O
activity	O	O
.	O	O
carinii	O	O
enzyme	O	O
,	O	O
with	O	O
most	O	O
of	O	O
the	O	O
analogues	O	O
giving	O	O
IC50	O	O
values	O	O
of	O	O
0.01-0.1	O	O
microM	O	O
.	O	O
as	O	O
tadpole	O	O
anesthetics	O	O
.	O	O
Sonicated	O	O
solutions	O	O
of	O	O
the	O	O
conjugates	O	O
existed	O	O
in	O	O
the	O	O
form	O	O
of	O	O
micellar	O	O
disks	O	O
(	O	O
size	O	O
0.01-0.04	O	O
microns	O	O
)	O	O
.	O	O
These	O	O
results	O	O
clearly	O	O
demonstrated	O	O
that	O	O
an	O	O
array	O	O
of	O	O
simple	O	O
RGD	O	O
tripeptides	O	O
on	O	O
a	O	O
NIR	O	O
fluorescent	O	O
dye	O	O
core	O	O
can	O	O
be	O	O
recognized	O	O
by	O	O
ABIR	O	O
.	O	O
In	O	O
cloned	O	O
human	O	O
nicotinic	O	O
acetylcholine	O	O
receptors	O	O
(	O	O
nAChR	O	O
)	O	O
expressed	O	O
in	O	O
Xenopus	O	O
oocytes	O	O
,	O	O
both	O	O
17c	O	O
and	O	O
26	O	O
activated	O	O
alpha7	O	O
and	O	O
alpha3beta2	O	O
receptor	O	O
subtypes	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
,	O	O
but	O	O
26	O	O
was	O	O
clearly	O	O
the	O	O
more	O	O
potent	O	O
agonist	O	O
.	O	O
It	O	O
has	O	O
been	O	O
observed	O	O
that	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
carbomethoxy	O	O
at	O	O
position	O	O
3	O	O
and	O	O
an	O	O
aryl	O	O
substituent	O	O
at	O	O
position	O	O
1	O	O
in	O	O
beta	O	O
-	O	O
carbolines	O	O
effectively	O	O
enhances	O	O
antifilarial	O	O
activity	O	O
particularly	O	O
against	O	O
A	O	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
relationships	O	O
are	O	O
also	O	O
considered	O	O
.	O	O
Reducing	O	O
the	O	O
long	O	O
acyl	O	O
chain	O	O
to	O	O
an	O	O
acetyl	O	O
moiety	O	O
and	O	O
attaching	O	O
a	O	O
compensating	O	O
lipophilic	O	O
chain	O	O
to	O	O
the	O	O
lactone	O	O
ring	O	O
as	O	O
an	O	O
alpha	B-IUPAC	O
-	I-IUPAC	O
alkylidene	I-IUPAC	O
moiety	B-MODIFIER	O
produced	O	O
compounds	O	O
10e	O	O
and	O	O
10f	O	O
(	O	O
Z	O	O
-	O	O
isomers	O	O
)	O	O
and	O	O
11e	O	O
and	O	O
11f	O	O
(	O	O
E	O	O
-	O	O
isomers	O	O
)	O	O
,	O	O
which	O	O
were	O	O
constructed	O	O
on	O	O
the	O	O
more	O	O
effective	O	O
5,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxymethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furanone	I-IUPAC	I-IUPAC
template	O	O
.	O	O
Some	O	O
of	O	O
the	O	O
compounds	O	O
,	O	O
in	O	O
particular	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tubercidinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
homocysteine	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
(	O	O
36	O	O
)	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoroacetyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tubercidinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
homocysteine	I-IUPAC	I-IUPAC
isopropyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
(	O	O
27	O	O
)	O	O
,	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxytubercidinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
homocysteine	I-IUPAC	I-IUPAC
(	O	O
58	O	O
)	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoracetyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tubercidinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
homocysteine	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
(	O	O
26	O	O
)	O	O
,	O	O
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methoxyacetyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tubercidinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
homocysteine	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
(	O	O
31	O	O
)	O	O
showed	O	O
potent	O	O
and	O	O
selective	O	O
activity	O	O
against	O	O
HSV	O	O
,	O	O
VV	O	O
,	O	O
and	O	O
VSV	O	O
.	O	O
31P	O	O
NMR	O	O
spectroscopy	O	O
was	O	O
used	O	O
to	O	O
study	O	O
the	O	O
products	O	O
of	O	O
the	O	O
decomposition	O	O
of	O	O
the	O	O
antitumor	O	O
drug	O	O
ifosfamide	O	O
(	O	O
IF	O	O
,	O	O
1d	O	O
)	O	O
and	O	O
its	O	O
N	B-IUPAC	O
-	I-IUPAC	O
dechloroethylated	I-IUPAC	O
metabolites	B-MODIFIER	O
,	O	O
namely	O	O
,	O	O
2,3	B-IUPAC	O
-	I-IUPAC	O
didechloroethylIF	I-IUPAC	O
(	O	O
1a	O	O
)	O	O
and	O	O
2	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
(	O	O
1b	O	O
)	O	O
and	O	O
3	B-IUPAC	O
-	I-IUPAC	O
dechloroethylIF	I-IUPAC	O
(	O	O
1c	O	O
)	O	O
,	O	O
in	O	O
buffered	O	O
solutions	O	O
at	O	O
acidic	O	O
pH	O	O
.	O	O
The	O	O
final	O	O
compound	O	O
,	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butynyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenzyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
22	O	O
)	O	O
,	O	O
was	O	O
both	O	O
potent	O	O
and	O	O
selective	O	O
against	O	O
M	O	O
.	O	O
This	O	O
finding	O	O
supports	O	O
our	O	O
previously	O	O
published	O	O
hypothesis	O	O
of	O	O
different	O	O
binding	O	O
modes	O	O
for	O	O
pyrrolopyrimidines	O	O
,	O	O
such	O	O
as	O	O
ADPEP	O	O
(	O	O
1	O	O
)	O	O
and	O	O
DPEAP	O	O
(	O	O
2	O	O
)	O	O
.	O	O
Amine	O	O
4	O	O
retains	O	O
the	O	O
dopaminergic	O	O
pharmacophore	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethylamine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
the	O	O
chlorine	O	O
atom	O	O
replaces	O	O
the	O	O
"	O	O
para	O	O
"	O	O
hydroxyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
DA	O	O
.	O	O
A	O	O
direct	O	O
correlation	O	O
was	O	O
observed	O	O
between	O	O
polyamine	O	O
-	O	O
conjugate	O	O
uptake	O	O
and	O	O
cytotoxicity	O	O
.	O	O
Compounds	O	O
4-6	O	O
were	O	O
all	O	O
inactive	O	O
against	O	O
HCMV	O	O
but	O	O
exhibited	O	O
appreciable	O	O
antiviral	O	O
activity	O	O
against	O	O
VZV	O	O
.	O	O
These	O	O
experiments	O	O
also	O	O
indicate	O	O
that	O	O
the	O	O
S	O	O
enantiomer	O	O
of	O	O
6b	O	O
is	O	O
a	O	O
specific	O	O
ligand	O	O
(	O	O
KD	O	O
=	O	O
1.2	O	O
nM	O	O
)	O	O
for	O	O
the	O	O
D	O	O
-	O	O
2	O	O
receptor	O	O
.	O	O
This	O	O
new	O	O
orientation	O	O
was	O	O
mainly	O	O
caused	O	O
by	O	O
the	O	O
space	O	O
filling	O	O
substitution	O	O
at	O	O
the	O	O
2	O	O
-	O	O
position	O	O
of	O	O
the	O	O
imidazole	O	O
ring	O	O
and	O	O
influenced	O	O
the	O	O
location	O	O
of	O	O
the	O	O
protonated	O	O
N	O	O
(	O	O
alpha	O	O
)	O	O
-	O	O
atom	O	O
which	O	O
was	O	O
positioned	O	O
more	O	O
between	O	O
TM	O	O
III	O	O
and	O	O
TM	O	O
VI	O	O
.	O	O
Three	O	O
simple	O	O
2	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,6,7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroquinazoline	I-IUPAC	I-IUPAC
model	B-MODIFIER	I-IUPAC
compounds	I-MODIFIER	B-MODIFIER
(	O	O
9a	O	O
-	O	O
c	O	O
)	O	O
were	O	O
also	O	O
prepared	O	O
in	O	O
one	O	O
step	O	O
from	O	O
commercially	O	O
available	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkylcyclohexanones	I-IUPAC	I-IUPAC
by	O	O
this	O	O
method	O	O
.	O	O
Three	O	O
of	O	O
10	O	O
synthesized	O	O
fluorescent	O	O
compounds	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
guanidinium	I-IUPAC	I-IUPAC
sulfate	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dibenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
f	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
azepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
guanidinium	I-IUPAC	I-IUPAC
sulfate	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
,	O	O
and	O	O
(	B-IUPAC	B-IUPAC
2R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethoxycarbonyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tropanyl	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
naphthalene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sulfonate	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
,	O	O
exhibited	O	O
high	O	O
affinity	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
about	O	O
50	O	O
nM	O	O
)	O	O
for	O	O
the	O	O
NET	O	O
.	O	O
The	O	O
presence	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propylidene	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
at	O	O
C	O	O
-	O	O
5	O	O
on	O	O
the	O	O
5H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dibenzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
cycloheptene	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
did	O	O
not	O	O
interfere	O	O
greatly	O	O
,	O	O
as	O	O
compared	O	O
to	O	O
clozapine	O	O
,	O	O
with	O	O
the	O	O
in	O	O
vitro	O	O
affinity	O	O
of	O	O
this	O	O
5,11	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dicarbo	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
of	O	O
clozapine	O	O
for	O	O
muscarinic	O	O
and	O	O
dopamine	O	O
D	O	O
-	O	O
1	O	O
and	O	O
D	O	O
-	O	O
2	O	O
binding	O	O
sites	O	O
in	O	O
rat	O	O
brain	O	O
.	O	O
3,5	O	O
-	O	O
Disubstitution	O	O
and	O	O
2	O	O
-	O	O
substitution	O	O
led	O	O
to	O	O
a	O	O
decline	O	O
in	O	O
activity	O	O
.	O	O
A	O	O
wide	O	O
range	O	O
of	O	O
IC50	O	O
values	O	O
were	O	O
observed	O	O
for	O	O
pyranones	O	O
and	O	O
thiopyranones	O	O
substituted	O	O
at	O	O
the	O	O
6	O	O
-	O	O
position	O	O
,	O	O
with	O	O
the	O	O
3	O	B-PARTIUPAC
-	O	I-PARTIUPAC
and	O	O
5	O	O
-	O	O
positions	O	O
proving	O	O
intolerant	O	O
to	O	O
substitution	O	O
.	O	O
Among	O	O
them	O	O
,	O	O
the	O	O
highest	O	O
activity	O	O
was	O	O
observed	O	O
for	O	O
the	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
rac	O	O
-	O	O
28	O	O
[	O	O
about	O	O
15	O	O
-	O	O
fold	O	O
more	O	O
active	O	O
than	O	O
THA	O	O
and	O	O
about	O	O
9	O	O
-	O	O
fold	O	O
more	O	O
active	O	O
than	O	O
(	O	O
-	O	O
)	O	O
-	O	O
huperzine	O	O
A	O	O
]	O	O
.	O	O
The	O	O
reduced	O	O
slope	O	O
for	O	O
the	O	O
more	O	O
hydrophilic	O	O
molecules	O	O
of	O	O
the	O	O
series	O	O
offers	O	O
some	O	O
advantage	O	O
for	O	O
this	O	O
type	O	O
of	O	O
hydroxypyridinone	O	O
as	O	O
the	O	O
distribution	O	O
coefficients	O	O
for	O	O
such	O	O
complexes	O	O
do	O	O
not	O	O
change	O	O
so	O	O
rapidly	O	O
with	O	O
increasing	O	O
ligand	O	O
hydrophilicity	O	O
.	O	O
The	O	O
new	O	O
compounds	O	O
of	O	O
each	O	O
type	O	O
were	O	O
active	O	O
against	O	O
aconitine	O	O
-	O	O
induced	O	O
arrhythmia	O	O
and	O	O
several	O	O
of	O	O
them	O	O
had	O	O
higher	O	O
activity	O	O
and	O	O
better	O	O
chemotherapeutic	O	O
index	O	O
than	O	O
quinidine	O	O
.	O	O
An	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylacetyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
was	O	O
the	O	O
most	O	O
potent	O	O
derivative	O	O
at	O	O
A3	O	O
receptors	O	O
,	O	O
with	O	O
a	O	O
Ki	O	O
value	O	O
of	O	O
0.36	O	O
nM	O	O
.	O	O
An	O	O
I2	O	O
-	O	O
catalyzed	O	O
isomerization	O	O
of	O	O
the	O	O
intermediate	O	O
9Z	B-IUPAC	O
-	I-IUPAC	O
aldehyde	I-IUPAC	O
yielded	O	O
the	O	O
all	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aldehyde	I-IUPAC	I-IUPAC
,	O	O
which	O	O
was	O	O
olefinated	O	O
as	O	O
above	O	O
to	O	O
yield	O	O
the	O	O
(	B-PARTIUPAC	O
all	I-PARTIUPAC	O
-	I-PARTIUPAC	O
E	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
(	B-IUPAC	B-IUPAC
13Z	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
retinoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
analogs	B-MODIFIER	B-MODIFIER
of	O	O
1	O	O
.	O	O
The	O	O
conformation	O	O
of	O	O
sulfonyl	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyguanidine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
,	O	O
such	O	O
as	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,1,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiadiazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
sulfonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
"	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyguanidine	I-IUPAC	I-IUPAC
(	O	O
4g	O	O
)	O	O
,	O	O
investigated	O	O
utilizing	O	O
HMBC	O	O
NMR	O	O
,	O	O
theoretical	O	O
calculations	O	O
,	O	O
and	O	O
X	O	O
-	O	O
ray	O	O
crystallography	O	O
,	O	O
indicated	O	O
stacking	O	O
of	O	O
the	O	O
two	O	O
aromatic	O	O
rings	O	O
.	O	O
Moreover	O	O
,	O	O
at	O	O
the	O	O
pH	O	O
of	O	O
the	O	O
in	O	O
vitro	O	O
assays	O	O
,	O	O
2b	O	O
was	O	O
very	O	O
stable	O	O
with	O	O
a	O	O
decomposition	O	O
(	O	O
to	O	O
aldehyde	O	O
)	O	O
half	O	O
-	O	O
life	O	O
of	O	O
&	O	O
gt	O	O
;	O	O
15	O	O
d	O	O
.	O	O
Compound	O	O
2	O	O
was	O	O
the	O	O
more	O	O
potent	O	O
(	O	O
anti	O	O
-	O	O
MES	O	O
ED50	O	O
=	O	O
66	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
and	O	O
its	O	O
in	O	O
vivo	O	O
anti	O	O
-	O	O
MES	O	O
effect	O	O
was	O	O
consistent	O	O
with	O	O
its	O	O
in	O	O
vitro	O	O
potency	O	O
of	O	O
binding	O	O
to	O	O
the	O	O
voltage	O	O
-	O	O
sensitive	O	O
sodium	O	O
channel	O	O
(	O	O
IC50	O	O
=	O	O
160	O	O
microM	O	O
for	O	O
the	O	O
inhibition	O	O
of	O	O
binding	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
BTX	O	O
-	O	O
B	O	O
)	O	O
,	O	O
suggesting	O	O
that	O	O
2	O	O
may	O	O
be	O	O
a	O	O
new	O	O
class	O	O
I	O	O
anticonvulsant	O	O
.	O	O
These	O	O
compounds	O	O
give	O	O
important	O	O
insight	O	O
into	O	O
the	O	O
steric	O	O
and	O	O
stereochemical	O	O
preferences	O	O
of	O	O
both	O	O
PNMT	O	O
and	O	O
the	O	O
alpha	O	O
(	O	O
2	O	O
)	O	O
-	O	O
adrenoceptor	O	O
,	O	O
which	O	O
should	O	O
assist	O	O
in	O	O
the	O	O
development	O	O
of	O	O
new	O	O
PNMT	O	O
inhibitors	O	O
.	O	O
The	O	O
in	O	O
vivo	O	O
efficacy	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyclopropyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
fluoromethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
piperazinyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxoquinoline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
20	O	O
)	O	O
was	O	O
excellent	O	O
with	O	O
better	O	O
oral	O	O
absorption	O	O
than	O	O
ciprofloxacin	O	O
(	O	O
2	O	O
)	O	O
.	O	O
The	O	O
four	O	O
corresponding	O	O
isomers	O	O
were	O	O
prepared	O	O
in	O	O
which	O	O
the	O	O
beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylphenylalanine	I-IUPAC	I-IUPAC
residue	B-MODIFIER	O
was	O	O
p	O	B-IUPAC
-	O	I-IUPAC
nitro	O	I-IUPAC
substituted	O	B-MODIFIER
,	O	O
that	O	O
is	O	O
with	O	O
a	O	O
beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrophenylalanine	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
Me	O	O
-	O	O
p	O	O
-	O	O
NO2Phe	O	O
)	O	O
residue	O	O
,	O	O
to	O	O
give	O	O
[	O	O
(	O	O
2S	O	O
,	O	O
3S	O	O
)	O	O
-	O	O
beta	O	O
-	O	O
Me	O	O
-	O	O
p	O	O
-	O	O
NO2Phe4	O	O
]	O	O
DPDPE	O	O
(	O	O
6	O	O
)	O	O
,	O	O
[	O	O
(	O	O
2R	O	O
,	O	O
3R	O	O
)	O	O
-	O	O
beta	O	O
-	O	O
Me	O	O
-	O	O
p	O	O
-	O	O
NO2Phe4	O	O
]	O	O
DPDPE	O	O
(	O	O
7	O	O
)	O	O
,	O	O
[	O	O
(	O	O
2S	O	O
,	O	O
3R	O	O
)	O	O
-	O	O
beta	O	O
-	O	O
Me	O	O
-	O	O
p	O	O
-	O	O
NO2Phe4	O	O
]	O	O
DPDPE	O	O
(	O	O
8	O	O
)	O	O
,	O	O
and	O	O
[	O	O
(	O	O
2R	O	O
,	O	O
3S	O	O
)	O	O
-	O	O
beta	O	O
-	O	O
Me	O	O
-	O	O
p	O	O
-	O	O
NO2Phe4	O	O
]	O	O
DPDPE	O	O
(	O	O
9	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
Both	O	O
a	O	O
carboxyl	O	B-IUPAC
group	O	B-MODIFIER
at	O	O
the	O	O
7	O	O
-	O	O
position	O	O
and	O	O
a	O	O
tetrazole	O	O
ring	O	O
at	O	O
the	O	O
2'	O	O
-	O	O
position	O	O
were	O	O
particularly	O	O
important	O	O
for	O	O
potent	O	O
and	O	O
orally	O	O
active	O	O
AII	O	O
antagonistic	O	O
activity	O	O
and	O	O
a	O	O
long	O	O
-	O	O
acting	O	O
hypotensive	O	O
effect	O	O
.	O	O
The	O	O
results	O	O
showed	O	O
stereospecificity	O	O
of	O	O
the	O	O
furnidipine	O	O
isomers	O	O
in	O	O
brain	O	O
,	O	O
ileum	O	O
,	O	O
and	O	O
cardiac	O	O
tissues	O	O
,	O	O
the	O	O
(	O	O
SS	O	O
)	O	O
-	O	O
and	O	O
(	O	O
SR	O	O
)	O	O
-	O	O
isomers	O	O
clearly	O	O
being	O	O
more	O	O
potent	O	O
than	O	O
their	O	O
(	O	O
RR	O	O
)	O	O
-	O	O
and	O	O
(	O	O
RS	O	O
)	O	O
-	O	O
enantiomers	O	O
.	O	O
The	O	O
AE	O	O
activity	O	O
score	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trifluoromethylbenzoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thiophene	I-IUPAC	I-IUPAC
(	O	O
PD	O	O
81,723	O	O
)	O	O
,	O	O
which	O	O
was	O	O
19%	O	O
,	O	O
served	O	O
as	O	O
a	O	O
standard	O	O
for	O	O
comparison	O	O
.	O	O
Desamination	O	O
of	O	O
the	O	O
N	O	O
-	O	O
terminus	O	O
of	O	O
17	O	O
to	O	O
yield	O	O
18	O	O
,	O	O
on	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
resulted	O	O
in	O	O
significant	O	O
loss	O	O
of	O	O
affinity	O	O
.	O	O
The	O	O
comparable	O	O
whole	O	O
brain	O	O
and	O	O
blood	O	O
half	O	O
-	O	O
lives	O	O
for	O	O
Me	O	O
[	O	O
18F	O	O
]	O	O
FBWAY	O	O
(	O	O
[	O	O
18F	O	O
]	O	O
4c	O	O
)	O	O
were	O	O
16	O	O
and	O	O
18	O	O
min	O	O
,	O	O
respectively	O	O
.	O	O
Direct	O	O
methylation	O	O
of	O	O
1	O	O
with	O	O
CH3I	O	O
furnished	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylpyrazofurin	I-IUPAC	I-IUPAC
(	O	O
6	O	O
)	O	O
.	O	O
The	O	O
binding	O	O
profiles	O	O
of	O	O
the	O	O
two	O	O
selective	O	O
muscarinic	O	O
antagonists	O	O
reveal	O	O
the	O	O
complexity	O	O
and	O	O
diversity	O	O
of	O	O
muscarinic	O	O
receptor	O	O
subtypes	O	O
throughout	O	O
the	O	O
brain	O	O
.	O	O
Among	O	O
the	O	O
synthesized	O	O
compounds	O	O
,	O	O
[	O	O
Dmt1	O	O
,	O	O
d	O	O
-	O	O
2	O	O
-	O	O
Nal4	O	O
]	O	O
endomorphin	O	O
-	O	O
1	O	O
,	O	O
designated	O	O
antanal	O	O
-	O	O
1	O	O
,	O	O
and	O	O
[	O	O
Dmt1	O	O
,	O	O
d	O	O
-	O	O
2	O	O
-	O	O
Nal4	O	O
]	O	O
endomorphin	O	O
-	O	O
2	O	O
,	O	O
designated	O	O
antanal	O	O
-	O	O
2	O	O
,	O	O
turned	O	O
out	O	O
to	O	O
be	O	O
highly	O	O
potent	O	O
and	O	O
selective	O	O
mu	O	O
-	O	O
opioid	O	O
receptor	O	O
antagonists	O	O
,	O	O
as	O	O
judged	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
two	O	O
functional	O	O
assays	O	O
,	O	O
the	O	O
receptor	O	O
binding	O	O
assay	O	O
and	O	O
the	O	O
hot	O	O
plate	O	O
test	O	O
of	O	O
analgesia	O	O
.	O	O
The	O	O
biological	O	O
activity	O	O
of	O	O
these	O	O
arotinoids	O	O
was	O	O
determined	O	O
in	O	O
the	O	O
tracheal	O	O
organ	O	O
culture	O	O
assay	O	O
and	O	O
compared	O	O
with	O	O
trans	O	O
-	O	O
retinoic	O	O
acid	O	O
for	O	O
ability	O	O
to	O	O
reverse	O	O
keratinization	O	O
in	O	O
vitamin	O	O
A	O	O
deficient	O	O
hamsters	O	O
.	O	O
None	O	O
of	O	O
the	O	O
chloro	O	O
derivatives	O	O
or	O	O
oxacyclopentenes	O	O
exhibited	O	O
an	O	O
antiviral	O	O
effect	O	O
at	O	O
noncytotoxic	O	O
concentrations	O	O
.	O	O
Mainly	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
acyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
esters	I-IUPAC	I-IUPAC
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
alkoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
esters	I-IUPAC	I-IUPAC
,	O	O
double	O	O
ester	O	O
derivatives	O	O
,	O	O
were	O	O
synthesized	O	O
.	O	O
The	O	O
influence	O	O
of	O	O
this	O	O
group	O	O
on	O	O
the	O	O
biological	O	O
activity	O	O
was	O	O
evaluated	O	O
by	O	O
testing	O	O
the	O	O
corresponding	O	O
derivatives	O	O
20-22	O	O
in	O	O
which	O	O
the	O	O
4	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
alkylsemicarbazono	I-PARTIUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
was	O	O
removed	O	O
(	O	O
compound	O	O
20	O	O
)	O	O
or	O	O
its	O	O
alkylureido	O	O
portion	O	O
shifted	O	O
at	O	O
position	O	O
1	O	O
(	O	O
compounds	O	O
21-22	O	O
)	O	O
.	O	O
This	O	O
selectivity	O	O
was	O	O
more	O	O
pronounced	O	O
for	O	O
9	O	O
,	O	O
which	O	O
showed	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
values	O	O
of	O	O
40	O	O
and	O	O
500	O	O
microM	O	O
as	O	O
an	O	O
inhibitor	O	O
of	O	O
glial	O	O
and	O	O
neuronal	O	O
GABA	O	O
uptake	O	O
,	O	O
respectively	O	O
.	O	O
They	O	O
were	O	O
also	O	O
highly	O	O
effective	O	O
6	O	O
h	O	O
after	O	O
a	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
oral	O	O
dose	O	O
.	O	O
Since	O	O
our	O	O
previous	O	O
studies	O	O
with	O	O
monophenyl	B-IUPAC	O
-	O	O
substituted	B-MODIFIER	O
bicyclic	B-MODIFIER	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxazolidinediones	I-IUPAC	I-IUPAC
suggested	O	O
that	O	O
N3	O	O
-	O	O
alkylation	O	O
and	O	O
the	O	O
conformational	O	O
constraint	O	O
of	O	O
a	O	O
5	O	B-IUPAC
-	O	I-IUPAC
alkyl	O	I-IUPAC
substituent	O	B-MODIFIER
over	O	O
one	O	O
face	O	O
of	O	O
the	O	O
oxazolidinedione	O	O
ring	O	O
improved	O	O
activity	O	O
,	O	O
we	O	O
synthesized	O	O
two	O	O
examples	O	O
of	O	O
analogous	O	O
bicyclic	O	O
hydantoins	O	O
.	O	O
Hydrophilicity	O	O
of	O	O
these	O	O
analogues	O	O
,	O	O
a	O	O
potential	O	O
measure	O	O
of	O	O
their	O	O
ability	O	O
to	O	O
be	O	O
formulated	O	O
for	O	O
sustained	O	O
release	O	O
,	O	O
was	O	O
determined	O	O
using	O	O
RP	O	O
-	O	O
HPLC	O	O
at	O	O
neutral	O	O
pH	O	O
yielding	O	O
analogues	O	O
with	O	O
shorter	O	O
as	O	O
well	O	O
as	O	O
longer	O	O
retention	O	O
times	O	O
.	O	O
Med.	O	O
Chem.	O	O
2002	O	O
,	O	O
45	O	O
,	O	O
208-218	O	O
.	O	O
Other	O	O
amino	O	O
acid	O	O
substitutions	O	O
in	O	O
this	O	O
series	O	O
,	O	O
such	O	O
as	O	O
those	O	O
with	O	O
Amp	O	O
(	O	O
25	O	O
,	O	O
26	O	O
)	O	O
,	O	O
Orn	O	O
(	O	O
27	O	O
)	O	O
,	O	O
or	O	O
IAmp	O	O
(	O	O
29	O	O
)	O	O
at	O	O
position	O	O
7	O	O
,	O	O
were	O	O
also	O	O
tolerated	O	O
but	O	O
with	O	O
a	O	O
2	O	O
-	O	O
to	O	O
3	O	O
-	O	O
fold	O	O
loss	O	O
of	O	O
affinity	O	O
and	O	O
concomitant	O	O
loss	O	O
of	O	O
selectivity	O	O
.	O	O
The	O	O
predicted	O	O
binding	O	O
model	O	O
for	O	O
PDBU	O	O
is	O	O
the	O	O
same	O	O
as	O	O
that	O	O
for	O	O
phorbol	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
13	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetate	I-IUPAC	I-IUPAC
in	O	O
terms	O	O
of	O	O
the	O	O
hydrogen	O	O
-	O	O
bonding	O	O
network	O	O
and	O	O
hydrophobic	O	O
contacts	O	O
.	O	O
N	B-MODIFIER	O
-	I-MODIFIER	O
Substituted	I-MODIFIER	O
and	O	O
unsubstituted	B-MODIFIER	O
4	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
chlorobenzene	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
nitrobenzenesulfonamides	I-IUPAC	I-IUPAC
were	O	O
also	O	O
synthesized	O	O
,	O	O
and	O	O
their	O	O
biochemical	O	O
characteristics	O	O
and	O	O
in	O	O
vivo	O	O
ability	O	O
to	O	O
lower	O	O
IOP	O	O
when	O	O
applied	O	O
topically	O	O
were	O	O
determined	O	O
.	O	O
Results	O	O
from	O	O
this	O	O
study	O	O
suggest	O	O
that	O	O
the	O	O
selectivity	O	O
of	O	O
1	O	O
is	O	O
not	O	O
solely	O	O
due	O	O
to	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
acidic	O	O
hydrogen	O	O
on	O	O
the	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminosulfonyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
of	O	O
1	O	O
but	O	O
is	O	O
likely	O	O
also	O	O
dependent	O	O
on	O	O
some	O	O
other	O	O
property	O	O
(	O	O
e.g.	O	O
electron	O	O
-	O	O
withdrawing	O	O
character	O	O
)	O	O
of	O	O
the	O	O
aminosulfonyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
.	O	O
5,11	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperazinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzodiazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
[	O	I-IUPAC
pirenzepine	O	I-IUPAC
(	O	O
compound	O	O
I	O	O
)	O	O
]	O	O
and	O	O
11	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
diethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidinyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzodiazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
[	O	O
AF	O	O
-	O	O
DX	O	O
116	O	O
(	O	O
compound	O	O
II	O	O
)	O	O
]	O	O
were	O	O
chosen	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
their	O	O
selectivity	O	O
for	O	O
M1	O	O
and	O	O
M2	O	O
muscarinic	O	O
receptors	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
similarities	O	O
in	O	O
chemical	O	O
structure	O	O
.	O	O
The	O	O
facile	O	O
reaction	O	O
of	O	O
cysteine	O	O
and	O	O
glutathione	O	O
with	O	O
2	O	O
might	O	O
represent	O	O
a	O	O
mechanism	O	O
designed	O	O
to	O	O
scavenge	O	O
the	O	O
biogenic	O	O
aldehyde	O	O
and	O	O
therefore	O	O
to	O	O
prevent	O	O
its	O	O
alkylation	O	O
of	O	O
key	O	O
intraneuronal	O	O
protein	O	O
nucleophiles	O	O
.	O	O
The	O	O
synthesis	O	O
of	O	O
aminoaceto	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
xylidides	I-IUPAC	I-IUPAC
substituted	B-MODIFIER	B-MODIFIER
on	O	O
the	O	O
amide	O	O
nitrogen	O	O
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
diethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminoethyl	I-IUPAC	I-IUPAC
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethyl	I-IUPAC	I-IUPAC
,	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethoxyethyl	I-IUPAC	I-IUPAC
groups	B-MODIFIER	B-MODIFIER
is	O	O
described	O	O
.	O	O
This	O	O
model	O	O
will	O	O
be	O	O
useful	O	O
for	O	O
the	O	O
prediction	O	O
of	O	O
high	O	O
-	O	O
affinity	O	O
ligands	O	O
at	O	O
radiolabeled	O	O
H	O	O
(	O	O
1	O	O
)	O	O
receptors	O	O
in	O	O
mammalian	O	O
brain	O	O
.	O	O
Among	O	O
the	O	O
studied	O	O
compounds	O	O
,	O	O
the	O	O
para	O	O
-	O	O
chlorophenyl	O	O
and	O	O
para	O	O
-	O	O
methylphenyl	O	O
derivatives	O	O
were	O	O
selective	O	O
substrates	O	O
of	O	O
NOS	O	O
II	O	O
.	O	O
General	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
reveal	O	O
that	O	O
optimal	O	O
enzyme	O	O
inhibitory	O	O
activity	O	O
is	O	O
displayed	O	O
by	O	O
those	O	O
compounds	O	O
possessing	O	O
the	O	O
acetic	B-IUPAC	O
acid	I-IUPAC	O
moiety	B-MODIFIER	O
.	O	O
The	O	O
analogues	O	O
3c	O	O
-	O	O
e	O	O
,	O	O
containing	O	O
C3	O	O
alkoxy	O	O
groups	O	O
,	O	O
were	O	O
an	O	O
order	O	O
of	O	O
magnitude	O	O
weaker	O	O
than	O	O
3b	O	O
,	O	O
whereas	O	O
the	O	O
additional	O	O
steric	O	O
bulk	O	O
of	O	O
the	O	O
alkoxy	O	O
groups	O	O
of	O	O
3f	O	O
-	O	O
i	O	O
or	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
acidic	O	O
hydroxyl	O	O
group	O	O
at	O	O
the	O	O
3	O	O
-	O	O
position	O	O
of	O	O
the	O	O
isoxazole	O	O
ring	O	O
of	O	O
3j	O	O
prevented	O	O
interaction	O	O
with	O	O
AMPA	O	O
receptor	O	O
sites	O	O
.	O	O
The	O	O
2'	B-IUPAC	O
,	I-IUPAC	O
3,4	I-IUPAC	O
'	I-IUPAC	O
,	I-IUPAC	O
7	I-IUPAC	O
-	I-IUPAC	O
tetraethyl	I-IUPAC	O
ether	I-IUPAC	O
derivative	B-MODIFIER	O
of	O	O
the	O	O
flavonol	O	O
morin	O	O
,	O	O
7	O	O
,	O	O
displayed	O	O
a	O	O
Ki	O	O
value	O	O
of	O	O
4.8	O	O
microM	O	O
at	O	O
human	O	O
A3	O	O
receptors	O	O
and	O	O
was	O	O
inactive	O	O
at	O	O
rat	O	O
A1	O	O
/	O	O
A2a	O	O
receptors	O	O
.	O	O
From	O	O
earlier	O	O
work	O	O
,	O	O
we	O	O
concluded	O	O
that	O	O
an	O	O
l	O	O
-	O	O
amino	O	O
acid	O	O
at	O	O
position	O	O
8	O	O
and	O	O
a	O	O
tyrosine	B-IUPAC	O
or	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminophenylalanine	I-IUPAC	I-IUPAC
substitution	B-MODIFIER	B-MODIFIER
at	O	O
position	O	O
7	O	O
may	O	O
lead	O	O
to	O	O
high	O	O
sst	O	O
(	O	O
4	O	O
)	O	O
selectivity	O	O
.	O	O
[	O	O
18F	O	O
]	O	O
FBWAY	O	O
(	O	O
[	O	O
18F	O	O
]	O	O
4b	O	O
)	O	O
showed	O	O
an	O	O
early	O	O
rapid	O	O
net	O	O
efflux	O	O
from	O	O
the	O	O
whole	O	O
brain	O	O
,	O	O
clearing	O	O
with	O	O
a	O	O
biological	O	O
half	O	O
-	O	O
life	O	O
of	O	O
35	O	O
min	O	O
.	O	O
New	O	O
1H	B-IUPAC	O
,	I-IUPAC	O
3H	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyrimido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
f	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
purine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dione	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
arylpiperazine	O	O
(	O	O
11-22	O	O
)	O	O
were	O	O
prepared	O	O
and	O	O
evaluated	O	O
in	O	O
vitro	O	O
for	O	O
their	O	O
affinity	O	O
for	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
1A	O	O
)	O	O
,	O	O
5	O	O
-	O	O
HT	O	O
(	O	O
2A	O	O
)	O	O
,	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
,	O	O
and	O	O
D	O	O
(	O	O
2	O	O
)	O	O
receptors	O	O
.	O	O
The	O	O
resultant	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deazaaminopterin	I-IUPAC	I-IUPAC
diesters	I-IUPAC	B-MODIFIER
were	O	O
saponified	O	O
to	O	O
provide	O	O
the	O	O
target	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
.	O	O
Palladium	O	O
(	O	O
0	O	O
)	O	O
-	O	O
mediated	O	O
Suzuki	O	O
-	O	O
Miyaura	O	O
and	O	O
Heck	O	O
transformations	O	O
have	O	O
been	O	O
exploited	O	O
to	O	O
provide	O	O
examples	O	O
of	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylquino	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
kl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
acridines	I-IUPAC	I-IUPAC
and	O	O
8,13	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethylquino	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,3,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
kl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
acridinium	I-IUPAC	I-IUPAC
iodides	I-IUPAC	O
bearing	O	O
bulky	O	O
saturated	O	O
(	B-IUPAC	O
3	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
acetoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
or	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
morpholin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxopropenyl	I-IUPAC	I-IUPAC
substituents	B-MODIFIER	B-MODIFIER
variously	O	O
in	O	O
the	O	O
3	O	O
-	O	O
,	O	O
6	O	O
-	O	O
,	O	O
or	O	O
10	O	O
-	O	O
positions	O	O
of	O	O
the	O	O
pentacyclic	O	O
nucleus	O	O
.	O	O
Adenosine	O	B-IUPAC
5'	O	I-IUPAC
-	O	I-IUPAC
triphosphate	O	I-IUPAC
(	O	O
ATP	O	O
)	O	O
derivatives	B-MODIFIER	O
of	O	O
the	O	O
types	O	O
N6	O	O
-	O	O
R	O	O
-	O	O
ATP	O	O
[	O	O
R	O	O
=	O	O
(	O	O
CH2	O	O
)	O	O
nNHCOCH2I	O	O
,	O	O
(	O	O
CH2	O	O
)	O	O
nNHCO	O	O
-	O	O
(	O	O
CH2	O	O
)	O	O
mNHCOCH2I	O	O
,	O	O
or	O	O
(	O	O
CH2	O	O
)	O	O
nCON	O	O
(	O	O
Me	O	O
)	O	O
(	O	O
CH2	O	O
)	O	O
mN	O	O
(	O	O
Me	O	O
)	O	O
CO	O	O
(	O	O
CH2	O	O
)	O	O
nNHCOCH2I	O	O
]	O	O
,	O	O
N6	O	O
-	O	O
Me	O	O
-	O	O
N6	O	O
-	O	O
R	O	O
-	O	O
ATP	O	O
[	O	O
R	O	O
=	O	O
(	O	O
CH2	O	O
)	O	O
nN	O	O
-	O	O
(	O	O
Me	O	O
)	O	O
CO	O	O
(	O	O
CH2	O	O
)	O	O
mNHCOCH2I	O	O
]	O	O
,	O	O
and	O	O
8	O	O
-	O	O
R	O	O
-	O	O
ATP	O	O
[	O	O
R	O	O
=	O	O
NM	O	O
(	O	O
CH2	O	O
)	O	O
nNHCOCH2I	O	O
]	O	O
with	O	O
5	O	O
-	O	O
-	O	O
19	O	O
spacer	O	O
atoms	O	O
between	O	O
N6	O	O
or	O	O
C	O	O
-	O	O
8	O	O
and	O	O
iodine	O	O
have	O	O
been	O	O
evaluated	O	O
as	O	O
potential	O	O
exo	O	O
-	O	O
ATP	O	O
-	O	O
site	O	O
-	O	O
directed	O	O
reagents	O	O
for	O	O
phosphokinases	O	O
.	O	O
This	O	O
suggests	O	O
the	O	O
requirement	O	O
of	O	O
an	O	O
aza	O	O
atom	O	O
in	O	O
the	O	O
7	O	O
-	O	O
but	O	O
not	O	O
the	O	O
5	O	O
-	O	O
position	O	O
(	O	O
i.e.	O	O
,	O	O
a	O	O
carbon	O	O
atom	O	O
in	O	O
the	O	O
5	O	O
-	O	O
position	O	O
)	O	O
for	O	O
the	O	O
enhanced	O	O
potency	O	O
shown	O	O
by	O	O
6	O	B-IUPAC
-	O	I-IUPAC
N	O	I-IUPAC
-	O	I-IUPAC
methylated	O	I-IUPAC
derivatives	O	B-MODIFIER
in	O	O
each	O	O
series	O	O
.	O	O
Replacement	O	O
of	O	O
the	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
by	O	O
chlorine	O	O
affords	O	O
the	O	O
potent	O	O
but	O	O
nonselective	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
6a	O	O
-	O	O
k	O	O
showing	O	O
similar	O	O
toxicities	O	O
under	O	O
both	O	O
aerobic	O	O
and	O	O
hypoxic	O	O
conditions	O	O
.	O	O
The	O	O
strongest	O	O
inhibitor	O	O
,	O	O
the	O	O
[	B-IUPAC	B-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4a	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
10a	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydrophenothiazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
dimethylammonium	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
0.12	O	O
microM	O	O
)	O	O
,	O	O
was	O	O
approximately	O	O
2	O	O
orders	O	O
of	O	O
magnitude	O	O
more	O	O
inhibitory	O	O
than	O	O
the	O	O
parent	O	O
chlorpromazine	O	O
.	O	O
The	O	O
reduction	O	O
of	O	O
acetylcholinesterase	O	O
(	O	O
AChE	O	O
)	O	O
activity	O	O
in	O	O
the	O	O
brain	O	O
has	O	O
been	O	O
measured	O	O
in	O	O
dementia	O	O
disorders	O	O
such	O	O
as	O	O
Alzheimer	O	O
's	O	O
disease	O	O
and	O	O
dementia	O	O
with	O	O
Lewy	O	O
bodies	O	O
using	O	O
(	O	O
11	O	O
)	O	O
C	O	O
-	O	O
labeled	O	O
acetylcholine	O	O
analogues	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
methylpiperidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
acetate	I-IUPAC	I-IUPAC
and	O	O
propionate	O	O
,	O	O
and	O	O
positron	O	O
emission	O	O
tomography	O	O
(	O	O
PET	O	O
)	O	O
.	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Iodothien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
was	O	O
used	O	O
as	O	O
starting	O	O
material	O	O
for	O	O
the	O	O
synthesis	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylthien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
vinylthien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethynylthien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
.	O	O
Treatment	O	O
of	O	O
7	O	O
with	O	O
bromine	O	O
afforded	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arabinofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
hydrobromide	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
.	O	O
Antimalarial	O	O
activity	O	O
was	O	O
general	O	O
among	O	O
the	O	O
N2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dialkylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinazolinediamines	I-IUPAC	I-IUPAC
(	O	O
VI	O	O
)	O	O
,	O	O
while	O	O
the	O	O
reverse	O	O
isomers	O	O
were	O	O
of	O	O
lower	O	O
activity	O	O
.	O	O
While	O	O
10	O	O
was	O	O
equipotent	O	O
with	O	O
histamine	O	O
(	O	O
1	O	O
)	O	O
,	O	O
methylhistaprodifen	O	O
(	O	O
13	O	O
)	O	O
and	O	O
dimethylhistaprodifen	O	O
(	O	O
14	O	O
)	O	O
exceeded	O	O
the	O	O
functional	O	O
potency	O	O
of	O	O
1	O	O
by	O	O
a	O	O
factor	O	O
of	O	O
3-5	O	O
(	O	O
13	O	O
)	O	O
and	O	O
2-3	O	O
(	O	O
14	O	O
)	O	O
.	O	O
It	O	O
is	O	O
interesting	O	O
to	O	O
note	O	O
that	O	O
such	O	O
a	O	O
small	O	O
modification	O	O
in	O	O
the	O	O
sugar	O	O
moiety	O	O
of	O	O
active	O	O
anti	O	O
-	O	O
HIV	O	O
nucleosides	O	O
(	O	O
i.e.	O	O
,	O	O
displacement	O	O
of	O	O
hydrogen	O	O
by	O	O
fluorine	O	O
)	O	O
almost	O	O
completely	O	O
inactivate	O	O
the	O	O
agents	O	O
.	O	O
These	O	O
compounds	O	O
have	O	O
MGMT	O	O
inhibitor	O	O
constants	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
values	O	O
)	O	O
of	O	O
0.8	O	O
and	O	O
0.45	O	O
microM	O	O
for	O	O
ITGG	O	O
and	O	O
IBGG	O	O
,	O	O
respectively	O	O
,	O	O
as	O	O
determined	O	O
in	O	O
HeLa	O	O
S3	O	O
cells	O	O
after	O	O
2	O	O
-	O	O
h	O	O
incubation	O	O
with	O	O
inhibitor	O	O
.	O	O
The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
further	O	O
demonstrate	O	O
the	O	O
possibility	O	O
of	O	O
tuning	O	O
the	O	O
selectivity	O	O
of	O	O
tropane	O	O
analogues	O	O
toward	O	O
the	O	O
SERT	O	O
or	O	O
NET	O	O
binding	O	O
site	O	O
.	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Ribofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
,	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arabinofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
erythro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
,	O	O
as	O	O
well	O	O
as	O	O
compound	O	O
6	O	O
,	O	O
showed	O	O
no	O	O
antimalarial	O	O
activity	O	O
.	O	O
The	O	O
stereoisomer	O	O
6	O	O
,	O	O
but	O	O
not	O	O
7	O	O
,	O	O
activated	O	O
cloned	O	O
AMPA	O	O
receptor	O	O
subunits	O	O
GluR1o	O	O
,	O	O
GluR3o	O	O
,	O	O
and	O	O
GluR4o	O	O
with	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
values	O	O
in	O	O
the	O	O
range	O	O
4.5-15	O	O
microM	O	O
and	O	O
the	O	O
coexpressed	O	O
kainate	O	O
-	O	O
preferring	O	O
subunits	O	O
GluR6	O	O
+	O	O
KA2	O	O
(	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
6.4	O	O
microM	O	O
)	O	O
.	O	O
The	O	O
highest	O	O
selectivity	O	O
achieved	O	O
in	O	O
this	O	O
limited	O	O
series	O	O
was	O	O
with	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trimethoxybenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinazoline	I-IUPAC	I-IUPAC
(	O	O
17	O	O
)	O	O
against	O	O
T	O	O
.	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylsulfonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
furoxan	I-IUPAC	I-IUPAC
(	O	O
10a	O	O
)	O	O
,	O	O
one	O	O
of	O	O
the	O	O
most	O	O
active	O	O
derivatives	O	O
,	O	O
inhibits	O	O
the	O	O
AA	O	O
-	O	O
induced	O	O
increase	O	O
of	O	O
cytosolic	O	O
free	O	O
Ca2+	O	O
and	O	O
production	O	O
of	O	O
malondialdehyde	O	O
.	O	O
The	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminoethyl	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
were	O	O
prepared	O	O
by	O	O
treatment	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phthalimidoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
xylidine	I-IUPAC	I-IUPAC
with	O	O
chloroacetyl	O	O
chloride	O	O
,	O	O
followed	O	O
by	O	O
treatment	O	O
with	O	O
either	O	O
potassium	O	O
phthalmide	O	O
or	O	O
diethylamine	O	O
.	O	O
Chemical	O	O
and	O	O
biological	O	O
similarities	O	O
of	O	O
plutonium	O	O
(	O	O
IV	O	O
)	O	O
and	O	O
iron	O	O
(	O	O
III	O	O
)	O	O
suggested	O	O
that	O	O
octadentate	O	O
ligands	O	O
containing	O	O
hydroxamate	O	O
or	O	O
catecholate	O	O
functional	O	O
groups	O	O
,	O	O
which	O	O
are	O	O
found	O	O
in	O	O
microbial	O	O
iron	O	O
chelating	O	O
agents	O	O
(	O	O
siderophores	O	O
)	O	O
,	O	O
would	O	O
be	O	O
effective	O	O
and	O	O
relatively	O	O
selective	O	O
complexing	O	O
agents	O	O
for	O	O
actinide	O	O
(	O	O
IV	O	O
)	O	O
ions	O	O
.	O	O
By	O	O
comparison	O	O
,	O	O
ciprofloxacin	O	O
and	O	O
aminopyrrolidine	O	O
28	O	O
gave	O	O
values	O	O
of	O	O
0.25	O	O
and	O	O
0.015	O	O
microgram	O	O
/	O	O
mL	O	O
,	O	O
respectively	O	O
,	O	O
against	O	O
this	O	O
organism	O	O
.	O	O
The	O	O
sugar	O	O
moiety	O	O
of	O	O
nucleosides	O	O
in	O	O
solution	O	O
is	O	O
known	O	O
to	O	O
exist	O	O
in	O	O
a	O	O
rapid	O	O
dynamic	O	O
equilibrium	O	O
between	O	O
extreme	O	O
Northern	O	O
and	O	O
Southern	O	O
conformations	O	O
as	O	O
defined	O	O
in	O	O
the	O	O
pseudorotational	O	O
cycle	O	O
.	O	O
Oral	O	O
activity	O	O
was	O	O
detected	O	O
in	O	O
diethyl	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
m	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
dioxamate	I-IUPAC	I-IUPAC
(	O	O
compound	O	O
38	O	O
)	O	O
at	O	O
levels	O	O
of	O	O
drug	O	O
as	O	O
low	O	O
as	O	O
0.1	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
Compounds	O	O
1a	O	O
-	O	O
c	O	O
and	O	O
some	O	O
of	O	O
their	O	O
hydrolytic	O	O
degradation	O	O
products	O	O
(	O	O
4b	O	O
-	O	O
1	O	O
,	O	O
4b	O	O
-	O	O
2	O	O
,	O	O
diphosphoric	O	O
diester	O	O
[	O	O
Cl	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
2	O	O
)	O	O
NH	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
3	O	O
)	O	O
OP	O	O
(	O	O
O	O	O
)	O	O
(	O	O
OH	O	O
)	O	O
]	O	O
(	O	O
2	O	O
)	O	O
O	O	O
(	O	O
5	O	O
)	O	O
,	O	O
and	O	O
chloroethylamine	O	O
)	O	O
did	O	O
not	O	O
exhibit	O	O
,	O	O
as	O	O
expected	O	O
,	O	O
any	O	O
antitumor	O	O
efficacy	O	O
in	O	O
vivo	O	O
against	O	O
P388	O	O
leukemia	O	O
.	O	O
Within	O	O
the	O	O
new	O	O
phenylaminotetralin	O	O
series	O	O
,	O	O
a	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
the	O	O
ability	O	O
to	O	O
stimulate	O	O
TH	O	O
and	O	O
the	O	O
potency	O	O
to	O	O
compete	O	O
for	O	O
binding	O	O
sites	O	O
labeled	O	O
by	O	O
(	B-IUPAC	O
+	I-IUPAC	O
/	I-IUPAC	O
-	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
[	I-IUPAC	O
3H	I-IUPAC	O
]	I-IUPAC	O
1	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydronaphthalene	I-IUPAC	I-IUPAC
(	O	O
[	O	O
3H	O	O
]	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
4	O	O
)	O	O
.	O	O
Compound	O	O
1e	O	O
produced	O	O
an	O	O
ILS	O	O
of	O	O
71%	O	O
at	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
X	O	O
5	O	O
(	O	O
ip	O	O
)	O	O
in	O	O
BDF	O	O
mice	O	O
inoculated	O	O
ip	O	O
with	O	O
10	O	O
(	O	O
6	O	O
)	O	O
L	O	O
-	O	O
1210	O	O
cells	O	O
.	O	O
A	O	O
new	O	O
class	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyanamido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
haloethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridines	I-IUPAC	I-IUPAC
(	O	O
4-6	O	O
)	O	O
and	O	O
arabinouridines	O	O
(	O	O
7	O	O
,	O	O
8	O	O
)	O	O
were	O	O
synthesized	O	O
by	O	O
the	O	O
regiospecific	O	O
addition	O	O
of	O	O
halogenocyanamides	O	O
(	O	O
X	O	O
-	O	O
NHCN	O	O
)	O	O
to	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
vinyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
of	O	O
the	O	O
respective	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
vinyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridine	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
and	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
arabinouridine	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
studies	O	O
compared	O	O
displacement	O	O
of	O	O
[	O	B-IUPAC
(	O	I-IUPAC
3	O	I-IUPAC
)	O	I-IUPAC
H	O	I-IUPAC
]	O	I-IUPAC
nicotine	O	I-IUPAC
binding	O	O
in	O	O
mammalian	O	O
alpha4beta2	O	O
nAChR	O	O
and	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
imidacloprid	O	O
binding	O	O
in	O	O
Drosophila	O	O
nAChR	O	O
.	O	O
None	O	O
of	O	O
the	O	O
compounds	O	O
showed	O	O
significant	O	O
activity	O	O
.	O	O
Compound	O	O
12	O	O
exhibited	O	O
a	O	O
4	O	O
-	O	O
fold	O	O
enantioselectivity	O	O
favoring	O	O
(	O	O
+	O	O
)	O	O
-	O	O
12	O	O
.	O	O
In	O	O
this	O	O
paper	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
synthesis	O	O
of	O	O
a	O	O
series	O	O
of	O	O
novel	O	O
substituted	B-MODIFIER	B-MODIFIER
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylenedioxyphthalazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
.	O	O
Analogues	O	O
1-14	O	O
also	O	O
antagonize	O	O
the	O	O
vascular	O	O
responses	O	O
to	O	O
arginine	O	O
-	O	O
vasopressin	O	O
(	O	O
AVP	O	O
)	O	O
and	O	O
the	O	O
in	O	O
vitro	O	O
oxytocic	O	O
responses	O	O
to	O	O
oxytocin	O	O
.	O	O
One	O	O
compound	O	O
,	O	O
(	B-IUPAC	B-IUPAC
Z	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylcyclopropane	I-IUPAC	I-IUPAC
(	O	O
7b	O	O
)	O	O
,	O	O
elicited	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
decrease	O	O
in	O	O
vivo	O	O
comparable	O	O
to	O	O
MER	O	O
25	O	O
.	O	O
This	O	O
series	O	O
of	O	O
compounds	O	O
were	O	O
slightly	O	O
less	O	O
potent	O	O
at	O	O
A2	O	O
receptors	O	O
.	O	O
Prodrugs	O	O
6b	O	O
and	O	O
6c	O	O
were	O	O
also	O	O
prepared	O	O
by	O	O
methylation	O	O
of	O	O
the	O	O
respective	O	O
diamidoximes	O	O
5b	O	O
and	O	O
5d	O	O
.	O	O
Although	O	O
additional	O	O
nitrogen	O	O
atoms	O	O
resulted	O	O
in	O	O
decreased	O	O
affinity	O	O
at	O	O
sigma	O	O
-	O	O
1	O	O
and	O	O
sigma	O	O
-	O	O
2	O	O
subtypes	O	O
,	O	O
an	O	O
increase	O	O
in	O	O
selectivity	O	O
for	O	O
sigma	O	O
-	O	O
2	O	O
subtypes	O	O
was	O	O
evident	O	O
;	O	O
the	O	O
parent	O	O
3	O	O
showed	O	O
greater	O	O
selectivity	O	O
for	O	O
sigma	O	O
-	O	O
1	O	O
subtypes	O	O
.	O	O
A	O	O
series	O	O
of	O	O
4	B-IUPAC	O
(	I-IUPAC	O
5	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
iodo	I-IUPAC	O
-	I-IUPAC	O
5	I-IUPAC	O
(	I-IUPAC	O
4	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
nitro	I-IUPAC	B-MODIFIER
-	I-IUPAC	I-MODIFIER
1	I-IUPAC	I-MODIFIER
-	O	I-MODIFIER
substituted	B-MODIFIER	I-MODIFIER
-	O	O
imidazoles	B-IUPAC	O
has	O	O
been	O	O
synthesized	O	O
and	O	O
tested	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
selectively	O	O
radiosensitize	O	O
hypoxic	O	O
Chinese	O	O
hamster	O	O
cells	O	O
(	O	O
V	O	O
-	O	O
79	O	O
)	O	O
to	O	O
the	O	O
lethal	O	O
effect	O	O
of	O	O
radiation	O	O
.	O	O
These	O	O
compounds	O	O
are	O	O
,	O	O
therefore	O	O
,	O	O
also	O	O
suitable	O	O
for	O	O
the	O	O
isolation	O	O
of	O	O
V	O	O
-	O	O
2	O	O
vasopressin	O	O
receptors	O	O
from	O	O
mammalian	O	O
tissues	O	O
.	O	O
The	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxides	I-IUPAC	I-IUPAC
VIII	O	O
did	O	O
not	O	O
exhibit	O	O
significant	O	O
activity	O	O
against	O	O
Plasmodium	O	O
berghei	O	O
infections	O	O
in	O	O
mice	O	O
.	O	O
Among	O	O
the	O	O
group	O	O
of	O	O
ring	O	O
substituents	O	O
studied	O	O
for	O	O
symmetrical	O	O
diarylguanidines	O	O
,	O	O
an	O	O
isopropyl	B-IUPAC	O
group	B-MODIFIER	O
was	O	O
preferred	O	O
at	O	O
the	O	O
ortho	O	O
position	O	O
and	O	O
an	O	O
ethyl	O	O
group	O	O
was	O	O
preferred	O	O
at	O	O
the	O	O
meta	O	O
position	O	O
.	O	O
The	O	O
X	O	O
-	O	O
ray	O	O
crystal	O	O
structure	O	O
of	O	O
5	O	O
with	O	O
pcDHFR	O	O
was	O	O
also	O	O
carried	O	O
out	O	O
,	O	O
which	O	O
corroborated	O	O
the	O	O
design	O	O
rationale	O	O
and	O	O
indicated	O	O
a	O	O
hydrophobic	O	O
interaction	O	O
of	O	O
the	O	O
naphthalene	O	O
ring	O	O
of	O	O
5	O	O
and	O	O
Phe69	O	O
of	O	O
pcDHFR	O	O
which	O	O
is	O	O
responsible	O	O
,	O	O
in	O	O
part	O	O
,	O	O
for	O	O
the	O	O
more	O	O
than	O	O
18	O	O
-	O	O
fold	O	O
selectivity	O	O
of	O	O
5	O	O
for	O	O
pcDHFR	O	O
as	O	O
compared	O	O
with	O	O
rat	O	O
liver	O	O
DHFR	O	O
.	O	O
Indeed	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxyalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
hydroxypyridinones	I-IUPAC	I-IUPAC
which	O	O
are	O	O
known	O	O
to	O	O
be	O	O
rapidly	O	O
converted	O	O
to	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
carboxyalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
hydroxypyridinones	I-IUPAC	I-IUPAC
are	O	O
also	O	O
marginally	O	O
superior	O	O
to	O	O
Deferiprone	O	O
.	O	O
A	O	O
series	O	O
of	O	O
secondary	O	O
and	O	O
tertiary	O	O
N	O	B-IUPAC
-	O	I-IUPAC
alkyl	O	I-IUPAC
derivatives	O	B-MODIFIER
of	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorotetralin	I-IUPAC	I-IUPAC
have	O	O
been	O	O
prepared	O	O
.	O	O
gondii	O	O
enzyme	O	O
were	O	O
those	O	O
with	O	O
an	O	O
ArCH2	O	O
-	O	O
NH	O	O
or	O	O
ArNHCH2	O	O
side	O	O
chain	O	O
.	O	O
Within	O	O
this	O	O
compound	O	O
series	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminocarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diphenylpiperidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
aminocarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
(	O	O
19	O	O
)	O	O
displayed	O	O
good	O	O
binding	O	O
affinity	O	O
and	O	O
selectivity	O	O
for	O	O
the	O	O
alpha1a	O	O
adrenoceptor	O	O
(	O	O
pKi	O	O
=	O	O
8.73	O	O
)	O	O
and	O	O
potently	O	O
inhibited	O	O
(	O	O
pA2	O	O
=	O	O
9.23	O	O
)	O	O
phenylephrine	O	O
-	O	O
induced	O	O
contraction	O	O
of	O	O
the	O	O
human	O	O
prostate	O	O
.	O	O
The	O	O
first	O	O
involved	O	O
substitution	O	O
of	O	O
the	O	O
N1	O	O
-	O	O
position	O	O
while	O	O
the	O	O
second	O	O
involved	O	O
substitution	O	O
of	O	O
the	O	O
N5	O	O
-	O	O
position	O	O
.	O	O
The	O	O
order	O	O
of	O	O
the	O	O
inhibitory	O	O
potency	O	O
was	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
glutathione	I-IUPAC	I-IUPAC
=	O	I-IUPAC
S	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzylglutathione	I-IUPAC	I-IUPAC
greater	O	O
than	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
glutathione	I-IUPAC	I-IUPAC
greater	O	O
than	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylglutathione	I-IUPAC	I-IUPAC
.	O	O
The	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
demethoxyacronycine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
were	O	O
found	O	O
to	O	O
be	O	O
inactive	O	O
,	O	O
whereas	O	O
in	O	O
contrast	O	O
,	O	O
all	O	O
of	O	O
the	O	O
acronycine	O	O
derivatives	O	O
were	O	O
more	O	O
potent	O	O
than	O	O
acronycine	O	O
itself	O	O
when	O	O
tested	O	O
against	O	O
L1210	O	O
cells	O	O
in	O	O
vitro	O	O
.	O	O
Analogous	O	O
peptides	O	O
with	O	O
a	O	O
tyrosine	O	O
at	O	O
position	O	O
11	O	O
(	O	O
31-36	O	O
)	O	O
were	O	O
less	O	O
selective	O	O
than	O	O
the	O	O
corresponding	O	O
peptides	O	O
with	O	O
a	O	O
tyrosine	O	O
at	O	O
position	O	O
2	O	O
.	O	O
Inhibitory	O	O
potency	O	O
of	O	O
the	O	O
unsubstituted	B-MODIFIER	O
aza	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenanthridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
(	O	O
i.e.	O	O
,	O	O
benzonaphthyridones	O	O
)	O	O
was	O	O
dependent	O	O
on	O	O
the	O	O
position	O	O
of	O	O
the	O	O
nitrogen	O	O
atom	O	O
within	O	O
the	O	O
core	O	O
structure	O	O
.	O	O
In	O	O
this	O	O
paper	O	O
,	O	O
it	O	O
is	O	O
hypothesized	O	O
that	O	O
the	O	O
distinction	O	O
between	O	O
certain	O	O
active	O	O
and	O	O
inactive	O	O
cannabinoids	O	O
is	O	O
that	O	O
the	O	O
inactive	O	O
analogs	O	O
possess	O	O
extra	O	O
volume	O	O
associated	O	O
with	O	O
their	O	O
carbocyclic	O	O
rings	O	O
that	O	O
may	O	O
be	O	O
responsible	O	O
for	O	O
an	O	O
unfavorable	O	O
interaction	O	O
at	O	O
the	O	O
cannabinoid	O	O
receptor	O	O
.	O	O
However	O	O
,	O	O
since	O	O
the	O	O
in	O	O
vitro	O	O
metabolic	O	O
stability	O	O
of	O	O
these	O	O
analogues	O	O
was	O	O
insufficient	O	O
compared	O	O
with	O	O
that	O	O
of	O	O
2	O	O
,	O	O
further	O	O
derivatization	O	O
was	O	O
performed	O	O
by	O	O
introducing	O	O
an	O	O
appropriate	O	O
hydrophilic	O	O
group	O	O
into	O	O
the	O	O
phenyl	B-IUPAC	O
or	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
ring	B-MODIFIER	O
.	O	O
(	B-IUPAC	B-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methanone	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
has	O	O
a	O	O
behavioral	O	O
profile	O	O
suggestive	O	O
of	O	O
antipsychotic	O	O
activity	O	O
and	O	O
gave	O	O
a	O	O
positive	O	O
Ames	O	O
test	O	O
result	O	O
.	O	O
Tissue	O	O
distribution	O	O
studies	O	O
revealed	O	O
that	O	O
a	O	O
number	O	O
of	O	O
radioiodinated	O	O
guanidines	O	O
showed	O	O
pronounced	O	O
localization	O	O
in	O	O
the	O	O
adrenal	O	O
medullae	O	O
following	O	O
intravenous	O	O
injection	O	O
,	O	O
in	O	O
certain	O	O
cases	O	O
exceeding	O	O
that	O	O
of	O	O
either	O	O
(	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
norepinephrine	I-IUPAC	I-IUPAC
or	O	O
[	B-IUPAC	B-IUPAC
14C	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
guanethidine	I-IUPAC	I-IUPAC
.	O	O
The	O	O
reaction	O	O
of	O	O
4	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitroimidazole	I-IUPAC	I-IUPAC
with	O	O
1,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
epoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxypropane	I-IUPAC	I-IUPAC
and	O	O
ethyl	B-IUPAC	B-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroacetate	I-IUPAC	I-IUPAC
produced	O	O
two	O	O
isomeric	O	O
products	O	O
in	O	O
each	O	O
case	O	O
,	O	O
which	O	O
were	O	O
identified	O	O
by	O	O
their	O	O
NMR	O	O
spectra	O	O
.	O	O
AMPA	O	O
(	O	O
7	O	O
)	O	O
and	O	O
the	O	O
higher	O	O
homologue	O	O
of	O	O
homo	O	O
-	O	O
AMPA	O	O
(	O	O
8	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylisoxazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pentanoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
,	O	O
showed	O	O
relatively	O	O
weak	O	O
agonist	O	O
effects	O	O
at	O	O
mGlu6	O	O
.	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Ethylaminomethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinolone	I-IUPAC	I-IUPAC
(	O	O
1a	O	O
)	O	O
and	O	O
its	O	O
6	O	O
-	O	O
CH3	O	O
,	O	O
6	O	O
-	O	O
OCH3	O	O
,	O	O
and	O	O
7	O	O
-	O	O
Cl	O	O
derivatives	O	O
were	O	O
prepared	O	O
by	O	O
means	O	O
of	O	O
the	O	O
Mannich	O	O
reaction	O	O
.	O	O
Replacement	O	O
of	O	O
pyroglutamic	O	O
acid	O	O
by	O	O
pyro	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoadipic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
oxoimidazolidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
or	O	O
gamma	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyrolactone	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
gamma	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
and	O	O
that	O	O
of	O	O
proline	O	O
by	O	O
pipecolic	O	O
acid	O	O
,	O	O
thiazolidine	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
,	O	O
or	O	O
homoproline	O	O
in	O	O
[	O	O
Leu2	O	O
]	O	O
-	O	O
and	O	O
[	O	O
Nva2	O	O
]	O	O
TRH	O	O
led	O	O
to	O	O
tripeptides	O	O
structurally	O	O
widely	O	O
different	O	O
from	O	O
TRH	O	O
.	O	O
Recombinant	O	O
NOS	O	O
I	O	O
and	O	O
NOS	O	O
III	O	O
also	O	O
oxidize	O	O
several	O	O
N	B-MODIFIER	B-IUPAC
-	I-MODIFIER	I-IUPAC
aryl	I-MODIFIER	I-IUPAC
N'	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyguanidines	I-IUPAC	I-IUPAC
with	O	O
the	O	O
formation	O	O
of	O	O
NO	O	O
,	O	O
with	O	O
a	O	O
clearly	O	O
different	O	O
substrate	O	O
specificity	O	O
.	O	O
Extended	O	O
libraries	O	O
exploring	O	O
the	O	O
6	O	O
-	O	O
position	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
morpholino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
morpholino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiopyrano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
identified	O	O
the	O	O
first	O	O
highly	O	O
potent	O	O
and	O	O
selective	O	O
ATM	O	O
inhibitor	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
morpholin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thianthren	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
151C	O	O
;	O	O
ATM	O	O
;	O	O
IC50	O	O
=	O	O
13	O	O
nM	O	O
)	O	O
and	O	O
revealed	O	O
constrained	O	O
SARs	O	O
for	O	O
ATM	O	O
inhibition	O	O
compared	O	O
with	O	O
DNA	O	O
-	O	O
PK	O	O
.	O	O
Substrate	O	O
enantioselectivity	O	O
in	O	O
the	O	O
conjugation	O	O
of	O	O
phenethyl	O	O
halides	O	O
catalyzed	O	O
by	O	O
the	O	O
glutathione	O	O
S	O	O
-	O	O
transferases	O	O
was	O	O
studied	O	O
with	O	O
partially	O	O
purified	O	O
isozymes	O	O
from	O	O
rat	O	O
liver	O	O
.	O	O
In	O	O
conclusion	O	O
,	O	O
the	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzhydryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylurea	I-IUPAC	I-IUPAC
scaffold	B-MODIFIER	O
seems	O	O
to	O	O
be	O	O
a	O	O
new	O	O
interesting	O	O
template	O	O
of	O	O
CB1	O	O
cannabinoid	O	O
receptor	O	O
inverse	O	O
agonists	O	O
.	O	O
This	O	O
represented	O	O
the	O	O
first	O	O
demonstration	O	O
of	O	O
the	O	O
stereoselective	O	O
product	O	O
inhibition	O	O
of	O	O
the	O	O
glutathione	O	O
S	O	O
-	O	O
transferases	O	O
.	O	O

